2012N150072_01 CONFIDENTIA L
The GlaxoSmithKline group of companies HZC102972
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: Multi -centre, randomized, double- blind, parallel -group study  
evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) 
Inhalation Powder once daily  compared with Vilanterol (VI) 
Inhalation Powder Once Daily  on Bone Mineral Density  (BMD) 
in subjects with Chronic Obstructive Pulmonary  Disease 
(COPD)
Compound Number: GW685698+GW642444
Effective Date: 14-AUG-2013
Protocol Amendment Number:  01
Subject: COPD, Bone Mineral Densit y, Fluticasone Furoate (FF), Vilanterol (VI), Novel 
Dry Powder Inhaler (NDPI )
Author:
Revision Chronology:
2012N150072_00 2013- JAN- 07 Original
2012N150072_01 2013- AUG -14 Amendment No.: 01 This protocol 
amendment is being implemented to 
revise and clarify  exclusion criteria 
concerning participation in pulmonary  
rehabilitation programs; clarify  the 
description of DEXA procedures and 
clinical labs; correction of 
typographical errors.
Copyright 2 013 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2018N368712_00
PPD
 
P P D 2 0 1 8 N 3 6 8 7 1 2 _ 0 0 
2012N150072_01 CONFIDENTIA L
HZC102972
3SPONSOR INFORMA TION PAGE
Clinical Study  Identifier: 
HZC102972
Sponsor Legal Registered Address:
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Sponsor Contact Address
GlaxoSmithKline Research &  Development Limited
Via 
2/4-37135
Verona, Italy
Telephone:  
GlaxoSmithKline Research & Development Limited
Addenbrooke’s Centre for Clinical I nvestigation (ACCI )
Addenbrooke’s Hospital
Hills Ro ad
Cambridge, Cambridgeshire, CB2 2GG, UK
Telephone:  
GlaxoSmithKline Research & Development Limited
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, UK
Telephone:   
GlaxoSmithKline Research & Dev elopment Limited
2301 Renaissance Boulevard
Building #510
Post Office Box 61540
King of Prussia, Penns ylvania 19406
Telephone number: 
or
GlaxoSmithKline Research & Development Limited
1250 South Collegeville Road
Collegeville, PA 19426, USA
Telephone Number: 
GlaxoSmithKline Research & Development Limited
Five Moore Drive  2018N368712_00
PPD
PPD
PPD
PPD
PPD
PPD
2012N150072_01 CONFIDENTIA L
HZC102972
4P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: 
In some countries, the clinical trial sponsor may  be the local GlaxoSmit hKline affiliate 
compan y (or designee). Where applicable, the details of the Sponsor and contact person 
will be provided to the relevant regulatory  authority  as part of the clinical trial 
submission.
Sponsor Medical Monitor Contact Information: 
 MD
GlaxoSmithKline
Five Moore Drive
P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: 
Sponsor Serious Adverse Events (SAE) Contact Information: 
Case Management Group, GCSP –Stockley  Park, UK
Email: 
Fax: 
Regulatory  Agency  Identify ing Number(s): FDA IND Numbers:  077855 and 050703; 
EudraCT #: 2012 -004801 -28 2018N368712_00
PPD
PPD
PPD
PPD
PPD
2012N150072_01 CONFIDENTIA L
HZC102972
5INVESTIGA TOR AGREEM ENT PA GE
For protocol number HZC102972
Iconfirm agreement to conduct the study  in compliance with the prot ocol, as amended b y 
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described clinical study .
I agree to ensure that all associates, colleagues and employ ees assisting i n the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:  _____________________________
Investigator Signature Date 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
6TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S............................................................................................. 9
PROTOCOL SUMMARY ............................................................................................... 11
1.INTRODUCTION ................................................................
.................................... 13
1.1. Background ................................................................................................ 13
1.2. Rationale .................................................................................................... 13
2.OBJECTIVE(S) ...................................................................................................... 14
3.INVESTIGATIONAL PLAN ..................................................................................... 14
3.1. Study Design .............................................................................................. 14
3.1.1. Study Schematic .......................................................................... 15
3.2. Discussion of Design .................................................................................. 15
4.SUBJECT SELECTION AN D WITHDRAW AL CRITERI A....................................... 16
4.1. Number of Subjects .................................................................................... 16
4.2. Inclusion Criteria ......................................................................................... 16
4.3. Exclusion Criteria ........................................................................................ 17
4.4. Withdrawal Criteria ..................................................................................... 20
4.5. Pre-Screen Failures and Screening Failures ............................................... 21
5. STUDY TREATMENTS .......................................................................................... 22
5.1. Investigational Product and Other Study Treatment .................................... 22
5.1.1. Storage ........................................................................................ 23
5.1.2. Study Drug Return ....................................................................... 23
5.2. Treatm ent Assignment ................................................................................ 23
5.3. Blinding ....................................................................................................... 24
5.4. Product Accountability ................................................................................ 24
5.5. Treatment Compliance................................................................................ 25
5.6. Concomitant Medications and Non -Drug Therapies .................................... 25
5.6.1. Permitted Medications and Non -Drug Therapies .......................... 25
5.6.2. Prohibited Medications and Non -Drug Therapies ......................... 26
5.7. Treatment after the End of the Study .......................................................... 27
5.8. Treatment of Study Treatment Overdose .................................................... 27
6.STUDY ASSESSMENTS AND PROCEDURES ..................................................... 27
6.1. Critical Baseline Assessments .................................................................... 31
6.2. Safety ......................................................................................................... 31
6.2.1. Primary Endpoint ......................................................................... 31
6.2.2. Secondary Endpoints ................................................................... 31
6.2.3. Other Endpoints ........................................................................... 31
6.2.4. Bone Mineral Density ................................................................... 32
6.2.5. Fractures ..................................................................................... 32
6.2.6. COPD Exacerbations and Pneumonias ....................................... 32
6.2.7. Liver chemistry stopping and follow up criteria ............................. 34
6.2.8. Adverse Events ............................................................................ 37
6.2.8.1. Definition of an AE ...................................................... 38 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
76.2.8.2. Definition of a SAE ..................................................... 39
6.2.9. Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAEs ......................................................... 40
6.2.10. Cardiovascular Events ................................................................ .40
6.2.11. Death Events ............................................................................... 41
6.2.12. Pregnancy ................................................................................... 41
6.2.13. Time Period and Frequency of Detecting AEs and SAEs ............. 41
6.2.14. Prompt Reporting of Serious Adverse Events and Other 
Events to GSK ............................................................................. 41
6.2.14.1. Regulatory reporting requirements for SAEs .............. 43
6.2.15. SpirometryTesting ........................................................................ 43
6.2.15.1. Reversibility Testing ................................................... 44
6.2.16. Laboratory Assessments ............................................................. 44
6.2.17. Oropharyngeal Examination ......................................................... 45
6.2.18. Diary Card -Medical Problems/Medicatio ns Taken ...................... 45
6.2.19. 12-lead ECG Assessment ............................................................ 45
6.2.20. Smoking Cessation Counselling .................................................. 46
6.3. Pharmacogenetic Research ........................................................................ 46
7.DATA MANAGEME NT........................................................................................... 47
8. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ................................... 47
8.1. Hypotheses ................................................................................................ .47
8.2. Study Design Considerations ...................................................................... 47
8.2.1. Sample Size Assum ptions ........................................................... 47
8.2.2. Sample Size Sensitivity ................................................................ 48
8.2.3. Sample Size Re- estimation .......................................................... 48
8.3. Data Analysis Considerations ..................................................................... 48
8.3.1. Analysis Populations .................................................................... 48
8.3.2. Analysis Data Sets ....................................................................... 48
8.3.3. Treatment Comparisons .............................................................. 48
8.3.3.1. Primary Comparisons of Interest ................................ 48
8.3.4. Interim Anal ysis........................................................................... 49
8.3.5. Key Elements of Analysis Plan .................................................... 49
8.3.5.1. Efficacy Analyses ....................................................... 49
8.3.5.2. Safety Analyses .......................................................... 49
8.3.5.2.1. Extent of Exposure ................................ .49
8.3.5.2.2. Adverse Events (AEs) ............................. 49
8.3.5.2.3. Deaths and SAEs ................................... 49
8.3.5.2.4. Fractures ................................................ 49
8.3.5.2.5. COPD Exacerbations and 
Pneumonias ........................................... 49
8.3.5.3. Pharmacogenetic Analyses ........................................ 49
9.STUDY CONDUCT CONSID ERATIONS ............................................................... 50
9.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 50
9.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 50
9.3. Quality Control (Study Monitoring) .............................................................. 51
9.4. Quality Assurance ....................................................................................... 51
9.5. Study and Site Closure ............................................................................... 51
9.6. Records Retention ...................................................................................... 52 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
89.7. Provision of Study Results to Investigators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publica tion.................... 52
9.8. Independent Data Monitoring Committee (IDMC) ....................................... 53
10.REFERENCES ....................................................................................................... 54
11.APPENDICES ........................................................................................................ 55
11.1. Appendix 1: Laboratory Assessment s......................................................... 55
11.2. Appendix 2: Pharmacogenetic Research .................................................... 56
11.3. Appendix 3: Country Specific Requirements ............................................... 61
11.4. Appendix 4: Liver Chemistry Stopping and Followup Criteria ...................... 62
11.5. Appendix 5: Protocol Changes .................................................................... 63 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
9LIST OF A BBREVIATIONS
AE Adverse Event
ALT Alanine Transaminase
AM Morning
ANCOVA Analy sis of Covariance
AST Aspartate Transaminase
AUC Area Unde r the Curve
ATS American Thoracic Society
BMD Bone Mineral Densit y
IB Investigator’s Brochure
COPD Chronic Obstructive Pulmonary  Disease
eCRF Electronic Case Report Form
DEXA Dual Energy  X-ray Absorptiometry
ECG Electrocardiogram
EISR Expedited I nvestigator Safet y Report
FEV 1 Forced Expiratory  Volume in one Second
FF Fluticasone Furoate
FF/V I Fluticasone Furoate/ Vilanterol Inhalation Powder 
Combination
FVC Forced Vital Capacity
GCP Good Clinical Practice
GCSP Global Clinical Safety  and Pharma covigilance
GCP Good Clinical Practice
GOLD Global I nitiative for Chronic Obstructive Lung Disease
GSK GlaxoSmithKline
IEC Independent Ethics Committee
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IDMC Independent Data Monitoring Committee
IRB Institutional Review Board
ITT Intent to Treat
IVRS Interactive Voice Response Sy stem
L Liter
LABA Long Acting Beta Agonist
LDH Lactate Deh ydrogenase
LSLV Last Subject Last Visit
LTOT Long Term Ox ygen Therapy
MAOI Monoamine Oxidase I nhibitor
Mcg Microgram
MDI Metered Dose Inhaler
MEDDRA Medical Dictionary  for Regulatory  Activities
mL Milliliter
MSDS Material Safet y Data Sheet
NDPI Novel Dry  Powder Inhaler
OTC Over the Counter
PD Pharmacod ynamics
PK Pharmacokinetics 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
10PEF Peak Expiratory  Flow
PFT Pulmonary  Function Test
PGx Pharmacogenetics
PM Evening
PR Pulse Rate
PRN As needed
QD Once Daily
RAMOS Registration and Medication Ordering Sy stem
RAP Reporting Analy sis Plan
RNA Ribonucleic Acid
SAE Serious Adverse Event
SD Standard D eviation
SPM Study  Procedures Manual
UC Urine Cortisol
ULN Upper Limit of Normal
VI Vilanterol
WHO World Health Organization
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmithKline group of companies
NONE NONE 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
11PROTOCOL SUMMA RY
Rationale
Chronic obstructive pulmonary  disease (COPD) has been defined as a preventable and 
treatable disease with some significant extra -pulmonary  effects that may  contribute to the 
severit y in individual pa tients. The pulmonary  component of COPD is characterized by  
airflow limitation that is not fully  reversible, which is usually  progressive and associated 
with an abnormal inflammatory  response of the lung to noxious particles or gases. COPD 
is a major cause of poor health, resulting in millions of deaths annually  worldwide 
[GOL D,2010] and contributing significantly to health care costs and morbidity  
[Chapman, 2006; Lo pez, 2006]. According to the World Health Organization, COPD was 
the fifth leading cause of death worldwide in 2002 and is estimated to be the third leading 
cause b y 2030 [ WHO , 2010].
Currently  published guidelines on COPD state that the goals of pharmacologic therap y 
should be to control sy mptoms, improve health status and exercise tolerance, and reduce 
the frequency  of COPD exacerbations [ GOL D, 2010]. Recent c linical research has 
indicated that an inhaled corticosteroid (ICS) combined with a long acting 2-agonist 
(LABA) is more effective than the individual components in managing stable COPD to 
reduce exacerbations and improve lung function and health statu
s [Ferguson, 2008; 
Calverley ,2007; Kardos , 2007]. 
Although inhaled corticosteroids have demonstrated utility  in patients with COPD, the re 
is a potential safety concern with long -term use on bone demineralization .  These 
concerns, for the most part, are derived from the well-documented effects of oral 
corticosteroids on bone density  and fracture; however the actual effects of inhaled 
corticosteroids are not clear and require further study .
Study  HZC102972 will prospectivel y assess the effects of 3 years (156 weeks) exposure 
to fluticasone furoate/vilanterol (FF/VI) Fluticasone Furoate /Vilanterol (FF/VI) 
inhalation powder once daily  versus 
VI once dail y on bone mineral densit y in adult 
subjects with COPD at approximately  40 centres.
Objective(s)
The primary  objective of this study  is to evaluate the effect of the inhaled corticosteroid 
FF on bone mineral density  (BMD) assessed at the total h ip by  comparing FF/VI 
treatment with VI treatment in subjects with moderate COPD. 
A secondary  objective is to evaluate the effect of the inhaled corticosteroid FF on bone 
mineral density  by gender by  comparing FF/VI treatment with VI  treatment in subjects
with moderate COPD.
Another secondary  objective is to evaluate the effect of FF on bone mineral density  as 
assessed at the lumbar spine (L1 -L4) b y comparing FF/VI treatment with VI treatment in 
subjects with moderate COPD. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
12Stud y Design
This is a multi -center, randomized, double -blind, parallel -group stud y.  The FF/VI 
inhalation powder once daily  and VI inhalation powder once dail y will be evaluated in 
subjects with COPD over 156 weeks. Subjects will sign the informed consent form (ICF) 
at Visit 0 and will be assigned a subject identifier. See Table 3 for further details. 
Subjects who meet all study  inclusion and none of the exclusion criteria will begin a 14 to 
21 day  single -blind run- in period following Visit 1.  B aseline BMD measurements will be 
collected between Visits 1 and 2.  At Visit 2, eligible subjects will be randomized to 
double -blind study  medication and entered into a 156 -week treatment period.  
Randomisation will be stratified based upon gender.  During the treatment period, clinic 
visits will occur every  3 months. BMD determined by  dual -energy  x-ray absorptiometry  
(DEXA) scans will be conducted every  6 months following randomization. A safet y 
Follow -up Visit 15 will occur 7 day s after the last treatment study  day as a telephone 
contact.  Subjects will be prescribed appropriate COPD therapy  at the end of Treatment 
Visit 14 if required.  There are no plans to provide the study  drug for compassionate use 
following stud y completion.
The target enrolment across approximately  40 study  centres is approximately  280
randomized subjects, to achieve approximately  224 who complete the 156 -week 
treatment period.  The total duration of subject participation will be approximately  159 to 
160 weeks.
Stud y Endpoints/Assess ments
Primary
BMD measured at the total hip 
Secondary
BMD measurements b y gender 
BMD measured at the lumbar spine (L1 -L4)
Other
Adverse Event reporting 
Serious Adverse Event reporting
Incidence of fractures
Incidence of pneumonias
COPD exacerbations 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
131. INTRODUCTION
1.1. Background
COPD has been defined as a preventable and treatable disease with some significant 
extra -pulmonary  effects that may  contribute to the severit y in individual patients. The 
pulmonary  component of COPD is characterized by  airflow limita tion that is not fully  
reversible, which is usually  progressive and associated with an abnormal inflammatory  
response of the lung to noxious particles or gases. COPD is a major cause of poor health, 
resulting in millions of deaths annuall y worldwide [ GOL D,2010] and contributing 
significantl y to health care costs and morbidity [ Chapman, 2006; Lopez, 2006]. 
According to the World Health Organiza tion, COPD was the fifth leading cause of death 
worldwide in 2002 and is estimated to be the third leading cause b y 2030 [ WHO , 2010].
Currently  published guidelines on COPD state that the goals of pharmacologic therap y 
should be to control sy mptoms, improve health status and exercise tolerance, and reduce 
the frequency  of COPD exacerbations [ GOL D, 2010]. Recent clinical research has 
indicated that an inhaled corticosteroid (ICS) combin ed with a long acting 2-agonist 
(LABA) is more effective than the individual components in managing stable COPD to 
reduce exacerbations and improve lung function and health status [ Ferguson, 2008; 
Calverley ,2007; Kardos , 2007]. 
Bronchodilators are considered key  to the s ymptomatic management of COPD and 
current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 
recommend the use of long -acting inhaled bronchodilators in moderate to very  severe 
COPD, because they  are more efficacious and more convenient to use than short -acting 
bronchodilators.  The benefits of bronchodilators include not only  the control of 
sympto ms but improvements in lung function, h yperinflation, exercise performance, and 
health status.
Inhaled corticosteroids are considered the most effective anti -inflammatory  treatments for 
all severities of COPD.  The benefits of I CS may  include control of CO PD sy mptoms, 
improvement in lung function, decrease in airway  hyper-responsiveness and 
improvement in health status and reduction in exacerbations.
1.2. Rationale
Although inhaled corticosteroids have demonstrated utility
 in patients with COPD, there 
is a potential safet y concern with long -term use of I CS on bone demineralization .  These 
concerns, for the most part, are derived from the well-documented effects of oral 
corticosteroids on bone density  and fracture; however the actual effects of inhaled 
corticoster oids are not clear and require further study .
Study  HZC102972 will prospectivel y assess the effects of 3 years (156 weeks) exposure 
to FF/VI Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder Once Daily  versus 
VI Once Dail y on bone mineral density i n adult subjects with chronic obstructive 
pulmonary  disease (COPD) at approximately  40 centres
. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
142. OBJECTIVE(S)
The primary  objective of this study  is to evaluate the effect of the inhaled corticosteroid 
FF on bone mineral density  assessed at the total hip by comparing FF/VI treatment with 
VI treatment in subjects with moderate COPD. 
A secondary  objective is to evaluate the effect of the inhaled corticosteroid Fluticasone 
Furoate (FF) on bone mineral densit y by gender by comparing FF/VI treatment with VI  
treatment in subjects with moderate COPD.
Another secondary  objective is to evaluate the effect of FF on bone mineral density  as 
assessed at the lumbar spine (L1 -L4) b y comparing FF/VI treatment with VI treatment in 
subjects with moderate COPD.
3. INVESTIGA TIONAL PLAN
3.1. Stud y Design
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table, are essential and required for study  conduct. 
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM). The SPM will provide 
the site personnel with administrative and detailed technical informati on that does not 
impact subject safet y.
This is a multi -center, randomized, double- blind, parallel -group stud y.  The FF/VI 
inhalation powder once daily  and VI inhalation powder once dail y will be evaluated in 
subjects with COPD over 156 weeks. Subjects wil l sign the ICF at Visit 0 and will be 
assigned a subject identifier. See Table 3for further details. Subjects who meet all study  
inclusion and none of the exclusion criteria will begin a 14 to 21 day  single -blind run-in 
period following Visit 1.  Baseline BMD measurements will be collected between Visits 
1 and 2.  At Visit 2, eligible subjects will be randomized to double -blind study  
medication and entered into a 156- week treatment period.  Randomisation will be 
stratified based upon gender.  During the treatment period, clinic visits will occur every  3 
months. BMD DEXA scans will be conducted every 6 months following randomization. 
A safet y Follow -up Visit 15 will occur 7 days after the last treatment study  day as a 
telephone contact.  Subjects will be prescribed appropriate COPD therap y at the end of 
Treatment Visit 14 if required.  There are no plans to provide the study  drug for 
compassionate use following stud y completion.
Systemic corticosteroid therapies will not be allowed during the run -in period.  Subjects 
may take courses of s ystemic corticosteroids, where necessary, for treatment of a COPD 
exacerbation during the double- blind treatment period. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
153.1.1. Study Schematic
FF/VI 100/25 once daily (N=140)
VI 25 once daily (N=140)
            │                          156 Week Treatment                                          │ Follow -up
│__│_│___│___│___│___│___│___│___│___│___│___│___│___│_│
Visits
0     1   2       3       4       5      6      7       8       9      10     11    12     13     14  15
                             
Randomization
3.2. Discussion of Design
The purpose of this stud y is primarily  to assess the long -term safet y effects of the FF 
component of the FF/VI inhalation powder on bone mineral densi ty when administered to 
subjects with COPD over 156 weeks.  The American Thoracic Societ y (ATS)/European 
Respiratory  Society definition of COPD defines the subject population that will be 
included in this study  [Celli ,2004].  BMD at the total hip was chosen as the primary  
endpoint due to the important morbidity /mortality  implications of hip fractures.  BMD at 
the lumbar spine (L1 -L4) will be measured and assessed as a secondary  endpoint.   2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
164. SUBJECT SELECTION A ND WITHDRA WAL CRITERI A
4.1. Number of Subjects
Approximately  400 male and female subjects will be screened to randomize 
approximately  280 subjects, to obtain at least 224 who complete 156 weeks of treatment.  
Approximately  40 centres in multiple countries will be require d to recruit for the study .
4.2. Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the GSK investigational product or other study  
treatment that may  impact subject elig ibility  is provided in the IB.
Deviations from inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, 
adherence to the criteria as specified in the protocol is essential.   
Subjects eligible for enrolment in the study  must meet all of the following criteria:
1.Informed consent: Subjects must give their signed and dated written informed 
consent to participate.
2.Gender: Male or female subjects. Fe male subjects must be post -menopausal or using 
a highl y effective method for avoidance of pregnancy . The decision to include or 
exclude women of childbearing potential may  be made at the discretion of the 
investigator in accordance with local practice in r elation to adequate contraception.
3.Age: ≥ 40 y ears of age at Screening (Visit 1)
4.COPD diagnosis: Subjects with a clinical history of COPD in accordance with the 
following definition by  the American Thoracic Society /European Respiratory  Societ y 
[Celli , 2004]: COPD is a preventable and treatable disease characterized b y airflow 
limitation that is not fully  reversible.  The airflow limitation is usually  progressive 
and is associated with an abnormal inflammatory  response of the lungs to noxious 
particles or gases, primarily  caused b y cigarette smoking.  Although COPD affects 
the lungs, it also produces significant s ystemic consequences.
5.Tobacco use: Subjects with a current or prior history of ≥10 pack -years of cigarette 
smoking at screening (Visit 1).  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Number of pack y ears = 
(number of cigarettes per day /20) x number of y ears smoked
Note: Pi pe and/or cigar use cannot be used to calculate pack year history .
6.Severity of Disease: Subject with a measured post -albuterol/salbutamol FEV 1/FVC 
ratio of < 0.70 at Screening (Visit 1).  Subjects with a measured post
- 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
17albuterol/salbutamol 50% ≤ FEV 1 ≤ 70% of predicted normal values calculated using 
NHANES III reference equations [ Hankinson, 1999] at Screening (Visit 1).
7.Native Hip: Have at least one evaluable native hip.
4.3. Exclusion Criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essential. 
Subjects meeting an y of the following criteria must not be enrolled in the study :
1.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study
.
2.Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history  
of asthma are e ligible if they  have a current diagnosis of COPD).
3.α1-antitrypsin deficiency: Subjects with α -1 antitry psin deficiency  as the underly ing 
cause of COPD.
4.Other respiratory disorders: Subjects with tuberculosis, lung cancer, 
bronchiectasis, sarcoidosis, lung fibrosis, pulmonary  hypertension, interstitial lung
diseases or other active pulmonary  diseases.
5.Lung resection or transplantation: Subjects with lung volume reduction surgery 
within the 12 months prior to Screening Visit 1 or having had a lung transplant.
6.Chest X -ray:  Subjects with a chest X -ray (or CT s can) that revealed evidence of 
clinically  significant abnormalities not believed to be due to the presence of COPD.  
A chest X -ray should be taken at Screening Visit 1 if a chest X- ray or CT scan is not 
available within 12 months prior to Visit 1.
7.Poorly c ontrolled COPD: Subjects with poorly  controlled COPD, defined as the 
occurrence of the following in the 12 weeks prior to Screening Visit 1: Acute 
worsening of COPD that is managed b y the subject with corticosteroids or antibiotics 
or that requires treatme nt prescribed b y a physician or requires hospitalization.
8.Moderate or severe COPD exacerbation or lower respiratory tract infection: 
Subjects with 2 or more moderate or severe COPD exacerbations and/or a lower 
respiratory  tract infection (including pneumon ia) within the 12 months prior to 
Screening Visit 1 or experience a moderate or severe COPD exacerbation and/or a 
lower respiratory  infection (including pneumonia) during the Run- In period.
NOTE: A moderate COPD exacerbation is defined as requiring s ystemic 
corticosteroids and/or antibiotics.  A severe COPD exacerbation is defined as 
requiring hospitalization.  2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
189.Abnormal clinically significant laboratory finding: Subjects who have an 
abnormal, clinicall y significant finding in an y liver chemistry, biochemica l, or 
haematology  tests at Screening Visit 1 or upon repeat prior to randomization.
10.Abnormal and clinically significant 12- lead ECG: Subjects who have an abnormal, 
clinically  significant ECG finding at Screening Visit 1.
11.Non-Compliance during Run- In Period : Failure to demonstrate adequate 
compliance with run -in medication (< 80% compliant), the ability  to withhold COPD 
medications, and to keep clinic visit appointments.
12.Bone disorders/conditions: Subjects with historical or current evidence of bone 
cancer, severe scoliosis, rheumatoid arthritis, metabolic bone diseases (other than 
osteoporosis) including hyper -or hypo-parathy roidism, Paget’s disease of bone, 
osteomalacia, or osteogenesis imperfecta. Removal of vertebrae between L1 and L 4 
of the lumbar spine and/or presence of metal implants or devices, such as plates, rods, 
or screws in the lumbar spine and/or hip.
13.Immobility: Wheel chair bound or paraplegic.
14.Low vitamin D: Previously  known low- serum 25 -hydroxy  vitamin D concentration 
(less than 10ng [25nmole s] per liter).
15.Other diseases/abnormalities: Serious, uncontrolled disease (including serious 
psychological disorders) likely to interfere with the study  within the 3- year study .
16.Cancer: Subjects with carcinoma that has not been in complete remission for a t least 
5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell 
carcinoma of the skin would not be excluded if the subject has been considered cured 
within 5 y ears since diagnosis.
17.Drug/food allergy: Subjects with a history  of hy persensitivity  to an y of the study  
medications (e.g. beta- agonists, corticosteroid) or components of the inhalation 
powder (e.g. lactose, magnesium stearate). In addition, patients with a history of 
severe milk protein allergy  that, in the opinion of the stu dy physician, contraindicates 
the subject’s participation will also be excluded. 
18.Drug/alcohol abuse: Subjects with a known or suspected history  of alcohol or drug 
abuse within the last 2 y ears. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
1919.Prohibited medications prior to spirometry at Visit 1: Subjec ts who are medically  
unable to withhold the following medications prior to spirometry  testing at Visit 1:
Medication No use within the following 
time intervals prior to Visit 1 
Spirometry Testing 
Inhaled corticosteroids 48 hours
Inhaled ICS/LABA combina tion products 48 hours 
Long- acting anticholinergics (e.g., tiotropium) 48 hours
Theophylline preparations 48 hours
Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton) 48 hours
Oral PDE -4 inhibitors (e.g. roflumilast) 48 hours
Oral beta -agonists 
     Long- acting
     Short -acting48 hours
12 hours
Inhaled long acting beta 2-agonist (LABA) -Indacaterol 48 hours
Other inhaled LABAs (e.g., salmeterol) 24 hours 
Inhaled sodium cromoglycate or nedocromil sodium 24 hours
Ipratropium/ albut erol (salbutamol) combination product 4 hours 
Inhaled short- acting beta 2-agonists 4 hours 
Short -acting anti -cholinergics (e.g., ipratropium bromide) 4 hours
20.Additional medication: Use of the following medications within the following time 
intervals prior to Visit 1 or during the study  (unless otherwise specified):
Medication No use within the following time intervals prior to 
Screening Visit 1 or thereafter at any time during the 
study (unless otherwise specified)
Depot corticosteroids 12 weeks
Systemic, Oral, parenteral, intra -
articular corticosteroids1 30 days   
Any other investigational drug 30 days or 5 half lives whichever is longer.
1. Subjects may take courses of systemic corticosteroids, where necessary, for treatment of an exacerbation 
during the double -blind treatment period.
21.COPD medications: Use of inhaled corticosteroids (I CS), long -acting beta 2-agonists 
(LABA), or ICS/LABA combination products (other than the stud y-provided double - 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
20blind study  medication) at Visit 2 (Randomization) or during the double- blind 
treatment period.
22.Oxygen therapy: Subjects receiving treatment with long -term oxy gen therapy  
(LTOT) or nocturnal oxygen therapy  required for greater than 12 hours a day .  
Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary .
23.Non-compliance: Subjects at risk of non- compliance, or unable to comply  with the 
study  procedures.  Any  infirmity, disability , or geographic location that would limit 
compliance for scheduled visits.
24.Questionable validity of consent: Subjects with a history  of ps ychiatric disease, 
intellectual deficiency , poor motivation or other conditions that will limit the validity  
of informed consent to participate in the stud y
25.Affiliation with investigator site: Study  investigators, sub- investigators, study  
coordinators, emplo yees of a participating investigator or immediate family  members 
of the aforementioned are excluded from participating in this study .
4.4. Withdrawal Criteria
A subject may  voluntarily  discontinue participation in this study  at any  time.  The 
investigator may also, at his or her discretion, discontinue a subject from this study  at any  
time.  Every  effort should be made b y the investigator to keep the subject in the study .  
The primary  reason for subject withd rawal will be recorded in the electronic Case Report 
Form (eCRF).  Primary  reasons for withdrawal will be categorised as:
adverse event
withdrew consent
lost to follow -up
protocol deviation
lack of efficacy
subject reached protocol -defined stopping criteri a
study  closed/terminated
investigator discretion
Subject compliance with double -blind study  medication will be assessed from Visits 2 
through 14, b y reviewing the dose counter on the NDPI .  Subjects must be ≥80% to 
≤120% compliant on taking stud y medicati on between each pair of on- treatment visits.  
Subjects who fall outside this range should be re -educated on treatment compliance by  
their site.  This re -education should be documented in the subject’s source document.  If 
the double- blind study  medication is prematurely  discontinued during the course of study  
or medication compliance repeatedl y falls outside of acceptable ranges, the study 
sponsor/site monitor must be contacted to discuss subject eligibility  for continued 
participation in the study . 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
21A subje ct will also be withdrawn from the study, in consultation with the medical
monitor and principal investigator, if an y of the following stopping criteria are met:
Liver Chemistry: Meets any  of the liver chemistry  stopping criteria as defined 
in Section 6.2.7 .
Pregnancy: 
Positive pregnancy  test
Laboratory Measurements:   Demonstrate a clinically  important change in a 
laboratory  parameter(s).
If a subject is withdrawn due to an exacerbation, the exacerbation section and SAE 
section, if applicable, of the eCRF should be completed and the subject should be 
followed until resolution of exacerbation.
If a subject is withdrawn due to pneumonia, the AE/SAE section and the 
pneumonia/chest x -ray section of the eCRF should be completed and the subject should 
be followed until clinical resolution of the pneumonia.
4.5. Pre
-Screen Failures and Screening Failures
A subject will be assigned a subject number at the time the informed consent is signed.
A subject who is assigned a subject number but does not have Visit 1 will be considered a 
pre-screen failure.
Any subject who performs a Visit 1 procedure but does not continue in the study  beyond 
Visit 1 or any  subject who completes Visit 1 and enters the run- in period, but is 
subsequently  found to be ineligible for the study  (e.g. exclusionary  laboratory , ECG, or 
spirometry  findings) conducted prior to randomization to the study  treatment medication 
(Visit 2), is classified as a ‘screen failure’.
The study  interactive voice response s ystem (IVRS) will be contacted to report pre -screen 
failures. The following information will be collected for subjects who are pre -screen 
failures:
Subject number
Date of ICF signature
Demographic information including race, age and gender
Details of COPD medica tions within 30 day s of Visit 0
Details of COPD exacerbation (y es/no status), if applicable
Serious Adverse Event information, if applicable, only  for an SAE considered as 
related to stud y participation (e.g. stud y treatment, protocol mandated 
procedures, invasive tests, or change in existing therapy ) or related to a GSK 
concomitant medication
Investigator signature page
IVRS will be contacted to report screen failures, In addition to the information above, the 
following information will be collected for sc reen failures:
Date of screening visit
Reason for screen failure (screening failure and inclusion/exclusion criteria) 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
225. STUDY TREA TMENTS
5.1. Investigational Product and Other Study  Treatment
GSK Clinical Trials Supplies will provide the investigational products for use in this 
study . All blinded study  medication will be delivered via the NDPI. At each dispensing 
each subject will receive NDPI  for once -daily administration. The contents of each 
treatment are described in Table 1 and Table 2.
The NDPI provides a total of 30 doses (60 blisters), with each actuation comprising the 
contents of one blister from each of the two internal foil strips simultaneously . The 
NDPI s containing ran domized treatment will appear identical on the outside to the 
subject (and his/her caregiver) and the Investigator.
All subjects will receive supplemental albuterol/salbutamol (MDI and/or nebules) to be 
used on an as -needed basis throughout the study ; for all sites this medication will be 
sourced locally
 where possible.
Following the 14 to 21 day , Run -In period, eligible subjects will be randomized (1:1) to 
one of the following two possible treatments, administered each morning for 156 weeks:
FF/V I Inhalati on Powder 100/25mcg QD
VI Inhalation Powder 25mcg QD
Randomization in each treatment group will be stratified (1:1) according to gender.
A description of the investigational treatments is provided below:
Table 1 Description of FF/VI Inhalation Po wder Novel Dry  Pow der Inhaler 
(NDPI)
Formulation First strip : Fluticasone Furoate  
blended with lactoseSecond strip : Vilanterol micronised 
drug (as the ‘M’ salt 
triphenylacetate) blended with 
lactose and magnesium stearate1
Dosage Form Nove l dry powder inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 100mcg per blister 25mcg per blister
Physical description Dry white powder Dry white powder
Route of Administration Inhaled Inhaled
1. Magnesium stearate 1% w/w o f total drug product
Table 2 Description of VI Inhalation Po wder Novel Dry  Powder Inhaler (NDPI)
Formulation First s trip: lactose  Second strip : Vilanterol micronised 
drug (as the ‘M’ salt 
triphenylacetate) blended with 
lactose a nd magnesium stearate1
Dosage Form NDPI with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths N/A 25mcg per blister
Physical description Dry white powder Dry white powder
Route of Administration Inhaled Inhaled
1. Magnesium stearate 1 % w/w of total drug product 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
23The contents of the label will be in accordance with all applicable regulatory  
requirements. Under normal conditions of handling and administration, investigational 
product is not expected to pose significant safet y risks to si te staff. Take adequate 
precautions to avoid direct ey e or skin contact and the generation of aerosols or mists. 
Notify  the monitor of any  unintentional occupational exposure. A Material Safety  Data 
Sheet (MSDS) describing the occupational hazards and reco mmended handling 
precautions will be provided to site staff if required by  local laws or will otherwise be 
available from GSK upon request.
Adequate precautions must be taken to avoid direct contact with the investigational 
product.  The occupational hazards and recommended handling procedures are provided 
in the Material Safet y Data Sheet (MSDS).
5.1.1. Storage
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and administration of the in vestigational product 
will be limited to the investigator and authorized site staff.  Investigational product must 
be dispensed or administered onl y to subjects enrolled in the study  and in accordance 
with the protocol.
The NDPIs are packaged in a foil ove rwrap with enclosed desiccant.  The foil overwrap 
must not be opened until immediately  prior to use.  Once the foil overwrap has been 
opened the NDPI has a 30 day  in-use shelf life.
5.1.2. Study Drug Return
At the end of the stud y, all study -supplied study medica tion (used and unused) will be 
destroy ed following local standard operating procedures, except where it is suspected that 
the NDPI or NDPI packaging is defective. The NDPI  and packaging should be returned 
to GSK.
Details for both destruction and return of study  medication are found in the SPM.
In addition, any  study  inhaler that fails to function properl y must be identified to GSK 
personnel for return to GSK for testing.  Details of the failure will be documented in the 
eCRF.  The subject should return the NDPI to the clinic as soon as possible and avoid 
missing an y doses if possible.  The site should then call IVRS and obtain a new treatment 
pack number for this subject and dispense a new study  medication kit from the site's 
investigational product supply  as instructed b y RAMOS, an Interactive Voice Response 
System (IVRS).
5.2. Treatment A ssignment
Subjects will be assigned to study  treatment in accordance with the randomization 
schedule.  Once a randomization number has been assigned to a subject, the same numbe r 
cannot be reassigned to any  other subject in the study . 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
24Subjects will be stratified based on gender.
Subjects will be site -based randomized using RAMOS, an I nteractive Voice Response 
System (IVRS).  This is a telephone based s ystem that will be used by  the investigator or 
designee to register the subject (initially  at Visit 0, and subsequentl y at each study visit), 
randomize the subject and provide medication assignment information.  Details on how 
to use RAMOS to register and randomize subjects is provid ed in the SPM.
Following the 14 -21 day , Run -In period, eligible subjects will be randomized (1:1) to one 
of the following 2 possible treatments, administered as one inhalation each morning:
Fluticasone Furoate /Vilanterol 100/25mcg once daily
Vilanterol 25 mcg once daily
5.3. Blinding
Study  Medication taken during the 156-week treatment period will be double- blind. 
Neither the subject nor the study  physician will know which study  medication the subject 
is receiving.
The investigator or treating ph ysician may  unbl ind a subject’s treatment assignment only 
in the case of an emergency , when knowledge of the study  treatment is essential for the 
appropriate clinical management or welfare of the subject.  Whenever possible, the 
investigator must first discuss options wit h the GSK Medical Monitor or appropriate 
GSK study  personnel 
before unblinding the subject’s treatment assignment.  If this is 
impractical, the investigator must notify  GSK as soon as possible, but without revealing 
the treatment assignment of the unblinde d subject, unless that information is important 
for the safet y of subjects currentl y in the stud y.  The date and reason for the unblinding 
must be recorded in the appropriate data collection tool.
GSK’s Global Clinical Safet y and Pharmacovigilance (GCSP) s taff may  unblind the 
treatment assignment for any  subject with an SAE.  If the SAE requires that an expedited 
regulatory  report be sent to one or more regulatory agencies, a copy  of the report, 
identify ing the subject’s treatment assignment, may  be sent to clinical investigators in 
accordance with local regulations and/or GSK policy.
Subjects will be withdrawn if the treatment code becomes unblinded.  The primary  reason 
for discontinuation (the event or condition which led to the unblinding) will be recorde d 
in the eCRF.
5.4. Product A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of 
investigational product dispensed and/or admi nistered to study  subjects, the amount 
returned b y stud y subjects, and the amount received from and returned to GSK, when 
applicable.  Product accountability  records must be maintained throughout the course of 
the study . 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
255.5. Treatment Compliance
An initial sup ply of albuterol (salbutamol), a short -acting, beta 2-agonist, will be provided 
to each subject to use as needed for s ymptomatic relief of COPD s ymptoms during both 
the Run- in and Treatment Periods.  The subject’s use of albuterol (salbutamol) will be 
asses sed at each clinic visit and additional albuterol (salbutamol) will be dispensed to the 
subject as needed.
Subject compliance with the single -blind placebo NDPI  during Run- In will be assessed at 
Visit 2 by  reviewing the dose counter on the NDPI.
Subject co mpliance with double -blind study  medication will be assessed at each 
treatment visit (from Visits 3 - Visit 14) and an y unscheduled visit where study drug is 
returned b y reviewing the dose counter on the NDPI.  Subjects must be ≥ 80% to ≤120% 
compliant on t aking study  medication between each pair of on -treatment visits.  Subjects 
who fall outside this range should be re- educated on treatment compliance by  their site. 
This re -education should be documented in the subject’s source document.  If the double-
blind study  medication is prematurel y discontinued during the course of study or 
medication compliance repeatedl y falls outside of acceptable ranges, the study  
sponsor/site monitor must be contacted to discuss subject eligibility  for continued 
participation in the study .
5.6. Concomitant Medications and Non -Drug Therapies
All COPD medications taken within 30 day s prior to Visit 0 and during the run -in period 
will be recorded in the eCRF.  All COPD and non-COPD concomitant medications taken 
during the stud y will be r ecorded in the eCRF.  The minimum requirement includes, but 
is not limited to name of the medications, and the dates of the administration.
Note: Care is advised when co -administering with strong CYP 3A4 inhibitors (e.g. 
ketoconazole, ritonavir) as there i s potential for an increased sy stemic exposure to both 
fluticasone furoate and vilanterol, which could lead to an increase in the potential for 
adverse reactions.
5.6.1. Permitted Medications and Non -Drug Therapies
The following medications are permitted during t he Screening and Treatment periods:
COPD Medications
Study  supplied albuterol/salbutamol (MDI or nebules) for s ymptomatic relief during 
the Run- In and Double -Blind Treatment period
Mucoly tics 
Oxygen for intermittent use or PRN therap y ≤ 12 hours per day  is allowed. (Subjects 
requiring LTOT or nocturnal oxy gen therap y required for greater than 12 hours a day 
are excluded from the study .) 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
26Theophy llines (long and short -acting)
Short -acting anti -cholinergic agents
Long -acting an ti-cholinergic agents
Short -acting beta2 -agonists; i.e. albuterol
Beta2 -agonist -anti-cholinergic combinations; i.e. Combivent
Subjects may  take courses of sy stemic corticosteroids, where necessary , for treatment 
of an exacerbation.
Non-COPD Medications
Cardioselective beta -blockers (stable dose) and ophthalmic beta -blockers. 
(Administer with caution as they  may  block bronchodilatory  effects of beta- agonists 
and produce severe bronchospasm).
Care is advised when co- administering with strong CYP 3A4 inhibitor s (e.g. 
ketoconazole, ritonavir) as there is potential for an increased sy stemic exposure to 
both fluticasone furoate and vilanterol, which could lead to an increase in the 
potential for adverse reactions.
Antihistamines and nasal decongestants
Over -the-counter (OTC) cough suppressants (for short term treatment ≤7day s)
Intranasal sodium cromogl ycate or nedocromil sodium
Intranasal corticosteroids, provided the subject is on a stable dail y dose for at least 4 
weeks prior to Visit 1 and remains on this dose thr oughout the stud y
Topical ( ≤1 % h ydrocortisone in strength) or ophthalmic corticosteroids
Influenza and/or pneumonia vaccination
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effects of beta -agonists on the vascular 
system.
Diuretics. Caution is advised in the co -administration of beta -agonists with 
nonpotassium sparing diuretics.
Treatment(s) for smoking cessation
All medications for other disorders as long as the dose remains constan t wherever 
possible.
5.6.2. Prohibited Medications and Non- Drug Therapies
Medications prohibited at specific time intervals prior to Screening Visit 1 and at any  
time during the stud
y are identified in Section 4.3Exclusion Criteria.
If a subject’s current medication is going to be changed in order to participate in the 
study , then consent must be obtained prior to an y medication change and the subject will  2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
27be required to return to the clinic to complete the Screening V isit 1 once the protocol 
specified time period has been completed.
5.7. Treatment after the End of the Study
At the end of the treatment period (Visit 14 or Early  Withdrawal), subjects can resume 
conventional COPD therapy  as prescribed by  the Investigator.  The re are no plans to 
provide the study  drug for compassionate use following study  completion.
The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the patient’s medical condition whether or not GSK is provi ding specific 
post study  treatment.
5.8. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than what is instructed (see Section 5.1), which 
results in clinical signs and sy mptoms.  In the event of an overdose of study  medication, 
the investigator should use clinical judgement in treating the overdose and contact the 
study  medical monitor.  GSK is not recommending specific treatment guidelines for 
overdose and toxicity  management.  The inve stigator should refer to the relevant 
document(s) for detailed information regarding warnings, precautions, contraindications, 
adverse events, and other significant data pertaining to the stud y drug(s) being used in 
this study .  Such documents may  include, but not be limited to, the approved product 
labeling for albuterol (salbutamol), and the IB or equivalent document provided by  GSK 
for double blind medications.
6. STUDY A SSESSMENTS A ND PROCEDURES
The Time and Events Table is provided in Table 3.  All study  assessments should be 
conducted b y the investigator or his/her qualified designee.  Please refer to the SPM for a 
suggested order of assessments. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
28Table 3 Time and Events Table
Double -Blind Treatment period
Visit Number0
Pre-
screen11
Screen -
ing22
Random -
ization3 4 5 6 7 8 9 10 11 12 13 14
Early 
With -
draw15
Follow
-up
Day 113 
wks 
1426 
wks 
1439 
wks 
1452 
wks 
1465 
wks 
1478 
wks 
1491 
wks 
14104 
wks 
14117 
wks 
14130 
wks 
14143 
wks 
14156 
wks 
14Visit 
14/EW 
+ 7±2
Days Days Days Days Days Days Days Days Days Days Days Days Days
Assessments
Informed consent3 X
PGx Consent & 
Sampling4X
Demography X
Medical History X
Physical Exam X X X X X
Spirometry Testing X X X X X X X X X
Reversibility Testing X
Smoking history/ 
smoking statusX X X X X X X X X X X X X X X
Smoking cessation 
counse ling X X X X X
Register visit on 
IVRS5X X X X X X X X X X X X X X X X X
Safety Assessments
BMD DEXA scans6 X X X X X X X X
Oropharyngeal 
examination7X X X X X X X X X X X X X X X
Chest X -ray8 X
Lab Tests9/ Serum 
Pregnancy Test10X 
 
 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
29Double -Blind Treatment period
Visit Number0
Pre-
screen11
Screen -
ing22
Random -
ization3 4 5 6 7 8 9 10 11 12 13 14
Early 
With -
draw15
Follow
-up
Day 113 
wks 
1426 
wks 
1439 
wks 
1452 
wks 
1465 
wks 
1478 
wks 
1491 
wks 
14104 
wks 
14117 
wks 
14130 
wks 
14143 
wks 
14156 
wks 
14Visit 
14/EW 
+ 7±2
Days Days Days Days Days Days Days Days Days Days Days Days Days
12-lead ECG & 
Rhythm StripX
Exacerbation 
AssessmentX X X X X X X X X X X X X X X X
Adverse Event 
Assessment11X X X X X X X X X X X X X X X
Serious Adverse 
Event Assessment12X X X X X X X X X X X X X X X X X
Dispense Diary X X X X X X X X X X X X X
Collect/Review Diary X X X X X X X X X X X X X X
Medication 
Assessments
Concurrent 
Medication 
Assessment13X X X X X X X X X X X X X X X X X
Dispense a lbuterol 
(salbutamol)14X X X X X X X X X X X X X
Collect albuterol 
(salbutamol)14X X X X X X X X X X X X X X
Dispense Single -Blind 
MedicationX
Dispense Double -
Blind MedicationX X X X X X X X X X X X
Collect Blinded 
Medic ationX X X X X X X X X X X X X X
Other Assessment  
 
 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
30Double -Blind Treatment period
Visit Number0
Pre-
screen11
Screen -
ing22
Random -
ization3 4 5 6 7 8 9 10 11 12 13 14
Early 
With -
draw15
Follow
-up
Day 113 
wks 
1426 
wks 
1439 
wks 
1452 
wks 
1465 
wks 
1478 
wks 
1491 
wks 
14104 
wks 
14117 
wks 
14130 
wks 
14143 
wks 
14156 
wks 
14Visit 
14/EW 
+ 7±2
Days Days Days Days Days Days Days Days Days Days Days Days Days
Discharge from 
Study15X X
1. Visit 0 and Visit 1 may occur on the same day if the subject does not take or has not taken any protocol excluded medications .
2. Following S creening Visit 1 , subjects enter a 14 to 21 day single -blind run- in period .
3. Subjects will be assigned a subject number at the time ICF is signed. The ICF must be signed before any study procedures incl uding medication exclusion period(s) .  
4. Saliva (2ml) sa mple is collected in the DNA self -collection kit.  This should ideally be taken as soon after randomization (Visit 2) as possible, but may be taken at any othe r visit 
after randomization if necessary.  PGx consent must be signed prior to PGx sampling.
5. A telephone based IVRS system (RAMOS) which will be used by the investigator or designate to register the subject, randomize the subject and provide medication assignment 
information.
6. Baseline BMD measurements will be collected between Visit 1 and Visit 2 .
7. If evidence of infection, culture swab may be taken and appropriate therapy should be instituted at Investigator discretion.  Su bjects with culture -positive infection may continue 
in the study on appropriate anti -infective treatment at Investigator discretion .
8. Chest X -ray must be taken if a Chest X -ray or CT scan is not available within the 12 months preceding Visit 1 . Chest x- rays will be requested for suspected cases of pneumonia.
9. Non-fasting and pre -dose. A blood sample for repeat analysis is collected only if any part of Screening lab needs to be repeated. Results of repeat labs should be received prior 
to Randomization at Visit 2.
10. Females of child -bearing potential only
11. Adverse events are to be collected from the start of blinded study medication (Visit 2) until the follow -up phone contact.
12. Serious adverse events are to be collected from the start of study drug (Visit 2) until the follow -up phone contact.  However, any SAEs assessed as related to study participation 
will be recorded from the time subjects s ign informed consent.
13. All COPD medications taken within 30 days prior to Visit 0 will be collected.
14. Collect and re -dispense as needed after Visit 1 .
15. Discharge from study on appropriate therapy. 
 
 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
316.1. Critical Baseline A ssessments
No study related procedures m ay be performed until the informed consent form 
document has been signed by the subject.  A pre -screening visit (Visit 0) may be 
required in order to administer the informed consent before any  changes are made to the 
subject’s current medication regimen. S election and modification of subject’s 
medications prior to study participation is based on the phy sician’s judgment according to 
sound medical practice, principles, and each subject’s needs. A subject‘s treatment must 
not be changed merel y for the purpose of enabling the subject’s participation in the study . 
The pre -screening visit and screening visit may  occur on the same day  if the subject does 
not take or has not taken any  protocol excluded medications. During the pre -screening 
visit, each subject will have the following demographic information collected:
Demographic history  (including gender, ethnic origin, date of birth)
During Screening Visit 1, each subject will undergo the following assessments :
Medical history  (including COPD and smoking history )
Cardiovascular medical history /risk factors will be assessed at baseline.
Inclusion/Exclusion criteria assessment
Concomitant medication review
ECG and rh ythm strip
Spirometry  with reversibility  testing
Physical exam (including vital signs)
Laboratory  assessments (including chemistry , hematology , hepatitis, and pregnancy )
See Section 4.5for information regarding Screening Failures. 
6.2. Safet y
6.2.1. Primary  Endpoint
BMD measured at the total hip 
6.2.2. Secondary  Endpoints
BMD me asured at the lumbar spine (L1- L4)
BMD measurements b y gender
6.2.3. Other Endpoints
Adverse Event reporting 
Serious Adverse Event reporting 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
32Incidence of fractures
Incidence of pneumonias
COPD exacerbations
6.2.4. Bone Mineral Density
Effects on the skeletal s ystem wi ll be assessed b y measuring bone mineral density  
(BMD) using dual energy x -ray absorptiometry  (DEXA) with established methodology .  
DEXA measurements of the total hip and the L 1-L4regions of the spine will be 
completed at baseline, 26 weeks, 52 weeks, 78 weeks, 104 weeks, 130 weeks, and 156 
weeks or end of stud y treatment.
All DEXA scans will be conducted by qualified technicians and sent electronically for 
centralized anal ysis.  Quality  assurance and calibration of DEXA equipment and 
densitometric measure ments will be monitored by this facility  to control for site -to-site 
variability  in BMD measurements.
Acceptable DEXA measurements must be conducted prior to the first dose of 
randomized study medication.
Subjects with DEXA results meeting pre -defined crit eria for clinicall y significant bone 
mineral density  loss from the Screening scan or any  visit scan after randomization will be 
counseled about the clinical implications of the scan results.
6.2.5. Fractures
For an y fractures that occur after the initiation of the double -blind study  drug, the 
location of the fracture, and whether it is considered traumatic or non -traumatic must be 
recorded on the Fractures page of the eCRF. Severity  of a fracture should be determined 
by the Investigator.  Details regarding the inf ormation to be captured for fractures will be 
provided in the SPM.
6.2.6. COPD Exacerbations and Pneumonias
For the purpose of this study , exacerbation of COPD is defined by a worsening of 
symptoms requiring additional treatment as follows:
•A mild COPD exacerbation: managed b y subject with increased use of prn 
medications
•A moderate COPD exacerbation: requires treatment with antibiotics and/or 
systemic corticosteroids
• A severe COPD exacerbation: requires hospitalization 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
33Any subject experiencing worsening of s ymptoms should:
•Contact his/her study  investigator and/or research coordinator immediatel y, and 
report to the study  clinic as required
•If the subject is unable to contact his/her stud y investigator and/or research 
coordinator, they  should contact their primary  care phy sician (or other health care 
practitioner as required) and contact their stud y site as soon as possible
•If the subject seeks emergent/acute care for worsening respiratory  symptoms, 
he/she should inform the caring Health Care Provider (HCP) to conta ct the 
investigator as soon as possible.
Subjects with presence of worsening respiratory  symptoms will be classified by  the 
Investigator as having:
•
A mild/moderate/severe COPD exacerbation and/or pneumonia
OR
•A lower respiratory  tract infection (LRTI) [i.e . other than pneumonia]
•Background variability  of COPD
•A non- respiratory  related disease
•Other respiratory  related disease
The time period for collection of COPD exacerbations will begin from the time of Visit 2 
(Randomization) and will end when the 7±2day Follow -up period has been completed.
COPD exacerbations should not be recorded as an adverse event, unless they meet the 
definition of a Serious Adverse Event.  For the purposes of this study , COPD 
exacerbations will be collected and recorded on the exace rbation log in the eCRF.  
Exacerbations that meet the definition of an SAE, will be recorded on the appropriate 
eCRF section and should be reported to GSK for all subjects regardless of whether or not 
they are randomized to blinded study  medication.
Subjec ts are excluded from participating if any  of the following appl y:
•They  have poorly  controlled COPD, defined as the occurrence of the following in 
the 12 weeks prior to Screening Visit 1: Acute worsening of COPD that is 
managed b y the subject with corticost eroids or antibiotics or that requires 
treatment prescribed b y a phy sician or requires hospitalization.
•They  have 2 or more moderate or severe COPD exacerbations and/or a lower 
respiratory  tract infection (including pneumonia) within the 12 months prior to
Screening Visit 1 or experience a moderate or severe COPD exacerbation and/or a 
lower respiratory  infection (including pneumonia) during the Run- In period. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
34The dates of onset and resolution of each COPD exacerbation should be based on when 
the Investigato r and/or subject determines that the COPD sy mptoms initially  started and 
then returned to pre -exacerbation levels.
If an exacerbation begins as mild, but becomes moderate or severe or begins as moderate 
and becomes severe, the exacerbation should be captur ed as one exacerbation and 
classified b y its highest level of severity.
For the purpose of this study , pneumonia is defined as new auscultatory  findings 
compatible with parenchy mal lung infection and/or radiographic evidence of 
parench ymal/air space disease. All suspected cases of pneumonia are encouraged to be 
confirmed radiographically  within 48 hours of diagnosis. All diagnoses of pneumonia 
(radiographicall y confirmed or unconfirmed) must be reported as an AE or SAE (if 
applicable). Information regarding chest X -ray-confirmed cases of pneumonia will be 
recorded in the eCRF. Details regarding the information to be captured for pneumonias 
will be provided in the SPM.
If, based upon these criteria, a subject’s s ymptoms do not fulfill the diagnosis of an 
exacerbation and/or pneumonia, then the investigator should use his/her clinical judgment 
to assess the subject’s s
ymptoms (including increased volume of sputum production 
and/or change in the sputum color) for a diagnosis of L RTI (e.g. acute bronchitis), 
back ground variability of COPD, a non -respiratory related disease or other respiratory  
related disease.
Investigator judgment should be used in deciding whether to report the signs and 
symptoms (and/or determined diagnosis) as an AE/SAE in the eCRF. Medication (s) used 
to treat a COPD exacerbation and/or pneumonia are to be recorded in the eCRF.
6.2.7. Liver chemistry  stopping and follow up criteria
Phase III -IVliver chemistry stopping and follow up criteria have been designed to 
assure subject safet y and evaluate liv er event etiology  (in alignment with the FDA 
premarketing clinical liver safety  guidance).  
Phase III -IV liver chemistry  stopping criteria 1- 5 are defined below and in Appendix 4 :
1. AL T 3xULN andbilirubin 2xUL N (>35% direct bilirubin) (or ALT 3xULN and
INR>1.5, if INR measured)
NOTE: if serum bilirubin fractionation is not immediatel y available, withdraw study drug 
for that subject if ALT 3xULN and bilirubin 2xULN. Serum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectable urinary bilirubin on dipstick , indicating direct bilirubin elevations and 
suggesting liver injury .
2. AL T 8xULN.
3. AL T 5xULN but <8 xULN persists for 2 weeks 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
354.ALT   3xULN if associated with sy mptoms (new or worsening) believed to be related 
to  hepatitis (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, 
or jaundice) or h ypersensitivity  (such as fever, rash or eosinophilia).
5. AL T 5xULN but <8 xULN and cannot be monitored weekl y for 2 weeks
When any of the liver chemistry stopping criteria 1- 5 is met, do the following:
Immediately withdraw investigational product for that subject
Report the event to GSK within 24 hours of learning its occurrence
Complete the liver event CRF and SAE data collection tool if the event also meets 
the criteria for an SAE. All events of ALT 3xULN andbilirubin 2xULN (>35% 
direct) (or ALT 3xULN and INR>1.5, if INR measured); INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants), termed ‘Hy ’s Law’, must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) . 
NOTE: if serum bilirubin fractionation is not immediatel y ava ilable, withdraw study  drug 
for that subject if ALT 3xULN andbilirubin 2xULN. Serum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectable urinary bilirubin on dipstick , indicating direct bilirubin elevations and 
suggesting liver injury .
Complete the liver imaging and/or liver biopsy  CRFs if these tests are performed
Perform liver event follow up assessments, and monitor the subject until liver 
chemistries resolve, stabilize, or ret urn to baseline values as described below. 
Withdraw the subject from the study  after completion of the liver chemistry 
monitoring (unless further safet y follow up is required).
Do not restart investigational product.  
In addition, for criterion 1:
Make e very reasonable attempt to have subjects return to clinic within 24 hours for 
repeat liver chemistries, liver event follow up assessments (see below), and close 
monitoring
A specialist or hepatology consultation is recommended
Monitor subjects twice weekl y until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values
For criteria 2, 3, 4 and 5:
Make every  reasonable attempt to have subjects return to clinic within 24-72 hrs for 
repeat liver chemis tries and liver event follow up assessments (see below)
Monitor subjects weekl y until liver chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) resolve, stabilize or return to within baseline values; criterion 5 subjects 
should be monitored as frequent ly as possible. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
36Subjects with AL T 5xULN and <8xULN which exhibit a decrease to ALT x 3xULN, 
but <5xUL N and bilirubin <2xULN without hepatitis sy mptoms or rash, and who can be 
monitored weekl y for 4 weeks:
Notify  the GSK medical monitor within 24 hours of learning of the abnormality  to 
discuss subject safet y
Can continue investigational product 
Must return weekl y for repeat liver chemistries (AL T, AST, alkaline phosphatase, 
bilirubin) until they  resolve, stabilize or return to within baseline 
If at an y time these subjects meet the liver chemistry  stopping criteria, proceed as 
described above
If, after 4 weeks of monitoring, ALT <3xUL N and bilirubin <2xUL N, monitor 
subjects twice monthly  until liver chemistries normalize or return to within baseline 
values.
For criteria 1 -5, make every  attempt to carry  out the liver event follow up assessments
described below:
Viral hepatitis serology  including:
Hepatitis A IgM antibody;
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM); 
Hepatitis C RNA; 
Cytomegalovirus IgM antibody
;  
Epstein- Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibod y or monospot testing);  
Hepatitis E IgM antibody 
Blood sample for PK analy sis, obtained within 72 hours of last dose.  Record the 
date/time of the PK blood sample draw and the date/time of the last dose of 
investigational product prior to blood sample draw on the CRF. If the date or time of 
the last dose is unclear, provide the subject’s best approximation. I f the date/time of 
the las
t dose cannot be approximated OR a PK sample cannot be collected in the 
time period indicated above, do not obtain a PK sample. I nstructions for sample 
handling and shipping are in the SPM. 
Serum creatine phosphokinase (CPK) and lactate dehy drogenase (LDH ).
Fractionate bilirubin, if total bilirubin 2xUL N.
Obtain complete blood count with differential to assess eosinophilia.
Record the appearance or worsening of clinical s ymptoms of hepatitis or 
hypersensitivity , such as fatigue, nausea, vomiting, right up per quadrant pain or 
tenderness, fever rash or eosinophilia as relevant on the AE report form. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
37Record use of concomitant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins, on the concomitant medicatio ns 
report form.
Record alcohol use on the liver event alcohol intake case report form.
The following are required for subjects with ALT 3xUL N and bilirubin  2xULN (>35% 
direct) but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti-smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies.
Serum acetaminophen adduct HPL C assay  (quantifies potential acetaminophen 
contribution to liver injury  in subjects with definite or likely acetaminophen use in 
the preceding w eek [ James, 2009]). NOTE: not required in China.
Only  in those with underly ing chronic hepatitis B at study  entry  (identified by  
positive hepatitis B surface antigen):  quantitative hepatitis B DNA and hepatitis 
delta antibody .  NOTE :  if hepatitis delta antibody assay  cannot be performed,, it can 
be replaced with a PCR of hepatitis D RNA virus (where needed) –as outlined in: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1153793/.
Liver imaging (ultrasound, magnetic res onance, or computerized tomography ) to 
evaluate liver disease.
6.2.8. Adverse Events
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
AEs will be collected from the start of double -blind I nvestigational Product and until the 
follow up contact.  
COPD exacerbations should not be recorded as an adverse event, unless they meet the 
definition of a Serious Adverse Event.  For the purposes of this study , COPD 
exacerbations will b e collected and recorded on the COPD exacerbation log in the eCRF.  
The time period for collection of COPD exacerbations will begin from the time of Visit 2 
(Randomization) and will end when the 7 -day Follow -
up period has been completed.
The investigators and site staff should remain vigilant for the possible development of 
pneumonia in patients with COPD as the clinical features of such infections overlap with 
the sy mptoms of COPD exacerbations. Risk factors for pneumonia in patients with 
COPD receiving fl uticasone furoate/vilanterol include current smokers, patients with a 
history  of prior pneumonia, patients with a body  mass index <25 kg/m2and patients with 
an FEV 1<50% predicted.  For all suspected cases of pneumonia, Investigators are 
encouraged to conf irm the diagnosis (this includes obtaining a chest x -ray) and to initiate 
appropriate therap y as promptly  as possible. All diagnoses of pneumonia 
(radiographicall y confirmed or unconfirmed) must be reported as an AE or SAE (if 
applicable).
All AEs and SAEs will be followed until resolution, until the condition stabilizes, until 
the event is otherwise explained, or until the subject is lost to follow- up.  Once resolved,  2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
38the appropriate AE/SAE CRF page will be updated.  The investigator will ensure that 
follow- up includes an y supplemental investigations as may  be indicated to elucidate the 
nature and/or causalit y of the AE or SAE.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care 
professionals.
6.2.8.1. Definition of an AE
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can t herefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits (i.e., lack of efficacy ), abuse or misuse.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the conditio n
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae .
“Lack of efficacy ” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. However, the signs and sy mptoms and/or clinical sequelae 
resulting from lack of efficacy  will be reported if they  fulfil the defini tion of an AE or 
SAE.  
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital)
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen
The disease/disorder being studied, or expected progression , signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
396.2.8.2. Definition of a SA E
A serious adverse event is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE:  The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospitalization or prolongation of existing hospitalization
NOTE:  In general, hospitalization signifies that the subject has been detained 
(usually  involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or tre atment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfills any  other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disabi lity/incapacity , or
NOTE:  The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated hea dache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect
f.Medical or scientific judg ement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize 
the subject or may  require me dical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.  Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home fo r allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
g.All events of possible drug -induced liver injury  with hy perbilirubinaemia defined as 
ALT 3xULN andbilirubin 2xUL N (>35% direct) (or ALT 3xUL N and 
INR>1.5, if INR measured) termed ‘Hy ’s Law’ events ( INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants). 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
40NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record presence of detectable urinary  bilirubin on dipstick indicating 
direct bilirubin elevations and suggesting liver injury . If testing is unavailable and a 
subject meets the criterion of total bilirubin 2xULN, then the event is still reported 
as an SAE. If INR is obtained, include values on the SAE form. INR elevations >1.5 
suggest severe liver injury .   
6.2.9. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as A Es and SA Es
Any abnormal labora tory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that worsen from baseline, and felt to be clinically  significant in the 
medical and sc ientific judgement of the investigator are to be recorded as AEs or SAEs. 
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by  the investigator to be more severe than expected for 
the subj ect’s condition, are notto be reported as AEs or SAEs.
6.2.10. Cardiovascular Events
Investigators will be required to fill out event specific data collection tools for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrhythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularization
This information should be recorded within one week of when the AE/SAE(s) are first 
reported. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
416.2.11. Death Events
In addition, all deaths, whether or not they  are considered SAEs, will require a specific 
death data collection tool to be completed.  The death data collection tool includes 
questions regarding cardiovascular (including sudde n cardiac death) and 
noncardiovascular death.
This information should be recorded within one week of when the death is first reported.
6.2.12. Pregnancy
Any pregnancy  that occurs during stud y participation must be reported using a clinical 
trial pregnancy  form.  T o ensure subject safet y, each pregnancy  must be reported to GSK 
within 2 weeks of learning of its occurrence.  The pregnancy  must be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE.
Any SAE occurring in association with a pregnancy , brought to the investigator’s 
attention after the subject has completed t he stud y and considered b y the investigator as 
possibly  related to the study  treatment, must be promptly  reported to GSK.
6.2.13. Time Period and Frequency  of Detecting AEs and SA Es
The investigator or site staff is responsible for detecting, documenting and repor ting 
events that meet the definition of an AE or SAE.
AEs will be collected from the start of study  treatment and until the follow up contact.  
SAEs will be collected over the same time period as stated above for AEs. However, any  
SAEs assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a GSK concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact. All SAEs will be reported to GSK within 24 
hours, as indicated in Section 6.2.14. 
6.2.14. Prompt Reporting of Serious A dverse Events and Other Events 
to GSK
SAEs, pregnancies, and live r function abnormalities meeting pre -defined criteria will be 
reported promptl y by the investigator to GSK as described in the following table once the 
investigator determines that the event meets the protocol definition for that event. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
42Initial Reports Follow-up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool
“CV events” 
and/or “death” 
data collection 
tool(s) if 
applicable24 hours Updated “SAE” 
data collection tool
“CV events” and/or 
“death” data 
collection tool(s) if 
applicable
Pregnancy 2 weeks “Pregnancy 
Notification Form”2 weeks “Pregnancy Follow -
up Form”
Non-serious adverse 
events related to 
study treatment5 calendar 
days“Adverse 
Reaction” data 
collection to ol2 weeks Updated “Adverse 
Reaction” data 
collection tool
Liver chemistry abnormalities for Phase I to IV:
ALT3xULN and
Bilirubin 2xULN 
(>35% direct) (or 
ALT3xULN and
INR>1.5, if INR 
measured)124 hours2 “SAE” data 
collection tool.  
“Liver Event CRF” 
and “Liver 
Imaging” and/or 
“Liver Biopsy” 
CRFs, if 
applicable324 hours Updated “SAE” 
data collection 
tool/“Liver Event” 
Documents3
Remaining liver chemistry abnormalities Phase III to IV:
ALT8xULN; 
ALT3xULN with 
hepatitis or rash or 
3xULN and <5xULN 
that persists 4 weeks24 hours2 “Liver Event” 
Documents 
(defined above)324 hours Updated “Liver 
Event” Documents3
ALT5xULN plus 
bilirubin <2xULN24 hours2 “Liver Event” 
Documents 
(defined above) 
do not need 
completing unless 
elevations persist 
for 2 we eks or 
subject cannot be 
monitored weekly 
for 2 weeks324 hours Updated “Liver 
Event” Documents, 
if applicable3
ALT5xULN and 
bilirubin <2xULN that 
persists 2 weeks24 hours2 “Liver Event” 
Documents 
(defined above) 324 hours Updated “Liver 
Event” Docume nts3 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
43ALT3xULN and <5x 
ULN and bilirubin 
<2xULN24 hours2 “Liver Event” 
Documents 
(defined above) 
do not need 
completing unless 
elevations persist 
for 4 weeks or 
subject cannot be 
monitored weekly 
for 4 weeks324 hours Updated “Liver 
Event” Documents, 
if applicable3
1. INR measurement is not required; if measured, the threshold value stated will not apply to patients receiving 
anticoagulants.
2. GSK must be contacted at onset of liver chemistry elevations to discuss subject safety
3. Liver Event Documents (i.e., “ Liver Event CRF” and “Liver Imaging CRF” and/or “Liver Biopsy CRF”, as 
applicable) should be completed as soon as possible.
The method of detecting, recording, evaluating and follow- up of AEs and SAEs plus 
procedures for completing and transmitting SAE re ports to GSK are provided in the 
SPM.  Procedures for post- study  AEs/SAEs are provided in the SPM.
6.2.14.1. Regulatory  reporting requirements for SA Es
Prompt notification of SAEs by  the investigator to GSK is essential so that legal 
obligations and ethical responsi bilities towards the safet y of subjects are met.
GSK has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  GSK will 
comply  with country  specific r egulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reacti ons according to local regulatory  requirements and GSK policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
6.2.15. Spirometry Testing
Lung function will be measured b y spirometry at Visits 1, 2, 4, 6, 8, 10, 12, and 14, or at 
Early Withdrawal using site a vailable spirometry  equipment that meets or exceeds the 
minimum performance recommendations of the ATS/ERS [ Miller , 2005].  For Visits 2 
onward, FEV 1 will be measured prior to administration of morning stud y medicatio n. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
44For each observation, at least 3 valid (with no more than 8) efforts will be obtained using 
ATS/ERS guidelines.  The largest FEV 1and FVC from the 3 acceptable efforts should be 
recorded, even if they  do not come from the same effort.  Acceptable spirom etry efforts 
should have a satisfactory  start of test and end of test (i.e. a plateau in the volume -time 
curve) and be free from artifacts due to cough, early termination, poor effort, obstructed 
mouthpiece, equipment malfunction, or other reasons [ Miller , 2005].  The subject’s 
position during spirometry measurements (sitting or standing) should remain constant for 
the duration of the stud y.
A post -albuterol (salbutamol) FEV 1/FVC ratio of < 0.70 and predicted normal va lue of 
50% ≤ FEV 1 ≤ 70% is required at Screening Visit 1.  
All predicted values will be taken from Hankinson [ Hankinson, 1999].
The investigator will retain a printed cop y of the spirometry data in the subject’s s ource 
documents.
6.2.15.1. Reversibility  Testing
At Visit 1, reversibility  to albuterol (salbutamol) will be assessed.  To determine 
reversibility , the subject will self -administer 4 puffs (360mcg) of albuterol (salbutamol) 
without the use of a spacer or holding cha mber.  Triplicate spirometry  efforts will be 
performed immediately  pre-albuterol (salbutamol) and within 30 minutes post -albuterol 
(salbutamol).  The highest FEV 1from three valid forced expiratory  curves will be used to 
determine reversibility .
Reversibil ity is defined as an increase in FEV 1of ≥12% and ≥200mL  following 
administration of albuterol (salbutamol).  Non- reversible is defined as a post -albuterol 
(salbutamol) increase in FEV 1of <200mL or a ≥200mL  increase that is <12% from pre -
albuterol (salbut amol) FEV 1.
6.2.16. Laboratory  Assessments
Routine, non-fasting clinical laboratory (hematology  and biochemistry ), will be 
performed in all subjects at the Screening Visit 1.  
For women of childbearing potential, a serum pregnancy  test will be included in the 
laboratory  panel collected at Visit 1 if applicable.  
At the discretion of the investigator, additional samples may be taken for safet y reasons.  
If the subject has an abnormal laboratory  finding for any  anal yte from the Screening Visit 
laboratory  panel, whi ch in the opinion of the Investigator does not preclude the subject 
from participating in the study , but for which the Investigator feels warrants 
treatment/correction with a non- excluded medication(s) (e.g., calcium supplement for 
hypocalcemia), a blood s ample for repeat anal ysis of the anal yte(s) should be collected 
prior to Visit 2 (Randomization). Results of repeat Screening labs should be received 
prior to Randomization at Visit 2. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
45All protocol required laboratory  assessments, as defined in Appendix 1 must be 
performed b y the central laboratory . Laboratory  assessments must be conducted in 
accordance with the Central Laboratory  Manual and Protocol Time and Events Schedule.
Laboratory  requisition forms must be comple ted and samples must be clearly  labelled 
with the subject number, protocol number, site/center number, and visit date. Details for 
the preparation and shipment of samples will be provided b y the central laboratory. 
Reference ranges for all safet y paramete rs will be provided to the site by  the central 
laboratory .
6.2.17. Orophary ngeal Examination
Orophary ngeal examinations for clinical evidence of infection (i.e., Candida albicans) 
will be performed at each study  visit as shown in the Time and Events Table. If th ere is 
evidence of infection, a culture swab may  be taken and appropriate therapy  should be 
instituted at the discretion of the Investigator. Subjects with culture -positive infection 
may continue in the study  on appropriate anti -infective treatment at the discretion of the 
Investigator. The results of these assessments, and any  relative pharmacotherapy , will be 
recorded in the subject’s clinic notes and in the eCRF. After randomization, all culture 
positive results must be reported as adverse events.
6.2.18. Diary  Card -Medical Problems/Medications Taken
Subjects will be instructed to record an y medical problems they may have experienced 
and an y medications used to treat those medical problems in their diaries from Screening 
(Visit 1) through the Follow -up Phone Contact.  
Subjects will be instructed on how to complete the diary and will be asked to return 
completed diaries at each clinic visit.  The study  coordinator must review the diary  at 
each clinic visit and will inquire about the diary  data during the Follow- up Phone Contact 
as well.  If the subject does not mention an event which is recorded on the diary , he/she 
should be questioned for further information in order to determine if there was the 
occurrence of an AE.  Any  confirmed AE and/or concurrent medicati on will be entered 
into the eCRF.
6.2.19. 12-lead ECG A ssessment
A single 12 -lead ECG and rhy thm strip will be recorded prior to spirometry at the 
Screening Visit 1.
All ECG measurements will be performed with the subject resting in a supine position for 
approxima tely 5 minutes before each reading, which should be carried out after 
measurement of vital signs and before spirometry .
The investigator, a designated sub -
investigator, or other appropriatel y trained site 
personnel, will be responsible for performing the 12- lead ECG recording on each stud y 
visit, if applicable.  The investigator must provide his/her dated signature on the original 
paper tracing, attesting to the authenticity  of the ECG machine interpretation. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
466.2.20. Smoking Cessation Counselling
During the Screeni ng Visit 1, 6, 10, and 14 or EW visit (if necessary ), subjects will be 
given smoking cessation counselling, which includes advice regarding the following:
the health effects that smoking may  cause.
the health benefits that may  result if they  stop smoking.
if they  do not feel capable of discontinuing smoking that their primary  care phy sician 
may be able to discuss anti -smoking strategies with them. 
that they  may  discontinue smoking at any  time during the study  and will not have to 
be withdrawn from the stud y if they do so.  
6.3. Pharmacogenetic Research
Information regarding pharmacogenetic research is included in Appendix 2 .  The 
IEC/IRB and, where required, the applicable regulatory  agency  must approve the PGx 
assessments before these can be conducted at the site.  The approval(s) must be in writing 
and will clearl y specify  approval of the PGx assessments.  I n some cases, approval of the 
PGx assessments can occur after approval is obtained for the rest of the study .  If so, then 
the written approval will clearl y indicate approval of the PGx assessments is being 
deferred and the study , except for PGx assessments, can be initiated.  When PGx 
assessments will not be approved, then the approval for the rest of the study  will cle arly 
indicate this and therefore, PGx assessments will not be conducted. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
477. DATA MANAG EMENT
For this study  subject data will be entered into GSK defined eCRFs, transmitted 
electronically  to GSK and combined with data (e.g. laboratory  data, diary  data) provided 
from other sources in a validated data s ystem.
Management of clinical data will be performed in accordance with applicable GSK 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using MedDRA and an internal validated medication dictionary , 
GSKDrug.  An appropriate medical dictionary  that covers all approved drugs in the 
region will be referenced.  eCRFs (including queries and audit trails) will be retained by  
GSK, and copies will be sent to the investigator to maintain as the investigator copy. In 
all cases, subject initials will not be collected or transmitted to GSK according to GSK 
policy .
8. DATA ANALYSIS AND STA TISTICAL CONSIDERA TIONS
8.1. Hypotheses
The null hy pothesis for the primary  measure is that the change in BMD assessed at the 
total hip is worse for the FF/VI combination product arm compared with the VI arm. The 
alternative h ypothesis that the change in BMD ass essed at the total hip is not worse for 
the FF/VI arm compared with the VI arm.
This is also the null and alternative h ypothesis for the secondary measure of BMD 
assessed at the L1 -L4 lumbar spine.
8.2. Stud y Design Considerations
8.2.1. Sample Size A ssumptions
This study  will evaluate non -inferiority in both males and females separately as key 
secondary  measures.  56 subjects per gender per treatment would provide 80% power to 
demonstrate non -inferiority  by comparing the lower boundary  of a two- sided 95% 
confidence in terval on the treatment difference to -1%/y ear assuming a true treatment 
difference of -0.3%/ year.  In study  SCO40041, approximately  20% of subjects did not 
provide post -baseline data, therefore 70 subjects per gender per treatment will be 
randomized (280 total subjects).  Randomization will be stratified by  gender.
For the primary  evaluation of BMD for the total hip, males and females will be 
combined, and will have >90% power to demonstrate non- inferiority  by comparing the 
lower boundary  of a two- sided 95% confidence interval on the treatment difference to      
-1%/y ear assuming a true treatment difference of - 0.3%/y ear. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
488.2.2. Sample Size Sensitivity
The following table presents the power of the study  under different circumstances in 
terms of the standard deviat ion and the observed treatment difference in change from 
baseline in bone mineral density  for the total hip.
True Treatment Difference between FF/VI and VI
SD -0.2%/yr -0.3%/yr -0.4%/yr
1.3%/yr >99% 99% 96%
1.4%/yr >99% 98% 94%
1.5%/yr >99% 97% 91%
8.2.3. Sample Size Re -estimation
No sample size re -estimation is planned for this study .
8.3. Data Analysis Considerations
8.3.1. Analysis Populations
All Subjects Enrolled Population: This population will consist of all subjects, for whom a 
record exists on the study  databa se, including screen failures and any  subject who was 
not screened but signed the informed consent form. This population will be used for 
reporting subject disposition, reasons for withdrawal prior to randomisation, and 
inclusion, exclusion and randomisation criteria deviations and SAEs for non -randomised 
subjects.
(Modified) Intent -to-Treat (ITT) Population: This population will consist of all subjects 
who are randomised and receive at least one dose of study  drug. The ITT Population will 
be the primary  population for all anal yses of safety  and efficacy  measures.
8.3.2. Analysis Data Sets
The bone mineral density data will comprise the primary  data set of interest.  Details of 
derived data in anal ysis datasets to be created will be provided in the Reporting and 
Analysis Plan (RAP).
8.3.3. Treatment Comparisons
8.3.3.1. Primary  Comparisons of Interest
BMD measured for the total hip will be summarized by
 visit and as change from baseline 
at each visit for raw values, percent changes from baseline, t -scores, and z -scores.  The 
percen t change from baseline in BMD for the total hip will be the primary  endpoint, and 
analyzed using a repeated measures model with terms for treatment, time, time by  
treatment, baseline BMD, baseline BM I and gender.  Contrasts will be formed using the 
time by treatment variable to provide 95% confidence intervals for the treatment 
difference with the unit of percent change per year.  The 95% confidence interval will be 
compared to a lower bound of -1%/year in order to assess clinical non -inferiority .  An y  2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
49additional covariates for the model, along with other details, including model inclusion 
and exclusion criteria for those covariates, will be determined a priori in a detailed 
Reporting and Anal ysis Plan (RAP) that will be completed prior to unblinding of the 
study .
The percent change from baseline in BMD at the L1 -L4 region of the spine will also by  
summarized and anal yzed in the same manner as the BMD data for the total hip.
8.3.4. Interim A nalysis
No interim anal ysis is planned for this study .
8.3.5. Key Elements of A nalysis Plan
8.3.5.1. Efficacy  Analyses
No efficacy  anal yses are planned for this study
8.3.5.2. Safety  Analyses
8.3.5.2.1. Extent of Exposure
The extent of exposure to study  drug will be summarized by  treatment group.
8.3.5.2.2. Adverse Events (A Es)
AEs will be coded using the standard GSK dictiona ry, Medical Dictionary  for Regulatory  
Activities (MedDRA), and grouped b y bod y system. AEs occurring pre -treatment, during 
active treatment and post- treatment will be summarized separatel y. The number and 
percentage of subjects experiencing at least one AE of an y type, AEs within each bod y 
system and AEs within each preferred term will be presented for each treatment group. 
Separate summaries will be provided for all AEs, drug related AEs, SAEs, and for AEs 
leading to withdrawal.
8.3.5.2.3. Deaths and SA Es
All SAEs wi ll be listed by treatment group. Deaths and SAEs will be documented in case 
narrative format.
8.3.5.2.4. Fractures
The number and percent of patients experiencing a bone fracture during the study  will be 
summarized.
8.3.5.2.5. COPD Exacerbations and Pneumonias
The number of mod erate or severe COPD exacerbations and the percent of patients 
experiencing moderate or severe COPD exacerbations will be summarized.
8.3.5.3. Pharmacogenetic A nalyses
See Appendix 2 : Pharmacogenetic Research for details about the Pharmacogenetics 
Analy sis Plan. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
509. STUDY CONDUCT CONSID ERA TIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of su bjects begins.
9.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a study site, GSK will obtain favourable opinion/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CHGood Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 
2008, including, but not limited to:
Institutional Review Board (IRB)/Independent Ethics Committee (I EC) review and 
favourable opinion/approval of study  protocol and any  subsequent amendments.
Subject informed consent.
Investigator reporting requirements.
GSK will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
No study related procedures may be performed until the informed consent form 
document has been signed by the subject .  A pre -screening visit may  be required in 
order to administer the informed consent before any  changes are mad e to the subject’s 
current medication regimen. The pre -screening visit and screening visit may  occur on the 
same day  if the subject does not take or has not taken an y protocol excluded medications .
In approving the clinical protocol the IEC/I RB and, where required, the applicable 
regulatory  agency  are also approving the optional assessments e.g., PGx assessme
nts 
described in Appendix 2 , unless otherwise indicated.  Where permitted by  regulatory  
authorities, approval of the optional assessments can occur after approval is obtained for 
the rest of the stud y.  If so, then the written approval will clearl y indicate approval of the 
optional assessments is being deferred and the study , except for the optional assessments, 
can be initiated.  When the optional assessments are not approved, then the approval for 
the rest of the stud y will clearl y indicate this and therefore, the optional assessments will 
not be conducted . 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
519.3. Qualit y Control (Study  Monitoring)
In accordance with appli cable regulations, GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study  to review with the site staff the protocol, 
study  requirements, and their responsibilities to satisfy  regulatory , ethical, and GSK 
requirements. When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the CRF will serve 
as the source document.
GSK will monitor the study  to ensure that the:
Data are authentic, accura te, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents.
9.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK may  
conduct a qualit y assurance assessment and/or a udit of the site records, and the regulatory  
agencies may  conduct a regulatory  inspection at any  time during or after completion of 
the study . In the event of an assessment, audit or inspection, the investigator (and 
institution) must agree to grant the ad visor(s), auditor(s) and inspector(s) direct access to 
all relevant documents and to allocate their time and the time of their staff to discuss the 
conduct of the stud y, an y findings/relevant issues and to implement any  corrective and/or 
preventative actio ns to address any  findings/issues identified.
9.5. Stud y and Site Closure
Upon completion or termination of the study , the GSK monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regul ations, GCP, and GSK Standard Operating Procedures.
GSK reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safety issues, ethical issues, or severe non -
compliance.  If GSK determines that such action is required, GSK will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
(where applicable).  When feasible, GSK will provide advance notice to the investigator 
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons, GSK will promptly inform all 
investigators, heads of the medical institutions (where applicable),and/or institutions 
conducting the study .  GSK will also promptly  inform t he relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y  2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
52applicable regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly  and provide the reason( s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the investigator or head of the medical institution (where 
applicable) must maintain all site study records (except for those required by  local 
regulations to be maintaine d elsewhere) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a GSK audit or regulatory inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard copy  (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In addition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investig ator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control procedure in place for creating the reproductions.
GSK will inform the investigator of the time period for retaining the site recor ds in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y local 
laws/regulations, GSK standard operating procedures, and/or institutional requirements.
The investigator must notify  GSK of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off- site facility  or transfer of ownership of the 
records in the event that the investigator is no longer as sociated with the site.
9.7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified f or the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK site or other mutually -
agree able location.
GSK will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
GSK will provide the investigator with the randomization codes for their site only after 
completion of the full statistical analy sis. 2018N368712_00
2012N150072_01 CONFIDENTI AL
HZC102972
53GSK aims to post a results summary  to the GSK Clinical Study  Register and other 
publicly  available registers no later than 8 months after the last subject’s last visit (L SLV) 
[this applies to each data anal ysis phase for studies with multiple phases, e.g., primary  
analysis, follow up anal ysis etc]. I n addition, the aim is to submit a manuscript to a peer-
reviewed journal for publication within 18 months of L SLV. GSK also aims to p ublish 
the full study  protocol on the GSK Clinical Study  Register at the time the results of the 
study  are published as a manuscript in the scientific literature. 
When manuscript publication in a peer -reviewed journal is not feasible, further study  
inform ation will be posted to the GSK Clinical Study Register to supplement the results 
summary . 
9.8. Independent Data Monitoring Committee (IDMC)
There is no IDMC in this study . 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
5410. REFERENCES
Calverley  PM, Anderson JA, Celli B. Salmeterol and fluticasone propionate and survival 
in chronic obstructive pulmonary  disease. NEJM. 2007;356:775 -89.
Celli BR, MacNee W. Standards of the diagnosis and treatment of patients with COPD: a 
summary  of the ATS/ERS position paper. Eur Respir J. 2004;23:932 -46.
Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C. 
Epidemiology  and costs of chronic obstructive pulmonary  disease. Eur Respir J. 
2006;27:188 -207.
Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.  Effect of fluticasone 
propionate/salmeter ol (50/250 g) or salmeterol (50 g) on COPD exacerbations. Resp 
Med. 2008;102:1099-1108.
GOLD. Global Initiative for Chronic Obstructive Lung Disease. Executive Summary : 
Global strategy  for the diagnosis, management, and prevention of chronic obstructive 
pulmonary  disease (Updated 2010).  http://www.gold.copd.org
Hankinson JL , Odencrantz JR, Fedan KB. Spirometric reference values from a sample of 
the general US population.  Am J Resp Crit Care Med. 1999;159:179 -
187.
James L P, Letzig L, Simpson PM, Capparell i E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37: 1779 -1784. 
Kardos P, Wencker M, Glaab T. Impact of Fluticasone Propionate/Sa lmeterol  versus 
salmeterol on exacerbations in severe chronic obstructive pulmonary  disease. Am J Resp 
Crit Care Med. 2007;175:144 -149.
Lopez AD, Shibu ya K, Rao C, Mathers CD, Hansell AL , Held L S, Schmid V, Buist S. 
Chronic obstructive pulmonary  disease: current burden and future projections. Eur Respir 
J. 2006;27:397-412.
Miller MR, Hankinson J, Brusasco Vet al. Standardisation of spirometry . Eur Respir J. 
2005;26:319 -338.
WHO. Chronic Obstructive Pulmonary  Disease (COPD). Burden of COPD. WHO. 2010. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
5511. APPENDICES
11.1. Appendix 1: Laboratory  Assessments
Refer to the Time and Events Table 3 for information regarding the timing of laboratory  
tests.
CHEMISTRY HEMATOLOGY OTHER
Albumin Hemoglobin Hepatitis B surface antigen1
Alkaline phosphatase Hematocrit Hepatitis C virus antibody1
Alanine amino -transferase (ALAT or SGPT) Platelet count Fungal culture of oral mucosa (if 
visual evidence of candidiasis )
Aspartate amino -transferase (ASAT or 
SGOT)WBC count hCG qualitativ e (serum 
pregnancy)2 
Bilirubin, direct Neutrophils, absolute
Bilirubin, indirect Neutrophils, segs (%)
Bilirubin, total Neutrophils, bands 
(%)
Calcium Basophils (%)
Chloride Eosinophils (%)
CO 2content/Bicarbonate Eosinophils , absolute
Creat inine Lymphocytes (%)
Creatine phosphokinase (CPK), total Monocytes (%)
Gamma glutamyl transferase (GGT)
Glucose
Phosphorus 
Potassium
Protein, total serum
Sodium
Urea nitrogen (BUN)
Uric Acid 
1. Assessed at Visit 1 (Screening) on ly, result is not exclusionary
2. Only females of child -bearing potential; refer to Time and Events Table for specific visit information 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
5611.2. Appendix 2: Pharmacogenetic Research
Pharmacogenetics –Background
Pharmacogenetics (PGx) is the study  of variability in drug response due to hereditary  
factors in populations.  There is increasing evidence that an individual's genetic 
background (i.e., genot ype) may  impact the pharmacokinetics (absorption, distribution, 
metabolism, elimination), pharmacod ynamics (relationship between concentrations and 
pharmacologic effects or the time course of pharmacologic effects) and/or clinical 
outcome (in terms of efficacy  and/or safety  and tolerability ).  Some reported examples of 
PGx associations with safety /adverse events include:
Drug Disease Gene Variant Outcome
Abacavir HIV 
[Hetherington ,2002; 
Mallal , 2002; 
Mallal ,2008]HLA-B* 5701 Carriage of the HLA -B*5701 variant has been shown to 
increase a patient's risk for experiencing 
hypersensitivity to abacavir.  Prospective HLA -B*5701 
screening and exclusion of HLA -B*5701 positive 
patients from abacavir treatment significantly decreased 
the incidence of abacavir hypersensitivity.  Treatment 
guidelines and abacavir product labeling in the United 
States and Europe now recommend (US) or require 
(EU) prospective HLA -B*5701 screening prior to 
initiation of abacavir to reduce the incidence of abacavir 
hypersensitivity.   HLA-B*5701 screening should 
supplement but must never replace clinical risk 
management strategies for abacavir hypersensitivity.
Carbamazepin
eSeizure, Bipolar 
disorders & 
Analgesia Chung , 
2010; Ferrell , 2008HLA-B*1502 Independent studies indicated that patients carrying 
HLA-B*1502 are at higher risk of Stevens -Johnson 
Syndrome and toxic epidermal necrolysis and that this 
marker is prevalent in some populations, particularly 
with Asian ancestry.  Regulators, including the US FDA 
and the Taiwanese TFDA, have updated the 
carbamazepine drug label to indicate that patients with 
ancestry in genetically at risk populations should be 
screened for the presence of HLA -B*1502 prior to 
initiating treatment with carbamazepine.
Irinotecan Cancer [ Innocenti , 
2004; Liu , 2008; 
Schulz, 2009]UGT1A1*28 Variations in the UGT1A1 gen e can influence a 
patient’s ability to break down irinotecan, which can 
lead to increased blood levels of the drug and a higher 
risk of side effects. A dose of irinotecan that is safe for 
one patient with a particular UGT1A1 gene variation 
might be too high for another patient without this 
variation, raising the risk of certain side -effects, that 
include neutropenia following initiation of Irinotecan 
treatment.  The irinotecan drug label indicates that 
individuals who have two copies of the UGT1A1*28 
varian t are at increased risk of neutropenia.  A genetic 
blood test is available that can detect variations in the 
gene.    
A key  component to successful PGx research is the collection of samples during the 
conduct of clinical studies. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
57Collection of whole blo od samples, even when no a priori hypothesis has been identified, 
may enable PGx anal ysis to be conducted if at any time it appears that there is a potential 
unexpected or unexplained variation in response to FF/VI Inhalation Powder. 
Pharmacogenetic Resea rch Objectives
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a relationship between genetic factors and response to FF/VI 
Inhalation Powder.  If at any  time it appears there is potential v ariability  in response in 
this clinical study  or in a series of clinical studies with FF/VI Inhalation Powder, the 
following objectives may be investigated – the relationship between genetic variants and 
study  treatment with respect to:
Relationship betwee n genetic variants and the pharmacokinetics and/or 
pharmacod ynamics of investigational product
Relationship between genetic variants and safet y and/or tolerability  of investigational 
product
Relationship between genetic variants and efficacy of investigati onal product
Study Population
Any subject who is enrolled in the clinical study , can participate in PGx research.  Any  
subject who has received an allogeneic bone marrow transplant must be excluded from 
the PGx research.
Subject participation in the PGx re search is voluntary and refusal to participate will not 
indicate withdrawal from the clinical study  or result in any  penalty  or loss of benefits to 
which the subject would otherwise be entitled.
Study Assessments and Procedures
Saliva samples can be taken for Deox yribonucleic acid (DNA) extraction and used in 
PGx assessments.
No additional whole blood samples will be necessary  for the PGx anal ysis. Saliva (2mL ) 
is collected into the DNA self
-collection kit. A single sample will be taken but can be 
duplicate d if the first sample is unusable. I t is recommended that the saliva sample be 
collected at Visit 2.  
The PGx sample is labelled (or “coded”) with a study  specific number that can be 
traced or linked back to the subject b y the investigator or site staff. Coded samples 
do not carry  personal identifiers (such as name or social securit y number).  The 
saliva sample is taken on a single occasion unless a duplicate sample is required due 
to inability  to utilize the original sample.  
The DNA extracted from the saliva sample may  be subjected to sample quality  control 
analysis.  This anal ysis will involve the genot yping of several genetic markers to confirm 
the integrit y of individual samples.  If inconsistencies are noted in the analysis, then those 
samples may  be destro yed. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
58The need to conduct PGx anal ysis may  be identified after a study  (or a set of studies) of 
FF/V I Inhalation Powder has been completed and the clinical study  data reviewed.  In 
some cases, the samples may  not be studied. e.g., no questions are r aised about how 
people respond to FF/VI Inhalation Powder.
Samples will be stored securel y and may be kept for up to 15 years after the last subject 
completes the study  or GSK may  destro y the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will use samples collected from the study  for 
the purpose stated in this protocol and in the informed consent form.  
Subjects can request their sample to be destro yed at any  time.
Subject Withdrawal from Study
If a subject who has consente d to participate in PGx research and has had a sample taken 
for PGx research withdraws from the clinical study  for any  reason other than lost to 
follow -up, the subject will be given the following options:
Retain the sample for PGx research 
Destro y the PGx sample 
If a subject withdraws consent for PGx research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y GSK and maintain the docume ntation in 
the site study  records . 
Screen and Baseline Failures
If a blood sample for PGx research has been collected and it is determined that the 
subject does not meet the entry  criteria for participation in the clinical study, then the 
investigator should instruct the participant that their PGx sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the consent 
and sample reconciliation process.  In this instance a sample destruction form will not be 
available to include in the site files.
Pharmacogenetics A nalyses
Pharmacogenetics Anal yses
1.Specific genes may  be studied that encode the drug targets, or drug mechanism of 
action pathway s, drug metabolizing enzymes, drug transporters or which may  
underpin adverse events, disease risk or drug response. These candidate genes may  
include a common set of ADME (Absorption, Distribution, Metabolism and 
Excretion) genes that are studied to determine the relationship between gene variants 
or treatment response and/ or tolerance. 
In addition, continuing research may  identify  other enzy mes, transporters, proteins or 
receptors that may  be involved in response to FF/VI Inhalation Powder.  The genes that 
may code for these proteins may  also be studied. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
592.Genome -wide scans involving a large number of poly morphic markers (e.g., single 
nucleotide poly morphisms) at defined locations in the genome, often correlated with 
a candidate gene, may  be studied to determine the relationship between genetic 
variants and treatment response or tolerance. This approach is often employ ed when 
a definitive candidate gene(s) does not exist and/or the potential genetic effects are 
not well understood. 
If applicable and PGx research is conducted, appropriate statistical anal ysis methods will 
be used to evaluate pharmacogenetic data in the context of the other clinical data. Results 
of PGx investigations will be reported either as part of the main clinical study  report or as 
a separate report. Endpoints of interest from all comparisons will be desc riptively  and/or 
graphicall y summarized as appropriate to the data.  A detailed description of the anal ysis 
to be performed will be documented in the study  reporting and anal ysis plan (RAP) or in 
a separate pharmacogenetics RAP, as appropriate.  
Informed Consent
Subjects who do not wish to participate in the PGx research may  still participate in the 
clinical study .  PGx informed consent must be obtained prior to an y saliva being taken for 
PGx research.
Provision of Study Results and Confidentiality  of Subj ect’s PGx Data
GSK may  summarize the PGx research results in the clinical study  report, or separatel y, 
or may  publish the results in scientific journals. 
GSK does not inform the investigator, subject, or any one else (e.g., family  members, 
study  investigat ors, primary  care ph ysicians, insurers, or emplo yers) of individual 
genot yping results that are not known to be relevant to the subject’s medical care at the 
time of the study , unless required b y law. This is due to the fact that the information 
generated 
from PGx studies is generall y preliminary in nature, and therefore the 
significance and scientific validity  of the results are undetermined. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
60References
Chung WH, Hung SL , Chen YT. Genetic predisposition of life -threatening antiepileptic -
induced skin reacti ons.  Expert Opin. Drug Saf. 2010; 9: 15-21.
Ferrell PB, McLeod HL.  Carbamazepine, HLA -B*1502 and risk of Stevens -Johnson 
syndrome and toxic epidermal necrol ysis: US FDA recommendations.  
Pharmacogenomics. 2008; 9: 1543 -46.
Hetherington S, Hughes AR, Most eller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley  A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond L M, Roses 
AD. Genetic variations in HLA- B region and h ypersensitivity  reactions to abacavir. 
Lancet . 2002; 359:1121-2.
Innocenti F, Undevia SD, Iy er L, Chen PX, Das S, Kocherginsky  M, Karrison T, Janisch 
L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ.  Genetic variants in the UDP -
glucuronosy ltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J 
Clin Oncol 2004; 22: 1382 -1388.
Liu CY, Chen PM, Chiou TJ, L iu JH, L
in JK, L in TC, Chen WS, Jiang JK, Wang HS, 
Wang WS.  UGT1A1*28 poly morphism predicts irinotecan- induced severe toxicities 
without affecting treatment outcome and survival in patients with metastatic colorectal 
carcino ma.  Cancer. 2008; 112: 1932 -40.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Say er D, Castley  A, Mamotte 
C, Maxwell D, James I .  Association between presence of HLA- B*5701, HLA -DR7, and 
HLA -DQ3 and hy
persensitivity  to HIV -1 reverse -transcriptas e inhibitor abacavir.  
Lancet . 2002; 359:727-32.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel -Guedes E, 
Rugina S, Kozy rev O, Cid JF, Hay  P, Nolan D, Hughes S, Hughes A, Ry an S, Fitch N, 
Thorborn D, Benbow A; PREDI CT-1 Study  Team. HLA -B*5701 screening for 
hypersensitivity  to abacavir. N Engl J Med. 2008; 358; 568 -78
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, 
Stemmler HJ. UGT1A1 gene pol ymorphism: I mpact on toxicity  and efficacy  of 
irinotecan -based regimens in metastatic colorectal cancer.  World J. Gastroenterol. 2009; 
15: 5058-66. 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
6111.3. Appendix 3: Country  Specific Requirements 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
6211.4. Appendix 4: Liver Chemistry  Stopping and Followup Criteria
Phase III -IV Liver Safety Algorithms
ALT>3xULN
plus 
bilirubin >2x 
ULN (>35%
direct) (or plus
INR >1.5, if   
measured)*NoYes
Yes•Instruct subject to stop investigational product (IP)
•Notify GSK within 24h and arrange clinical followup 
within 24-72h
•Perform liver chemistries and liver event follow up 
assessments (serology , PK sample etc as in protocol) 
•Complete liver event CRF , SAE data collection tool if 
appropriate, and liver imaging and/or biopsy  CRFs if  
tests performed.
•Obtain weekly liver chemistries [**as far as possible in 
these subjects] until resolved, stabilised or returned to 
baseline 
•Withdraw subject from study  after monitoring 
complete unless protocol has option to restart drug•Instruct subject to stop investigational product (IP)
•Notify GSK and arrange clinical followup within 24h
•Perform liver chemistries and liver event follow up 
assessments (serology , PK sample etc as in protocol) 
•Report as SAE (excl. hepatic impairment or cirrhosis 
studies) and complete liver event CRF , SAE data 
collection tool, and liver imaging and/or biopsy  CRFs if 
tests performed.
•Obtain twice weekly liver chemistries until resolved, 
stabilised or returned to baseline values
•Consultation with hepatologist/specialist recommended
•Withdraw subject from study  after monitoring 
complete unless protocol has option to restart drugHepatitis 
symptoms
or rash?NoAble to 
monitor 
weekly for 
4 weeks?Yes
No**
YesContinue IP
Obtain twice 
monthly liver 
chemistries until 
normalised or 
back to baseline 
values
YesYesALT<3xULN 
+ bilirubin 
<2xULN 
after ≤ 4 
wks?
Yes
ALT 
>5xULN 
but 
<8xULNNo ALT  
>8xULNYesALT >5 
and 
<8xULN 
for >2 
wks
Yes NoALT>3xULN 
but <5xULN + 
bilirubin 
<2xULN+no 
symptomsNoAble to 
monitor 
weekly for 
>2 wks?No
NoNotify GSK within 24h 
to discuss subject 
safety; continue IP;
check liver chemistry 
weekly for 4 weeksYesNo
*INR value not applicable to subjects on anticoagulants 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
6311.5. Appendix 5: Protocol Changes
This amendment applies to all study  centers participating in HZC102972
Rationale
This protocol amendment is being implemented to revise and clarify  exclusion criteria 
concerning participation in pulmonary  rehabilitation progra ms; clarify  the d escription of 
DEXA procedure sand clinical labs
; correction of ty pographical errors.
Section - Study Design 
Original Text:
The target enrolment across approximately  40 study  centres is approximately  400
randomized subjects, to achieve approximately  280 who complete the 156-week 
treatment period.  
Amended Text:
The target enrolment across approximately  40 study  centres is approximately  280
randomized subjects, to achieve approximately  224 who complete the 156 -week 
treatment period.  
Section 4.2
.Inclusion Criteria - #6
Original Text:
Severity  of Disease: Subject with a measured pre -and post -albuterol/salbutamol 
FEV 1/FVC ratio of < 0.70 at Screening (Visit 1).  
Amended Text:
Severity  of Disease: Subject with a measured post -albuterol/salbutamol FEV 1/FVC ratio 
of < 0.70 at Screening (Visit 1).  
Section 4.3. Exclusion Criteria  
Deleted Text (formerly  criteria #23) :
Pulmonary rehabilitation: Subjects who have participated in the acute phase of a 
Pulmonary  Rehabilitation Program within 4 weeks prior to Screening Visit 1 or who will 
enter the acute phase of a Pulmonary  Rehabilitation Program during the study . Subjects 
who are in the maintenance phase of a Pulmonary  Rehabilitation Program are not 
excluded.
Section 4.4. Withdrawal Criteria – 3rdparagraph
Original Text: 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
64Subje ct compliance with double -blind study  medication will be assessed at Visits 2 
through 14, b y reviewing the dose counter on the NDPI .  
Amended Text:
Subject compliance with double -blind study  medication will be assessed from Visits 2 
through 14, b y reviewi ng the dose counter on the NDPI . 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
65Section 6. Time and Events –Table 3 
Original Text:
Collect Double -Blind 
MedicationX X X X X X X X X X X X X X
Amended Text:
Collect albuterol 
(salbutamol)14X X X X X X X X X X X X X X
Dispense Single -Blind 
MedicationX
Collect Blinded 
MedicationX X X X X X X X X X X X X X
Section 6. Time and Events –Table 3 Footnotes
Original Text:
1.  Visit 0 and Visit 1 may occur on the same day.
3.  Subjects will be assigned a subject number at the tim e ICF is signed. The ICF must be signed before any study procedures including drug washout(s).
9.   Non -fasting and pre -dose. Visit 2: pre-dose lab only completed if any part of Screening lab needs to be repeated
Amended Text:
1.  Visit 0 and Visit 1 may occur on the same day if the subject does not take or has not taken any protocol excluded medications.
3.  Subjects will be assigned a subject number at the time ICF is signed. The ICF must be signed before any study procedures incl uding medication exclusion period(s).
9.   Non -fasting and pre -dose. A blood sample for repeat analysis is collected only if any part of Screening lab needs to be repeated. Results of repe at labs should be received prior to 
      Randomization at Visit 2. 
 
 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
66Section 6.1. Critical Baseline Assessments and Section 9.2. Regulatory and Ethical 
Considerations, Including the Informed Consent Process
Original Text:
The informed consent may  be given at the screening visit if the subject does not take or 
has not taken an y protocol ex cluded medications. 
Amended Text:
The pre -screening visit and screening visit may  occur on the same day  if the subject does 
not take or has not taken any  protocol excluded medications. 
Section 6.2.6. COPD Exacerbations and Pneumonias
Added Text:
COPD exa cerbations should not be recorded as an adverse event, unless they meet the 
definition of a Serious Adverse Event.  For the purposes of this study , COPD 
exacerbations will be collected and recorded on the exacerbation log in the eCRF.  
Section 6.2.4. Bone Mineral Density –
4thparagraph
Original Text:
DEXA Assessments
At Screening, an y subject with a T score < -1.5 (assessed from the L 1-L4regions of 
the spine or the total hip) will be counseled about the clinical implications of this 
value.
At any  visit a fter randomization to double -blind treatment (Visit 2) through Visit 10, 
any subject with a bone mineral density  loss of  8% from baseline (assessed from 
the L 1-L4regions of the spine or the total hip) will be counseled about the clinical 
implications of this value.
At any  visit after 2 y ears (Visit 10), any  subject with a bone mineral densit y loss of 
10% from baseline (assessed from the L 1-L4regions of the spine or the total hip) 
will be counseled about the clinical implications of this value.
Amended Text:
Subjects with DEXA results meeting pre -defined criteria for clinicall y significant bone 
mineral density  loss from the Screening scan or any  visit scan after randomization will be 
counseled about the clinical implications of the scan results.
Section 6.2.16. Laboratory Assessments – 3rdparagraph 2018N368712_00
2012N150072_01 CONFIDENTIA L
HZC102972
67Original Text:
a blood sample for repeat anal ysis of the anal yte(s) should be collected pre -dose at Visit 2 
(Randomization).
Amended Text:
a blood sample for repeat anal ysis of the anal yte(s) should be collecte d prior to Visit 2 
(Randomization). Results of repeat Screening labs should be received prior to 
Randomization at Visit 2.
Section 11.1. Appendix 1: Laboratory Assessments –third column
Deleted Text:
Urine pregnancy test (in clinic/home test)2 2018N368712_00
2012N150072_00 CONFID ENTIA L
GlaxoSmithKline group of companies HZC102972
1TITLE PA GE
Division:   Worldwide Development
Title: Multi -centre, randomized, double- blind, parallel -group study  
evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) 
Inhalation Powder once daily  compared with Vilanterol (VI) 
Inhalation Powder O nce Daily  on Bone Mineral Density  (BMD) 
in subjects with Chronic Obstructive Pulmonary  Disease 
(COPD)
Compound Number: GW685698+GW642444
Development Phase IV
Effective Date: 07-JAN-2013
Subject: COPD, Bone Mineral Densit y, Fluticasone Furoate (FF), Vil anterol (VI), Novel 
Dry Powder Inhaler (NDPI )
Author(s):
Copy right 2013 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibi ted. 2018N368712_00
PPD
 
P P D 2 0 1 8 N 3 6 8 7 1 2 _ 0 0 
P P D P P D 
2012N150072_00 CONFIDENTIA L
HZC102972
3SPONSOR INFORMA TION PAGE
Clinical Study  Identifier:
HZC102972
Sponsor Legal Registered Address:
GlaxoSmith Kline Research &Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Sponsor Contact Address
GlaxoSmithKline Research & Development Limited
Via 
2/4-37135
Verona, Italy
Telephone:  
GlaxoSmithKline Research & Development Limited
Addenbrooke’s Centre for Clinical I nvestigation (ACCI )
Addenbrooke’s Hospital
Hills Road
Cambridge, Cambridgeshire, CB2 2GG, UK
Telephone:  
GlaxoSmithKline Research &Development Limited
Iron Bridge Road
Stockley  Park West, Uxbridge, Middlesex, UB 11 1BU , UK
Telephone:  
GlaxoSmithKline Research &Development Limited
2301 Renaissance Boulevard
Building #510
Post Office Box 61540
King of Prussia, Penns ylvania 19406
Telephone number: 
o
r
GlaxoSmithKline Research &Development Limited
1250 South Collegeville Road
Collegeville, PA 19426, USA
Telephone Number: 
GlaxoSmithKline Research &Development Limited
Five Moore Drive 
P.O. 13398 2018N368712_00
PPD
PPD
PPD
PPD
PPD
PPD
2012N150072_00 CONFIDENTIA L
HZC102972
4Research Triangle Park, NC 27709- 3398, USA
Telephone: 
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate 
compan y (or designee). Where applicable, the details of the Sponsor and contact person 
will be provided to the relevant regul atory  authority  as part of the clinical trial 
submission.
Sponsor Medical Monitor Contact Information: 
 MD
GlaxoSmithKline
Five Moore Drive
P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: 
Sponsor Serious A dverse Events (SAE) Contact Information: 
Case Management Group, GCSP –
Stockley  Park, UK
Email: 
Fax: 
Regulatory  Agency  Identify ing Number(s): FDA IND Numbers:  077855 and 050703; 
EudraCT #: 2012- 004801 - 28 2018N368712_00
PPD
PPD
PPD
PPD
PPD
2012N150072_00 CONFIDENTIA L
HZC102972
5INVESTIGA TOR PROTOCOL A GREEMENT P AGE
Required Standard Wording:
I confirm agreement to conduct the study  in compliance with the protocol.
I acknowledge that I am responsible for overall study  conduct. I agree to 
personall y conduct or supervise the described clinical st udy.
I agree to ensure that all associates, colleagues and employ ees assisting in the 
conduct of the stud y are informed about their obligations. Mechanisms are in 
place to ensure that site staff receive sthe appropriate information throughout the 
study .
Investigator Name:  _____________________________
Investigator Signature Date 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
6TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S............................................................................................. 9
PROTOCOL SUMMARY ............................................................................................... 11
1.INTRODUCTION ................................................................
.................................... 14
1.1. Background ................................................................................................ 14
1.2. Rationale .................................................................................................... 14
2.OBJECTIVE(S) ...................................................................................................... 15
3.INVESTIGATIONAL P LAN..................................................................................... 15
3.1. Study Design .............................................................................................. 15
3.1.1. Study Schematic .......................................................................... 16
3.2. Discussion of Design .................................................................................. 16
4.SUBJECT SELECTION AN D WITHDRAW AL CRITERI A....................................... 16
4.1. Number of Subjects .................................................................................... 16
4.2. Inclusion Criteria ......................................................................................... 16
4.3. Exclusion Criteria ........................................................................................ 17
4.4. Withdrawal Criteria ..................................................................................... 20
4.5. Pre-Screen Failures and Screening Failures ............................................... 22
5. STUDY TREATMENTS .......................................................................................... 22
5.1. Investigational Product and Other Study Treatment .................................... 22
5.1.1. Storage ........................................................................................ 24
5.1.2. Study Drug Return ....................................................................... 24
5.2. Treatment Assignment ................................................................................ 24
5.3. Blinding ....................................................................................................... 25
5.4. Product Accountability ................................................................................ 25
5.5. Treatment Comp liance ................................................................................ 25
5.6. Concomitant Medications and Non -Drug Therapies .................................... 26
5.6.1. Permitted Medications and Non -Drug Therapies .......................... 26
5.6.2. Prohibited Medications and Non -Drug The rapies ......................... 27
5.7. Treatment after the End of the Study .......................................................... 27
5.8. Treatment of Study Treatment Overdose .................................................... 28
6.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 28
6.1. Critical Baseline Assessments .................................................................... 32
6.2. Safety ......................................................................................................... 32
6.2.1. Primary Endpoint ......................................................................... 32
6.2.2. Secondary Endpoints ................................................................... 32
6.2.3. Other Endpoints ........................................................................... 32
6.2.4. Bone Mineral Density ................................................................... 33
6.2.5. Fractures ..................................................................................... 33
6.2.6. COPD Exacerbations and Pneumonias ....................................... 33
6.2.7. Liver chemistry stopping and f ollow up criteria ............................. 35
6.2.8. Adverse Events ............................................................................ 38
6.2.8.1. Definition of an AE ...................................................... 39 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
76.2.8.2. Definition of a SAE ..................................................... 40
6.2.9. Laboratory and Othe r Safety Assessment Abnormalities 
Reported as AEs and SAEs ......................................................... 41
6.2.10. Cardiovascular Events ................................................................ .41
6.2.11. Death Events ............................................................................... 42
6.2.12. Pregnancy ................................................................................... 42
6.2.13. Time Period and Frequency of Detecting AEs and SAEs ............. 42
6.2.14. Prompt Reporting of Serious Adverse Events and Other 
Events to GSK ............................................................................. 42
6.2.14.1. Regulatory reporting requirements for SAE s.............. 44
6.2.15. SpirometryTesting ........................................................................ 44
6.2.15.1. Reversibility Testing ................................................... 45
6.2.16. Laboratory Assessments ............................................................. 45
6.2.17. Oropharyngeal Examination ......................................................... 46
6.2.18. Diary Card -Medical Problems/Medications Taken ...................... 46
6.2.19. 12-lead ECG Assessment ............................................................ 46
6.2.20. Smoking Cessation Counselling .................................................. 46
6.3. Pharmacogenetic Research ........................................................................ 47
7.DATA MANAGEMENT ........................................................................................... 47
8.DATA ANALYSIS AND ST ATISTICAL CONSIDERAT IONS ................................... 47
8.1. Hypotheses ................................................................................................ .47
8.2. Study Design Considerations ...................................................................... 48
8.2.1. Sample Size Assumptions ........................................................... 48
8.2.2. Sample Size Sensitivity ................................................................ 48
8.2.3. Sample Size Re- estimation .......................................................... 48
8.3. Data Analysis Considerations ..................................................................... 48
8.3.1. Analysis Populations .................................................................... 48
8.3.2. Analysis Data Sets ....................................................................... 49
8.3.3. Treatment Comparisons .............................................................. 49
8.3.3.1. Primary Comparisons of Interest ................................ 49
8.3.4. Interim Analysis ........................................................................... 49
8.3.5. Key Elements of Analysis Plan .................................................... 49
8.3.5.1. Efficacy Analyses ....................................................... 49
8.3.5.2 .Safety Analyses .......................................................... 49
8.3.5.2.1. Extent of Exposure ................................ .49
8.3.5.2.2. Adverse Events (AEs) ............................. 49
8.3.5.2.3. Deaths and SAEs ................................... 50
8.3.5.2.4. Fractu res................................................ 50
8.3.5.2.5. COPD Exacerbations and 
Pneumonias ........................................... 50
8.3.5.3. Pharmacogenetic Analyses ........................................ 50
9.STUDY CONDUCT CONSID ERATIONS ............................................................... 50
9.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 50
9.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 50
9.3. Quality Control (Study Monitoring) .............................................................. 51
9.4. Quality Assurance ....................................................................................... 51
9.5. Study and Site Closure ............................................................................... 52
9.6. Records Retention ...................................................................................... 52 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
89.7. Provision of Study Results to Investigators, P osting of Information 
on Publicly Available Clinical Trials Registers and Publication .................... 53
9.8. Independent Data Monitoring Committee (IDMC) ....................................... 53
10.REFERENCES ....................................................................................................... 54
11.APPENDICES ........................................................................................................ 55
11.1. Appendix 1: Laboratory Assessments ......................................................... 55
11.2. Appendix 2: Pharmacogenetic Research .................................................... 55
11.3. Appendix 3: Country Specific Requirements ............................................... 61
11.4. Appendix 4: Liver Chemistry Stopping and Followup Criteria ...................... 62 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
9LIST OF ABBREVIATIONS
AE Adverse Event
ALT Alanine Transaminase
AM Morning
ANCOVA Analy sis of Covariance
AST Aspartate Transaminase
AUC Area Under the Curve
ATS American Thoracic Society
BMD Bone Mineral Densit y
IB Investigator’s Brochure
COPD Chronic Obstructive Pulmonary  Disease
eCRF Electronic Case Report Form
DEXA Dual Energy  X-ray Absorptiometry
ECG Electrocardiogram
EISR Expedited I nvestigator Safet y Report
FEV 1 Forced Expiratory  Volume in one Second
FF Fluticasone Furoate
FF/V I Fluticasone Furoate/ Vilanterol Inhalation Powder 
Combination
FVC Forced Vital Capacity
GCP Good Clinical Practice
GCSP Global Clinical Safet y and Pharmacovigilance
GCP Good Clinical Practice
GOLD Global I nitiative for Chronic Obstructive Lung Disease
GSK GlaxoSmithKline
IEC Independent Ethics Committee
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IDMC Independent Data Monitoring Committee
IRB Institutional Review Board
ITT Intent to Treat
IVRS Interactive Voice Response Sy stem
L Liter
LABA Long Acting Beta Agonist
LDH Lactate Deh ydrogenase
LSLV Last Subject Last Visit
LTOT Long Term Ox ygen Therapy
MAOI Monoamine Oxidase Inhibitor
Mcg Microgram
MDI Metered Dose Inhaler
MEDDRA Medical Dictionary  for Regulatory  Activities
mL Milliliter
MSDS Material Safet y Data Sheet
NDPI Novel Dry  Powder Inhaler
OTC Over the Counter
PD Pharmacod ynamics
PK Pharmacokinetics 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
10PEF Peak Expiratory  Flow
PFT Pulmonary  Function Test
PGx Pharmacogenetics
PM Evening
PR Pulse Rate
PRN As needed
QD Once Daily
RAMOS Registration and Medication Ordering Sy stem
RAP Reporting Analy sis Plan
RNA Ribonucleic Acid
SAE Serious Adverse Event
SD Standard Deviation
SPM Study  Procedures Manual
UC Urine Cortisol
ULN Upper Limit of Normal
VI Vilanterol
WHO World Health Organization
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by the 
GlaxoSmi thKline group of companies
NONE None 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
11PROTOCOL SUMMA RY
Rationale
Chronic obstructive pulmonary  disease (COPD) has been defined as a preventable and 
treatable disease with some significant extra -pulmonary  effects that may  contribute to the 
severit y in i ndividual patients. The pulmonary  component of COPD is characterized by  
airflow limitation that is not fully  reversible, which is usually  progressive and associated 
with an abnormal inflammatory  response of the lung to noxious particles or gases. COPD 
is amajor cause of poor health, resulting in millions of deaths annually  worldwide 
[GOL D, 2010] and contributing significantly to health care costs and morbidity  
[Chapman
, 2006; Lo pez, 2006]. According to the World Health Organization, COPD was 
the fifth leading cause of death worldwide in 2002 and is estimated to be the third leading 
cause b y 2030 [WHO , 2010].
Currently  published guidelines on COPD state that the goals of pharmacologic therap y 
should be to control sy mptoms, improve health status and exercise tolerance, and reduce 
the frequency  of COPD exacerbations [ GOL D, 201 0]. Recent clinical research has 
indicated that an inhaled corticosteroid (ICS) combined with a long acting 2-agonist 
(LABA) is more effective than the individual components in managing stable COPD to 
reduce exacerbations and improve lung function and hea lth status [ Ferguson
,2008; 
Calver ley,2007; Kardos , 2007]. 
Although inhaled corticosteroids have demonstrated utility  in patients wi th COPD, there 
is a potential safet y concern with long -term use on bone demineralization .  These 
concerns, for the most part, are derived from the well-documented effects of oral 
corticosteroids on bone density  and fracture, however the actual effects of i nhaled 
corticosteroids are not clear and require further study .
Study 
HZC102972 will prospectivel y assess the effects of 3 years (156 weeks) exposure 
tofluticasone furoate/vilanterol (FF/VI) versus 
VIon bone mineral density in adult 
subjects with COPD at approximately  40 centers.
Objective(s)
The primary  objective of this study  is
to evaluate the effect of the inhaled corticosteroid 
FF on bone mineral density (BMD) assessed at the total hip by  comparing FF/VI 
treatment with VI treatment in subjects with moderate COPD. 
A secondary  objective is to evaluat ethe effect of the inhaled corticosteroid FF on bone 
mineral density  by gender by  comparing FF/VI treatment with VI  treatment in subjects 
with moderate COPD.
Another secondary  objective is to evaluate the effect of FF on bone mineral density  as 
assessed at the lumbar spine (L1 -L4) b y comparing FF/VI treatment with VI treatment in 
subjects with moderate COPD. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
12Stud y Design
This is a multi -center, randomized, double- blind, parallel -group stud y.  The FF/VI 
inhalation powder once daily  and VI inhalation powder once dail y will be evaluated in 
subjects with COPD over 156 weeks. Subjects will sign the informed consent form ( ICF)
at Visit 0 and will be assigned a subject identifier. See Table 3 for further details. 
Subjects who meet all study  inclusion and none of the exclusion criteria will begin a 14to 
21day single -blind run-in period following Visit 1.  Basel ine BMD measurements will be 
collected between Visits 1 and 2.  At Visit 2, eligible subjects will be randomized to 
double -blind study  medication and entered into a 156 -week treatment period.  
Randomisation will be stratified based upon gender.  During the treatment period, clinic 
visits will occur every 3 months. BMD determined by  dual -energy  x-ray absorptiometry
(DEXA) scans will be conducted every  6 months following randomization. A safet y 
Follow -up Visit 15 will occur 7 days after the last treatment stu dy day as a telephone 
contact.  Subjects will be prescribed appropriate COPD therapy  at the end of Treatment 
Visit 14 if required.  There are no plans to provide the study  drug for compassionate use 
following stud y completion.
The target enrolment across a pproximately  40 s tudy centres is approximately  400
randomized subj ects, to achieve approximately  280 who complete the 156- week 
treatment period.  The total duration of subject partic ipation will be approximately  159 to 
160weeks.
Stud y Endpoints/ Assessment s
Primary
BMD measured at the total hip 
Secondary
BMD measurements b y gender
BMD measured at the lumbar spine (L1 -L4) 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
13Other
Adverse Event reporting 
Serious Adverse Event reporting
Incidence of fractures
Incidence of pneumonias
COPD exacerbations 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
141. INTRODU CTION
1.1. Background
COPD has been defined as a preventable and treatable disease with some significant 
extra -pulmonary  effects that may  contribute to the severit y in individual patients. The 
pulmonary  component of COPD is characterized by  airflow limitation t hat is not fully  
reversible, which is usually  progressive and associated with an abnormal inflammatory  
response of the lung to noxious particles or gases. COPD is a major cause of poor health, 
resulting in millions of deaths annuall y worldwide [ GOL D, 2010] and contributing 
significantl y to health care costs and morbidity [ Chapman
, 2006; Lopez, 2006]. 
According to the World Health Organization, COPD was the fifth leading cause of death 
worldwide in 2002 and is estimated to be the third leading cause b y 2030 [WHO , 2010].
Currently  published guidelines on COPD state that the goals of pharmacologic therap y 
should be to control sy m
ptoms, improve health status and exercise tolerance, and reduce 
the frequency  of COPD exacerbations [ GOL D, 2010 ]. Recent clinical research has 
indicated that an inhaled corticosteroid (ICS) combined wit h a long acting 2-agonist 
(LABA) is more effective than the individual components in managing stable COPD to 
reduce exacerbations and improve lung function and health status [ Ferguson, 2008; 
Calver ley,2007; Kardos , 2007]. 
Bronchodilators are considered key  to the s ymptomatic management of COPD and 
current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 
recomme nd the use of long -acting inhaled bronchodilators in moderate to very  severe 
COPD, because they  are more efficacious and more convenient to use than short -acting 
bronchodilators.  The benefits of bronchodilators include not only  the control of 
symptoms but improvements in lung function, hyperinflation, exercise performance ,and 
health status.
Inhaled corticosteroids are considered the most effective anti -inflammatory  treatments for 
all severities of COPD.  The benefits of I CS may  include control of COPD sy mptoms, 
improvement in lung function, decrease in airway  hyper-responsiveness and 
improvement in health status and reduction in exacerbations.
1.2. Rationale
Although inhaled corticosteroids have demonstrated utility in patients with COPD, there 
is a potential safet y concern with long -term use of ICS on bone demineralization .  These 
concerns, for the most part, are derived from the well-documented effects of oral 
corticosteroids on bone density  and fracture, however the actual effects of inhaled 
corticosteroids a re not clear and require further study .
Study 
HZC102972 will prospectivel y assess the effects of 3 years (156 weeks) exposure 
to versus VIon bone mineral density inadult subj ects with chronic obstructive 
pulmonary  disease (COPD) at approximately  40 centers. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
152. OBJECTIVE(S)
The primary  objective of this study  is to evaluate the effect of the inhaled corticosteroid 
FF on bone mineral density  assessed at the total hip by  comparing F F/VI treatment with 
VI treatment in subjects with moderate COPD. 
A secondary  objective is to evaluate the effect of the inhaled corticosteroid Fluticasone 
Furoate (FF) on bone mineral densit y by gender by comparing FF/VI treatment with VI  
treatment in sub jects with moderate COPD.
Another secondary  objective is to evaluate the effect of FF on bone mineral density  as 
assessed at the lumbar spine (L1 -L4) b y comparing FF/VI treatment with VI treatment in 
subjects with moderate COPD.
3. INVESTIGA TIONAL PLA N
3.1. Stud y Design
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table, are essential and required for stud y condu ct. 
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM). The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
This is a multi -center, randomized, double- blind, parallel -group stud y.  The FF/VI 
inhalation powder once daily  and VI inhalation powder once dail y will be evaluated in 
subjects with COPD over 156 weeks. Subjects will sign the I CF at Visit 0 and will be 
assigned a subject identifier. See Table 3for further details. Subjects who meet all study  
inclusion and none of the exclusion criteria will begin a 14to 21day single -blind run- in 
period following Visi t 1.  Baseline BMD measurements will be collected between Visits 
1 and 2.  At Visit 2, eligible subjects will be randomized to double -blind study  
medication and entered into a 156- week treatment period.  Randomisation will be 
stratified based upon gender. During the treatment period, clinic visits will occur every  3 
months. BMD DEXA scans will be conducted every 6 months following randomization. 
A safet y Follow -up Visit 15 will occur 7 days after the last treatment study  day as a 
telephone contact.  Subjec ts will be prescribed appropriate COPD therapy  at the end of 
Treatment Visit 14 if required.  There are no plans to provide the study  drug for 
compassionate use following stud y completion.
Systemic corticosteroid therapies will not be allowed during the ru n-in period.  Subjects 
may take courses of systemic corticosteroids, where necessary , for treatment of a COPD 
exacerbation during the double- blind treatment period. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
163.1.1. Study Schematic
FF/VI 100/25 once daily (N=140)
VI 25 once daily (N=140)
           │                          156Week Treatment                                          │ Follow -up
│__│_│__ _│___│_ __│___│___│___│___│___│___│___│___│___│_│
Visits
0     1  2       3       4       5     6     7       8       9      10     11    12     13     14  15
                             
Randomization
3.2. Discussion of Design
The purpose of this stud y is primarily  to assess the long -term safet y effects of the FF 
component of the FF/VI inhalation powder on bone mineral densit y when administered to 
subjects with COPD over 156 weeks.  The American Thoracic Societ y (ATS)/European 
Respiratory  Society definition of COPD defines the subject population that will be 
included in this study  [Celli , 2004].  BMD at the total hip was chosen as the primary  
endpoint due to the important morbidity /mortality implications of hip fractures.  BMD at 
the lumbar spine (L1 -L4) will be measured and assessed as asecondary  endpoint.   
4. SUBJECT SELECTION A ND WITHDRA WAL CRITERI A
4.1. Number of Subjects
Approximatel y 400male and female subjects will be screened to randomize 
approximately  280 subjects, to obtain at least 224who complete 156 weeks of treatment.  
Approximately  40centres in multiple countries will be required to recruit for the study .
4.2. Inclusion Criter ia
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the GSK investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IB.
Deviations f rom inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrit
y of the study, regulatory acceptability or subject safety. Therefore, 
adherence to the criteria as specified in the protocol is essential .    2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
17Subjects el igible for enrolment in the study  must meet all of the following criteria:
1.Informed consent: Subjects must give their signed and dated written informed 
consent to participate.
2.Gender: Male or female subjects. Female subjects must be post -menopausal or usi ng 
a highl y effective method for avoidance of pregnancy . The decision to include or 
exclude women of childbearing potential may  be made at the discretion of the 
investigator in accordance with local practice in relation to adequate contraception.
3.Age: ≥ 40 y ears of age at Screening (Visit 1)
4.COPD diagnosis: Subjects with a clinical history of COPD in accordance with the 
following definition by  the American Thoracic Society /European Respiratory  Societ y 
[Celli , 2004]: COPD is a prev entable and treatable disease characterized by  airflow 
limitation that is not fully  reversible.  The airflow limitation is usually  progressive 
and is associated with an abnormal inflammatory  response of the lungs to noxious 
particles or gases, primarily  caused by  cigarette smoking.  Although COPD affects 
the lungs, it also produces significant s ystemic consequences.
5.Tobacco use: Subjects with a current or prior history  of≥10 pack -years of cigarette 
smoking at screening (Visit 1).  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Number of pack y ears = 
(number of cigarettes per day /20) x number of y ears smoked
Note: Pipe and/or cigar use cannot be used to calculate pack year history .
6.Severity of Disease: Subject with a measured pre -and post-albuterol/salbutamol 
FEV 1/FVC ratio of < 0.70 at Screening (Visit 1).  Subjects with a measured post -
albuterol/salbutamol 50% ≤ FEV 1≤ 70% of predicted normal values calculated using 
NHANES III reference equations [ Hankinson, 1999] at Screening (Visit 1).
7.Native Hip: Have at least one evaluable native hip.
4.3. Exclusion Criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essential. 
Subjects meeting any of the followin g criteria must not be enrolled in the study :
1.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
2.Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history  
of asthma are eligible i f they  have a current diagnosis of COPD).
3.α1-antitrypsin deficiency: Subjects with α -1 antitry psin deficiency  as the underly ing 
cause of COPD. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
184.Other respiratory disorders: Subjects with tuberculosis, lung cancer, 
bronchiectasis, sarcoidosis, lung fibrosis, pulmonary  hypertension, interstitial lung 
diseases or other active pulmonary  diseases.
5.Lung resection or transplantation: Subjects with lung volume reduction surgery 
within the 12 months prior to Screening Visit 1 or having had a lung transplant.
6.Chest X -ray:  Subjects with a chest X -ray (or CT scan) that revealed evidence of 
clinically  significant abnormalities not believed to be due to the presence of COPD.  
A chest X -ray should be taken at Screening Visit 1 if a chest X -ray or CT scan is not 
available w ithin 12 months prior to Visit 1.
7.Poorly controlled COPD: Subjects with poorly  controlled COPD, defined as the 
occurrence of the following in the 12weeks prior to Screening Visit 1
: Acute 
worsening of COPD that is managed b y the subject with corticosteroi ds or antibiotics 
or that requires treatment prescribed b y a physician or requires hospitalization.
8.Moderate or severe COPD exacerbation or lower respiratory tract infection:
Subjects with 2 or more moderate or severe COPD exacerbations and/or a lower 
respiratory  tract infection (including pneumonia) within th e 12 months prior to 
Screening Visit 1 or experience a moderate or severe COPD exacerbation and/or a 
lower respiratory  infection (including pneumonia) during the Run- In period.
NOTE: A moderate COPD exacerbation is defined as requiring s ystemic 
corticosteroids and/or antibiotics.  A severe COPD exacerbation is defined as 
requiring hospitalization.
9.Abnormal clinically significant laboratory finding: Subjects who have an 
abnormal, clinicall y significant finding in any  liver chemistry , biochemical, or 
haematology  tests at Screening Visit 1 or upon repeat prior to randomization.
10.Abnormal and clinically signif icant 12- lead ECG :Subjects who have an abnormal, 
clinically  signif icant ECG finding at Screening Visit 1.
11.Non-Compliance during Run- In Period : Failure to demonstrate adequate 
compliance with run -in medication (< 80% compliant), the ability  to withhold COPD 
medications, and to keep clinic visit appointments.
12.Bone disorders/conditions: Subjects with historical or current evidence of bone 
cancer, severe scoliosis, rheumatoid arthritis, metabolic bone diseases (other than 
osteoporosis) including hyper -or hypo-parathy roidism, Paget’s disease of bone, 
osteomalacia, or osteogenesis imperfecta. Removal of verteb rae between L1 and L 4 
of the lumbar spine and/or presence of metal implants or devices, such as plates, rods, 
or screws in the lumbar spine and/or hip.
13.Immobility: Wheel chair bound or paraplegic.
14.Low vitamin D: Previously  known low- serum 25 -hydroxy  vitami n D concentration 
(less than 10ng [25nmoles] per liter). 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
1915.Other diseases/abnormalities: Serious, uncontrolled disease (including serious 
psychological disorders) likely to interfere with the study  within the 3- year study .
16.Cancer: Subjects with carcinoma tha t has not been in complete remission for at least 
5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell 
carcinoma of the skin would not be excluded if the subject has been considered cured 
within 5 y ears since diagnosis.
17.Drug/food allergy: Subjects with a history  of hy persensitivity  to an y of the study  
medications (e.g. beta- agonists, corticosteroid) or components of the inhalation 
powder (e.g. lactose, magnesium stearate). In addition, patients with a history of 
severe milk prote in allergy  that, in the opinion of the study  physician, contraindicates 
the subject’s participation will also be excluded. 
18.Drug/alcohol abuse: Subjects with a known or suspected history  of alcohol or drug 
abuse within the last 2 y ears.
19.Prohibited medicati ons prior to spirometry at Visit 1: Subjects who are medically  
unable to withhold the following medications prior to spirometr y testing at Visit 1:
Medication No use within the following 
time intervals prior to Visit 1 
Spirometry Testing 
Inhaled corticos teroids 48 hours
Inhaled ICS/LABA combination products 48 hours 
Long- acting anticholinergics (e.g., tiotropium) 48 hours
Theophylline preparations 48 hours
Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton) 48 hours
Oral PDE -4 inhibitors (e.g. roflumilast) 48 hours
Oral beta -agonists 
     Long- acting
     Short -acting48 hours
12 hours
Inhaled long acting beta 2-agonist (LABA) -Indacaterol 48 hours
Other i nhaled LABA s(e.g., salmeterol) 24 hours 
Inhaled sodium cromoglycate or nedo cromil sodium 24 hours
Ipratropium/ albuterol (salbutamol) combination product 4 hours 
Inhaled short- acting beta 2-agonists 4 hours 
Short -acting anti -cholinergics (e.g., ipratropium bromide) 4 hours 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
2020.Additional medication: Use of the following medications within the following time 
intervals prior to Visit 1 or during the study  (unless otherwise specified):
Medication No use within the following time intervals prior to 
Screening Visit 1 or thereafter at any time during the 
study (unless otherwise spec ified)
Depot corticosteroids 12 weeks
Systemic, Oral, parenteral, intra -
articular corticosteroids130 days   
Any other investigational drug 30 days or 5 half lives whichever is longer.
1. Subjects may take courses of systemic corticosteroids, where neces sary, for treatment of an exacerbation 
during the double -blind treatment period .
21.COPD medications: Use of inhaled corticosteroids (I CS), long -acting beta 2-agonists 
(LABA), or ICS/LABA combination products (other than the stud y-provided double -
blind study medication) at Visit 2 (Randomization) or during the double -blind 
treatment period.
22.Oxygen therapy: Subjects receiving treatment with long -term oxy gen therapy  
(LTOT) or nocturnal oxygen therapy  required for greater than 12 hours a day .  
Oxygen prn use (i.e., ≤12 hours per day) is not exclusionary .
23.Pulmonary rehabilitation: Subjects who have participated in the acute phase of a 
Pulmonary  Rehabilitation Program wit hin 4 weeks prior to Screening Visit 1 or who 
will enter the acute phase of a Pulmonary  Rehabil itation Program during the study . 
Subjects who are in the maintenance phase of a Pulmonary  Rehabilitation Program 
are not excluded.
24.Non-compliance: Subjects at risk of non- compliance, or unable to comply  with the 
study  procedures.  Any  infirmity , disabilit y, or geographic location that would limit 
compliance for scheduled visits.
25.Questionable validity of consent: Subjects with a history  of ps ychiatric disease, 
intellectual deficiency , poor motivation or other conditions that will limit the validity  
of infor med consent to participate in the study
26.Affiliation with investigator site: Study  investigators, sub- investigators, study  
coordinators, emplo yees of a participating investigator or immediate family  members 
of the aforementioned are excluded from participat ing in this study .
4.4. Withdrawal Criteria
A subject may  voluntarily  discontinue participation in this study  at any  time.  The 
investigator may
 also, at his or her discretion, discontinue a subject from this study  at any  
time.  Every  effort should be made b y the investigator to keep the subject in the study .   2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
21The primary  reason for subject withdrawal will be recorded in the electronic Case Report 
Form (eCRF). Primary  reasons for withdrawal will be categorised as:
adverse event
withdrew consent
lost to follow -up
protocol deviation
lack of efficacy
subject reached protocol -defined stopping criteria
study  closed/terminated
investigator discretion
Subject compliance with double -blind study  medication will be assessed at Visits 2 
through 14, by  reviewing the dose c ounter on the N DPI.  Subjects must be ≥80% to 
≤120% compliant on taking stud y medication between each pair of on -treatment visits. 
Subjects who fall outside this range should be re -educated on treatment compliance by  
their site. This re -education should be documented in the subject’s source document. If 
the double- blind study  medication is prematurely  discontinued during the course of study  
or medication compliance repeatedl y falls outside of acceptable ranges, the study 
sponsor/site monitor must be cont acted to discuss subject eligibility  for continued 
participation in the study .
A subject will also be withdrawn from the study , in consultation with the medical
monitor and principal investigator, if an y of the following stopping criteria are met:
Liver Ch emistry : Meets any  of the liver chemistry  stopping criteria as defined 
in Section 6.2.7.
Pregnancy: 
Positive pregnancy  test
Laboratory Measurements:   Demonstrate a clinically  important change in a 
laboratory  parameter(s).
If a subject is withdrawn due to an exacerbation, the exacerbation section and SAE 
section, if applicable, of the eCRF should be completed and the subject should be 
followed until resolution of exacerbation.
If a subject is withdrawn due to pneumonia, the AE/SA E section and the 
pneumonia/chest x -ray section of the eCRF should be completed and the subject should 
be followed until clinical resolution of the pneumonia. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
224.5. Pre-Screen Failures and Screening Failures
A subject will be assigned a subject number at the tim e the informed consent is signed.
A subject who is assigned a subject number but does not have Visit 1 will be considered a 
pre-screen failure.
Any subject who performs a Visit 1 procedure but does not continue in the study  beyond 
Visit 1 or any  subject wh o completes Visit 1 and enters the run -in period, but is 
subsequently  found to be ineligible for the study  (e.g. exclusionary  laboratory , ECG, or 
spirometry  findings) conducted prior to randomization to the study  treatment medication
(Visit 2) , is classifi ed as a ‘screen failure’.
The study  interactive voice response s ystem (IVRS) will be contacted to report pre -screen 
failures. The following information will be collected for subjects who are pre -screen 
failures:
Subject number
Date of ICF signature
Demogra phic information including race, age and gender
Details of COPD medications within 3 0daysof Visit 0
Details of COPD exacerbation (yes/no status), if applicable
Serious Adverse Event information, if applicable, only  for an SAE considered as 
related to stu dy participation (e.g. stud y treatment, protocol mandated 
procedures, invasive tests, or change in existing therap y) or related to a GSK 
concomitant medication
Investigator signature page
IVRS will be contacted to report screen failures, In addition to the information above, the 
following information will be collected for screen failures:
Date of screening visit
Reason for screen failure (screening failure and inclusion/exclusion criteria)
5. STUDY TREA TMENTS
5.1. Investigational Product and Other Study  Treatment
GSK Clinical Trials Supplies will provide the investigational products for use in this 
study . All blinded study  medication will be delivered via the NDPI. At each dispensing 
each subject will receive one NDPI for once -daily  administration. The contents of e ach 
treatment are described in Table 1 andTable 2
The NDPI provides a total of 30 doses (60 blisters), with each actuation comprising the 
contents of one blister from each of the two internal foil strip s simultaneously . The  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
23NDPI s containing randomized treatment and dummy  medication (placebo) will appear 
identical on the outside to the subject (and his/her caregiver) and the Investigator.
All subjects will receive supplemental albuterol/salbutamol (MDI an d/or nebules) to be 
used on an as -needed basis throughout the study ; for all sites this medication will be 
sourced locally where possible.
Following the 14 to 21 day , Run -In period, eligible subjects will be randomized (1:1) to 
one of the following two pos sible treatments, administered each morning for 156 weeks:
FF/V I Inhalation Powder 100/25mcg QD
VI Inhalation Powder 25mcg QD
Randomization in each treatment group will be stratified (1:1) according to gender.
A description of the investigational treatment s is provided below:
Table 1 Description of FF/VI Inhalation Po wder Novel Dry  Pow der Inhaler
(NDPI)
Formulation First strip : Fluticasone Furoate  
blended with lactoseSecond strip : Vilanterol micronised 
drug (as the ‘M’ salt 
triphen ylacetate) blended with 
lactose and magnesium stearate1
Dosage Form Novel dry powder inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 100mcg per blister 25mcg per blister
Physical description Dry white powder Dry white pow der
Route of Administration Inhaled Inhaled
1. Magnesium stearate 1% w/w of total drug product
Table 2 Description of VI Inhalation Powder Novel Dry  Powder Inhaler (NDPI)
Formulation First s trip: lactose  Second strip : Vilanterol micronised 
drug (as the ‘M’ salt 
triphenylacetate) blended with 
lactose and magnesium stearate1
Dosage Form NDPI with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths N/A 25mcg per blister
Physical description Dry white powder Dry wh ite powder
Route of Administration Inhaled Inhaled
1. Magnesium stearate 1% w/w of total drug product
The contents of the label will be in accordance with all applicable regulatory  
requirements. Under normal conditions of handling and administration, inve stigational 
product is not expected to pose significant safet y risks to site staff. Take adequate 
precautions to avoid direct ey e or skin contact and the generation of aerosols or mists. 
Notify  the monitor of any  unintentional occupational exposure. A Mate rial Safety  Data 
Sheet (MSDS) describing the occupational hazards and recommended handling 
precautions will be provided to site staff if required by  local laws or will otherwise be 
available from GSK upon request. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
24Adequate precautions must be taken to avoid direct contact with the investigational 
product. The occupational hazards and recommended handling procedures are provided 
in the Material Safet y Data Sheet (MSDS) .
5.1.1. Storage
Investigational product must be stored in a secure area under the appropriate ph ysical 
conditions for the product.  Access to and administration of the investigational product 
will be limited to the investigator and authorized site staff.  Investigational product must 
be dispensed or administered onl y to subjects enrolled in the study and in accordance 
with the protocol.
The NDPIs are packaged in a foil overwrap with enclosed desiccant.  The foil overwrap 
must not be opened until immediately  prior to use.  Once the foil overwrap has been 
opened the NDPI has a 30 day  in-use shelf life.
5.1.2. Study Drug Return
At the end of the stud y, all study -supplied study  medication (used and unused) will be 
destroy ed following local standard operating procedures, except where it is suspected that 
the NDPI or NDPI packaging is defective. The NDPI and packag ing should be returned 
to GSK.
Details for both destruction and return of study  medication are found in the SPM.
In addition, any  study  inhaler that fails to function pro perly must be identified to GSK 
personnel for return to GSK for testing. Details of t he fa ilure will be documented in the 
eCRF. The subject should return the NDPI to the clini c as soon as possible and avoid 
missing an y doses if possible. The site should then call IVRS and obtain a new treatment 
pack number for this subject and dispense a new study medication kit from the site's 
investigational product supply  as instructed b y RAMOS, an Interactive Voice Response 
System (IVRS).
5.2. Treatment A ssignment
Subjects will be assigned to study  treatment in accordance with the randomization 
schedule. Once a randomization number has been assigned to a subject, the same number 
cannot be reassigned to any  other subject in the study .
Subjects will be stratified based on gender .
Subjects will be site -based randomized using RAMOS , an I nteractive Voice Respon se 
System (IVRS). This is a telephone based s ystem thatwill be used by  the investigator or 
designee to register the subject (initially  at Visit 0 , and subsequentl y at each study visit) , 
randomize the subject and provide medication assignment information. Details on how 
to use RAMOS to register and randomize subjects is provided in the SPM. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
25Following the 14- 21 day , Run -In period, eligible subjects will be randomized ( 1:1) to one 
of the following 2 possible treatments, administered as one inhalation each m orning and 
evening for 156 weeks:
Fluticasone Furoate /Vilanterol 100/25mcg once daily
Vilanterol 25mcg once daily
5.3. Blinding
Study  Medication taken during the 156-week treatment period will be double- blind. 
Neither the subject nor the study  physician will k now which study  medication the subject 
is receiving.
The investigator or treating ph ysician may  unblind a subject’s treatment assignment only 
in the case of an emergency , when knowledge of the study  treatment is essential for the 
appropriate clinical manag ement or welfare of the subject.  Whenever possible, the 
investigator must first discuss options with the GSK Medical Monitor or appropriate 
GSK study  personnel before unblinding the subject’s treatment assignment.  If this is 
impractical, the investigator must notify  GSK as soon as possible, but without revealing 
the treatment assignment of the unblinded subject, unless that information is important 
for the safet y of subjects currentl y in the stud y.  The date and reason for the unblinding 
must be recorded in the appropriate data collection tool.
GSK’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  subject with an SAE.  If the SAE requires that an expedited 
regulatory  report be sent to one or more regul atory agencies, a cop y of the report, 
identify ing the subject’s treatment assignment, may  be sent to clinical investigators in 
accordance with local regulations and/or GSK policy.
Subjects will be withdrawn if the treatment code becomes unblinded. The pri mary  reason 
for discontinuation (the event or condition which led to the unblinding) will be recorded 
in the eCRF.
5.4. Product A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical inst itution (where applicable) must document the amount of 
investigational product dispensed and/or administered to study  subjects, the amount 
returned b y stud y subjects, and the amount received from and returned to GSK , when 
applicable .  Product accountabilit y records must be maintained throughout the course of 
the study .
5.5. Treatment Compliance
An initial supply  of albuterol (salbutamol), a short -acting, beta 2-agonist, will be provided 
to each subject to use as needed for s ymptomatic relief of COPD s ymptoms duri ng both 
the Run
-in and Treatment Periods.  The subject’s use of albuterol (salbutamol) will be 
assessed at each clinic visit and additional albuterol (salbutamol) will be dispensed to the 
subject as needed. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
26Subject compliance with the single -blind placebo NDPI  during Run- In will be assessed at 
Visit 2 by  reviewing the dose counter on the NDPI.
Subject compliance with double -blind study  medication will be assessed at each 
treatment visit (from Visits 3 - Visit 14) and an y unscheduled visit where study drug i s 
returned b y reviewing the dose counter on the NDPI
.  Subjects must be ≥ 80% to ≤120% 
compliant on taking study medication between each pair of on -treatment visits. Subjects 
who fall outside this range should be re- educated on treatment compliance by  their site. 
This re -education should be documented in the subject’s source document.  If the double-
blind study  medication is prematurel y discontinued during the course of study or 
medication compliance repeatedl y falls outside of acceptable ranges, the study  
sponsor/site monitor must be contacted to discuss subject eligibility  for continued 
participation in the study .
5.6. Concomitant Medications and Non -Drug Therapies
All COPD medications taken within 30 day sprior to Visit 0and during the run -in period 
will be r
ecorded in the eCRF.  All COPD and non-COPD concomitant medications taken 
during the stud y will be recorded in the eCRF.  The minimum requirement includes, but 
is not limited to name of the medications, and the dates of the administration.
Note: Care is advised when co- administering with strong CYP 3A4 inhibitors (e.g. 
ketoconazole, ritonavir) as there is potential for an increased sy stemic exposure to both 
fluticasone furoate and vilanterol, which could lead to an increase in the potential for 
adverse reac tions.
5.6.1. Permitted Medications and Non -Drug Therapies
The following medications are permitted during the Screening and Treatment periods:
COPD Medications
Study  supplied albuterol/salbutamol (MDI or nebules) for s ymptomatic relief during 
the Run- In and Doubl e-Blind Treatment period
Mucoly tics at constant dosage
Oxygen for intermittent use or PRN therap y ≤ 12 hours per day  is allowed. (Subjects 
requiring LTOT or nocturnal oxy gen therap y required for greater than 12 hours a day  
are excluded from the study .)
Theophy llines (long and short -acting)
Short -acting anti -cholinergic agents
Long -acting anti -cholinergic agents
Short -acting beta2 -agonists; i.e. albuterol
Beta2 -agonist -anti-cholinergic combinations; i.e. Combivent
Subjects may  take courses of sy stemic corticosteroids, where necessary , for treatment 
of an exacerb ation. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
27Non-COPD Medications
Cardioselective beta -blockers (stable dose) and ophthalmic beta -blockers.
(Administer with caution as they  may  block bronchodilatory  effects of beta -agonists 
and produce severe bronchospasm).
Care is advised when co-administering with strong CYP 3A4 inhibitors (e.g. 
ketoconazole, ritonavir) as there is potential for an increased sy stemic exposure to 
both fluticasone furoate and vilanterol, which could lead to an increase in the 
potential for adverse reactions.
Antihistamines and nasal decongestants
Over -the-
counter (OTC) cough suppressants (for short term treatment ≤7day s)
Intranasal sodium cromogl ycate or nedocromil sodium
Intranasal corticosteroids, provided the subject is on a stable dail y dose for at least 4 
weeks prior to Visit 1 and remains on this dose throughout the stud y
Topical ( ≤1 % h ydrocortisone in strength) or ophthalmic corticosteroids
Influenza and/or pneumonia vaccination
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effects of beta- agonists on the vascular 
system.
Diuretics. Caution is advised in the co -administration of beta -agonists with 
nonpotassium sparing diuretics.
Treatment(s) for smoking cessation
All medications for other disorders as long as the dose re mains constant wherever 
possible.
5.6.2. Prohibited Medications and Non- Drug Therapies
Medications prohibited at specific tim e intervals prior to Screening Visit 1 and at any  
time during the stud
y are identified in Section 4.3Exclus ion Criteria.
If a subject’s current medication is going to be changed in order to participate in the 
study , then consent must be obtained prior to an y medication change and the subject will 
be required to return to the clinic to complete the Screening Visit 1 once the protocol 
specified time period has been completed.
5.7. Treatment after the End of the Study
At the end of the treatment period (Visit 14 or Early  Withdrawal), subjects can resume 
conventional COPD therapy  as prescribed by  the Investigator.  There are no plans to 
provide the study  drug for compassionate use following study  completion. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
28The investigator is responsible for ensuring that consideration has been given to the post -
study  care of the patient’s medical condition whether or not GSK is providi ng specific 
post study  treatment.
5.8. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than what is instructed (see Section 5.1), which 
results in clinical signs and sy mptoms.  In the event of an overd ose of study  medication, 
the investigator should use clinical judgement in treating the overdose and contact the 
study  medical monitor. GSK is not recommending specific treatment guidelines for 
overdose and toxicity  management.  The investigator should re fer to the relevant 
document(s) for detailed information regarding warnings, precautions, contraindications, 
adverse events, and other significant data pertaining to the stud y drug(s) being used in 
this study .  Such documents may  include, but not be limite d to, the approved product 
labeling for 
albuterol (salbutamol) , and the IB or equivalent document provided by  GSK 
for double blind medications.
6. STUDY A SSESSMENTS A ND PROCEDURES
The Time and Events Table is provided in Table 3.  Al l study  assessments should be 
conducted b y the investigator or his/her qualified designee. Please refer to the SPM for a 
suggested order of assessments.  2018N368712_00
2012N150072_00 CONFIDE NTIA L
HZC102972
29Table 3 Time and Events Table
Double -Blind Treatment period
Visit Numb er0
Pre-
screen11
Screen -
ing22
Random -
ization3 4 5 6 7 8 9 10 11 12 13 14
Early 
With -
draw15
Follow
-up
Day 113 
wks 
1426 
wks 
1439 
wks 
1452 
wks 
1465 
wks 
1478 
wks 
1491 
wks 
14104 
wks 
14117 
wks 
14130 
wks 
14143 
wks 
14156 
wks 
14Visit 
14/EW 
+ 7±2
Days Days Days Days Days Days Days Days Days Days Days Days Days
Assessments
Informed consent3 X
PGx Consent & 
Sampling4X
Demography X
Medical History X
Physical Exam X X X X X
Spirometry Testing X X X X X X X X X
Reversibility Testing X
Smoking history/
smoking statusX X X X X X X X X X X X X X X
Smoking cessation 
counseling X X X X X
Register visit on 
IVRS5X X X X X X X X X X X X X X X X X
Safety Assessments
BMD DEXA scans6 X X X X X X X X
Oropharyngeal 
examination7X X X X X X X X X X X X X X X
Chest X -ray8 X
Lab Tests9/ Serum 
Pregnancy T est10X 
 
 2018N368712_00
2012N150072_00 CONFIDE NTIA L
HZC102972
30Double -Blind Treatment period
Visit Numb er0
Pre-
screen11
Screen -
ing22
Random -
ization3 4 5 6 7 8 9 10 11 12 13 14
Early 
With -
draw15
Follow
-up
Day 113 
wks 
1426 
wks 
1439 
wks 
1452 
wks 
1465 
wks 
1478 
wks 
1491 
wks 
14104 
wks 
14117 
wks 
14130 
wks 
14143 
wks 
14156 
wks 
14Visit 
14/EW 
+ 7±2
Days Days Days Days Days Days Days Days Days Days Days Days Days
12-lead ECG & 
Rhythm StripX
Exacerbation 
AssessmentX X X X X X X X X X X X X X X X
Adverse Event 
Assessment11X X X X X X X X X X X X X X X
Serious Adverse 
Event Assessment12X X X X X X X X X X X X X X X X X
Dispense Diary X X X X X X X X X X X X X
Collect/ Review Diary X X X X X X X X X X X X X X
Medication 
Assessments
Concurrent 
Medication 
Assessment13X X X X X X X X X X X X X X X X X
Dispense albuterol 
(salbutamol)14X X X X X X X X X X X X X
Dispense Double -
Blind MedicationX X X X X X X X X X X X X
Collect Double -Blind 
MedicationX X X X X X X X X X X X X X X
Other Assessment 
Discharge from 
Study15X X 
 
 2018N368712_00
2012N150072_00 CONFIDE NTIA L
HZC102972
311. Visit 0 and Visit 1 may oc cur on the same day.
2. Following Screening Visit 1 , subjects enter a 14 to 21 day single -blind run- in period
3. Subjects will be assigned a subject number at the time ICF is signed. The ICF must be signed before any study procedures incl uding drug washout(s).  
4. Saliva (2ml) sample is collected in the DNA self -collection kit.  This should ideally be taken as soon after randomization (Visit 2) as possible, but may be taken at any othe r visit 
after randomization if necessary.  PGx consent must be signed prior to PG x sampling.
5. A telephone based IVRS system (RAMOS) which will be used by the investigator or designate to register the subject, randomize the subject and provide medication assignment 
information.
6. Baseline BMD measurements will be collected between Visit 1 and Visit 2 .
7. If evidence of infection, culture swab may be taken and appropriate therapy should be instituted at Investigator discretion. Subjects with culture -positive infection may continue 
in the study on appropriate anti -infective treatment at Investi gator discretion.
8. Chest X -ray must be taken if a Chest X -ray or CT scan is not available within the 12months preceding Visit 1 . Chest x- rays will be requested for suspected cases of pneumonia.
9. Non-fasting and pre -dose. Visit 2: pre-dose lab only completed if any part of Screening lab needs to be repeated
10. Females of child -bearing potential only
11. Adverse events are to be collected from the start of blinded study medication (Visit 2) until the follow -up phone contact.
12. Serious adverse events are to be collected from the start of study drug (Visit 2) until the follow -up phone contact.  However, any SAEs assessed as related to study participation 
will be recorded from the time subjects sign informed consent.
13. All COPD medications taken within 30 days prior to Visit 0will be collected.
14. Collect and re -dispense as needed after Visit 1 .
15. Discharge from study on appropriate therapy. 
 
 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
326.1. Critical Baseline A ssessments
No study related procedures may be performed until the informed consent form 
document has been signed by t he subject.  A pre -screening visit may be required in 
order to administer the informed consent before any changes are made to the subject’s 
current medication regimen. Selection and modification of subject’s medications prior to 
study  participation is base d on the ph ysician’s judgment according to sound medical 
practice, principles, and each subject’s needs. A subject‘s treatment must not be changed 
merel y for the purpose of enabling the subject’s participation in the study. The informed 
consent may  be give n at the screening visit if the subject does not take or has not taken 
any protocol excluded medications. During the pre -screening visit (Visit 0), each subject 
will have the following demographic information collected:
Demographic history  (including gende r, ethnic origin, date of birth)
During Screening Visit 1, each subject will undergo the following assessments :
Medical history  (including COPD and smoking history )
Cardiovascular medical history /risk factors will be assess ed at baseline.
Inclusion/Exclusi on criteria assessment
Concomitant medication review
ECG and rh ythm strip
Spirometry  with reversibility  testing
Physical exam (including vital signs)
Laboratory  assessments (including chemistry , hematology , hepatitis, and pregnancy )
See Section 4.5for information regarding Screen ing Failures.
6.2. Safet y
6.2.1. Primary  Endpoint
BMD measured at the total hip 
6.2.2. Secondary  Endpoint s
BMD measured at the lumbar spine (L1 -L4)
BMD measurements b y gender
6.2.3. Other Endpoints
Adverse Event reporting 
Serious Adverse Event reporting
Incidence of fractures 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
33Incidence of pneumonias
COPD exacerbations
6.2.4. Bone Mineral Density
Effects on the skeletal s ystem will be assessed b y measuring bone mineral density  
(BMD) using dual energy x -ray absorptiometry  (DEXA) with established methodology .  
DEXA measurements of the total hip and the L 1-L4regions of the spine will be 
completed at baseline, 26 weeks, 52 weeks, 78 weeks, 104 weeks, 130 weeks, and 156 
weeks or end of stud y treatment.
All DEXA scans will be conducted b y qualified technicians and sent electronically  for 
centralized anal ysis.  Quality  assurance and calibration of DEXA equipment and 
densitometric measurements will be monitored by this facility  to control for site -to-site 
variability  in BMD measurements.
Acce ptable DEXA measurements must be conducted prior to the first dose of 
randomized study medication.
DEXA Assessments
At Screening, an y subject with a T score < -1.5 (assessed from the L 1-L4regions of 
the spine or the total hip) will be counseled about the clinical implications of this 
value.
At any  visit after randomization to double -
blind treatment (Visit 2) through Visit 10, 
any subject with a bone mineral density  loss of  8% from baseline (assessed from 
the L 1-L4regions of the spine or the total hip) wi ll be counseled about the clinical 
implications of this value.
At any  visit after 2 y ears (Visit 10), any  subject with a bone mineral densit y loss of 
10% from baseline (assessed from the L 1-L4regions of the spine or the total hip) 
will be counseled about the clinical implications of this value.
6.2.5. Fractures
For an y fractures that occur after the initiation of the double -blind study  drug, the 
location of the fracture, and whether it is considered traumatic or non -traumatic must be 
recorded on the Fractures pa ge of the eCRF. Severity  of a fracture should be determined 
by the Investigator.  Details regarding the information to be captured for fractures will be 
provided in the SPM.
6.2.6. COPD Exacerbations and Pneumonias
For the purpose of this study , exacerbation of C OPD is defined by  a worsening of 
symptoms requiring additional treatment as follows: 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
34•A mild COPD exacerbation: managed b y subject with increased use of prn 
medications
•A moderate COPD exacerbation: requires treatment with antibiotics and/or 
systemic cortic osteroids
• A severe COPD exacerbation: requires hospitalization
Any subject experiencing worsening of s ymptoms should:
•Contact his/her study  investigator and/or research coordinator immediatel y, and 
report to the study  clinic as required
•If the subject is u nable to contact his/her study  investigator and/or research 
coordinator, they  should contact their primary  care phy sician (or other health care 
practitioner as required) and contact their stud y site as soon as possible
•If the subject seeks emergent/acute c are for worsening respiratory  symptoms, 
he/she should inform the caring Health Care Provider (HCP) to contact the 
investigator as soon as possible.
Subjects with presence of worsening respiratory  symptoms will be classified by  the 
Investigator as having:
• A mild/moderate/severe COPD exacerbation and/or pneumonia
OR
•A lower respiratory  tract infection (LRTI) [i.e. other than pneumonia]
•Background variability  of COPD
•A non- respiratory  related disease
•Other respiratory  related disease
The time period for collection of COPD exacerbations will begin from the time of Visit 2 
(Randomization) and will end when the 7±2day  Follow -up period has been completed.
Exacerbations that meet the definition of an SAE, will be recorded on the appropriate 
eCRF section and should be reported to GSK for all subjects regardless of whether or not 
they are randomized to blinded study  medication.
Subjects are excluded from participating if any  of the following appl y:
•They  have poorly  controlled COPD, defined as the occurrence of the foll owing in 
the 12 weeks prior to Screening Visit 1 : Acute worsening of COPD that is 
managed b y the subject with corticosteroids or antibiotics or that requires 
treatment prescribed b y a phy sician or requires hospitalization . 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
35•They  have 2 or more moderate or severe COPD exacerbations and/or a lower 
respiratory  tract infection 
(including pneumonia) within th e 12 months prior to 
Screening Visit 1 or experience a moderate or severe COPD exacerbation and/or a 
lower respiratory  infection (including pneumonia) during the Run- In period.
The dates of onset and resolution of each COPD exacerbation should be based on when 
the Investigator and/or subject determines that the COPD sy mptoms initially  started and 
then returned to pre -exacerbation levels.
If an exacerbation beg ins as mild, but becomes moderate or severe or begins as moderate 
and becomes severe, the exacerbation should be captured as one exacerbation and 
classified b y its highest level of severity.
For the purpose of this study , pneumonia is defined as new auscul tatory  findings 
compatible with parenchy mal lung infection and/or radiographic evidence of 
parench ymal/air space disease. All suspected cases of pneumonia are encouraged to be 
confirmed radiographically  within 48 hours of diagnosis. All diagnoses of pneumo nia 
(radiographicall y confirmed or unconfirmed) must be reported as an AE or SAE (if 
applicable). Information regarding chest X -ray-confirmed cases of pneumonia will be 
recorded in the eCRF. Details regarding the information to be captured for pneumonias 
will be provided in the SPM.
Definitions for COPD exacerbations and pneumonia are given above. If, based upon 
these criteria, a subject’s sy mptoms do not fulfill the diagnosis of an exacerbation and/or 
pneumonia, then the investigator should use his/her cli nical judgment to assess the 
subject’s sy mptoms (including increased volume of sputum production and/or change in 
the sputum color) for a diagnosis of LRTI (e.g. acute bronchitis), background variability  
of COPD, a non -respiratory  related disease or other respiratory  related disease.
Investigator judgment should be used in deciding whether to report the signs and 
symptoms (and/or determined diagnosis) as an AE/SAE in the eCRF. Medication(s) used 
to treat a COPD exacerbation and/or pneumonia are to be record ed in the eCRF.
6.2.7. Liver chemistry  stopping and follow up criteria
Phase III -IVliver chemistry stopping and follow up criteria have been designed to 
assure subject safet y and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical live r safety  guidance) .  
Phase III -IV liver chemistry  stopping criteria 1-5 are defined below and in Appendix 4:
1. AL T 3xULN andbilirubin 2xUL N (>35% direct bilirubin) (or ALT 3xULN and
INR>1.5, if INR measured)
NOTE: 
if serum bi lirubin fractionation is not immediatel y available, withdraw study  drug
for that subject if ALT  3xULN and bilirubin 2xULN. S erum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectab le urinary bilirubin on dipstick , indicating direct bilirubin elevations and 
suggesting liver injury . 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
362. AL T 8xULN.
3. AL T 5xULN but <8 xULN persists for 2weeks
4. AL T  3xULN if associated with sy mptoms (new or worsening) believed to be related 
to hepatitis (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, 
or jaundice) or h ypersensitivity  (such as fever, rash or eosinophilia).
5. AL T 5xULN but <8 xULN and cannot be monitored weekl y for 2 weeks
When any of the liver che mistry stopping criteria 1- 5 is met, do the following:
Immediately 
withdraw investigational product for that subject
Report the event to GSK within 24 hours of learning its occurrence
Complete the liver event CRF and SAE data collection tool if the event a lso meets 
the criteria for an SAE. All events of ALT 3xULN andbilirubin 2xULN (>35% 
direct) (or ALT 3xULN and INR>1.5, if INR measured); INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagula nts), termed ‘Hy ’s Law’, must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) . 
NOTE: 
if serum bilirubin fractionation is not immediatel y available, withdraw study  drug
for that subject ifALT 3xULN andbilirubin 2xULN. S erum bilirubin fractionation 
should be performed if testing is available. If testing is unavailable, record presence of 
detectable urinary bilirubin on dipstick , indicating direct bilirubin elevations and 
suggesting liver injury .
Complete the liver imaging an d/or liver biopsy  CRFs if these tests are performed
Perform liver event follow up assessments, and monitor the subject until liver 
chemistries resolve, stabilize, or return to baseline values as described below. 
Withdraw the subject from the study  after c ompletion of the liver chemistry 
monitoring (unless further safet y follow up is required).
Do not restart investigational product.  
In addition, for criterion 1:
Make every  reasonable attempt to have subjects return to clinic within 24 hours for 
repeat li ver chemistries, liver event follow up assessments (see below), and close 
monitoring
A specialist or hepatology consultation is recommended
Monitor subjects twice weekl y until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values
For criteria 2, 3, 4 and 5:
Make every  reasonable attempt to have subjects return to clinic within 24-72 hrs for 
repeat liver chemistries and liver event follow up assessments (see below) 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
37Monitor subjects weekl y until l iver chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) resolve, stabilize or return to within baseline values; criterion 5 subjects 
should be monitored as frequently  as possible.
Subjects with AL T 5xULN and< 8xULN which exhibit a decrease to ALT x 3 x ULN, 
but <5xUL N and bilirubin <2xUL N without hepatitis sy mptoms or rash, and who can be 
monitored weekl y for 4 weeks :
Notify  the GSK medical monitor within 24 hours of learning of the abnormality  to 
discuss subject safet y
Can continue investigational prod uct 
Must return weekl y for repeat liver chemistries (AL T, AST, alkaline phosphatase, 
bilirubin) until they  resolve, stabilize or return to within baseline 
If at an y time these subjects meet the liver chemistry  stopping criteria, proceed as 
described above
If, after 4 weeks of monitoring, ALT <3xUL N and bilirubin <2xUL N, monitor 
subjects twice monthly  until liver chemistries normalize or return to within baseline 
values. 
For criteria 1 -5, make every  attempt to carry  out the liver event follow up assessmen ts
described below:
Viral hepatitis serology  including:
Hepatitis A IgM antibody;
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM); 
Hepatitis C RNA; 
Cytomegalovirus IgM antibody
;  
Epstein- Barr viral capsid antigen IgM antibod y (or if unav ailable, obtain 
heterophile antibod y or monospot testing);  
Hepatitis E IgM antibody 
Blood sample for PK analy sis, obtained within 72 hours of last dose .  Record the 
date/time of the PK blood sample draw and the date/time of the last dose of 
investigatio nal product prior to blood sample draw on the CRF. If the date or time of 
the last dose is unclear, provide the subject’s best approximation. I f the date/time of 
the last dose cannot be approximated OR a PK sample cannot be collected in the 
time period ind icated above, do not obtain a PK sample. I nstructions for sample 
handling and shipping are in the SPM. 
Serum creatine phosphokinase (CPK) and lactate dehy drogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xUL N
.
Obtain complete blood count with d ifferential to assess eosinophilia. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
38Record the appearance or worsening of clinical s ymptoms of hepatitis or 
hypersensitivity , such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever rash or eosinophilia as relevant on the AE repor t form .
Record use of concomitant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins, on the concomitant medications 
report form.
Record alcohol use on the liver event alcohol intake case report form .
The following are required for subjects with ALT 3xUL N and bilirubin  2xULN (>35% 
direct) but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies.
Serum acetaminophen adduct HPL C assay  (quantifies potential acetaminophen 
contribution to liver injury  in subjects with definite or likely acetaminophen use in 
the preceding week [James, 2009]). NOTE : not required in China.
Only  in those w ith underly ing chronic hepatitis B at study  entry  (identified by  
positive hepatitis B surface antigen):  quantitative hepatitis B DNA and hepatitis 
delta antibody .  NOTE :  if hepatitis delta antibody assay  cannot be performed,, it can 
be replaced with a PC R of hepatitis D RNA virus (where needed) 
–as outlined in: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1153793/.
Liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to 
evaluate liver disease.
6.2.8. Adverse Events
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
AEs will be collected from the start of double -blind Investigational Product and until the 
follow up contact.  
COPD exacerbations should no t be recorded as an adverse event, unless they meet the 
definition of a Serious Adverse Event.  For the purposes of this study , COPD 
exacerbations will be collected and recorded on the COPD exacerbation log in the eCRF.  
The time period for collection of COPD exacerbations will begin from the time of Visit 2 
(Randomization) and will end when the 7 -day Follow -up period has been completed.
The investigators and site staff should remain vigilant for the possible development of 
pneumonia in patients with COPD a s the clinical features of such infections overlap with 
the sy mptoms of COPD exacerbations. Risk factors for pneumonia in patients with 
COPD receiving fluticasone furoate/vilanterol include current smokers, patients with a 
history  of prior pneumonia, patie nts with a body  mass index <25 kg/m2and patients with 
an FEV 1<50% predicted.  For all suspected cases of pneumonia, Investigators are
encouraged to confirm the diagnosis ( this includ esobtaining a chest x -ray) and to initiate 
appropriate therap y as prompt ly as possible. All diagnoses of pneumonia 
(radiographicall y confirmed or unconfirmed) must be reported as an AE or SAE (if 
applicable). 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
39All AEs and SAEs will be followed until resolution, until the condition stabilizes, until 
the event is otherwise explai ned, or until the subject is lost to follow -up.  Once resolved, 
the appropriate AE/SAE CRF page will be updated.  The investigator will ensure that 
follow -up includes an y supplemental investigations as may  be indicated to elucidate the 
nature and/or causality  of the AE or SAE.  This may  include additional laboratory  tests or 
investigations, histopathological examinations, or consultation with other health care 
professionals.
6.2.8.1. Definition of an AE
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits (i.e. ,lack of efficacy ), abuse or misuse.
Events meeting the definition of a n AE include:
Exacerbation of a chronic or intermittent pre- existing condition including either an 
increase in frequency  and/or intensity  of the condition
New conditions detected or diagnosed after study  treatment administration even 
though it may  have bee n present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae .
“Lack of efficacy ” or “failure of expected pharmacological action” per se will n ot be 
reported as an AE or SAE. However, the signs and sy mptoms and/or clinical sequelae 
resulting from lack of efficacy  will be reported if they  fulfil the definition of an AE or 
SAE.  
Events that do not meet the definition of an AE include:
Medical or surgical pr ocedure (e.g., endoscopy , appendectom y); the condition that 
leads to the procedure is an AE
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital)
Anticipated day -to-day fluctuations of pre -existin g disease(s) or condition(s) present 
or detected at the start of the study
 that do not worsen 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
40The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the su bject’s 
condition
6.2.8.2. Definition of a SA E
A serious adverse event is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE:  The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subj ect was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospitalization or prolongation of existing hospitalization
NOTE:  In general, hospitalization signifies that the subject has been detained 
(usually  involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospitalization are 
AEs.  If a complication prolongs hospitalization or fulfills any  other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability /incapacity , or
NOTE:  The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect
f.Medical or scientific judgement should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may  jeopardize 
the subject or may  require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.  Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or deve lopment of 
drug dependency  or drug abuse.
g.All events of possible drug -induced liver i njury  with hy perbilirubinaemia defined as 
ALT 3xULN andbilirubin 2xUL N (>35% direct) (or ALT 3xUL N and 
INR>1.5, if INR measured) termed ‘Hy ’s Law’ events ( INR measu rement is not  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
41required and the threshold value stated will not apply  to patients receiving 
anticoagula nts).
NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record presence of detectable urinary  bilirubin on di pstick indicating 
direct bilirubin elevations and suggesting liver injury . If testing is unavailable and a 
subject meets the criterion of total bilirubin 2xULN, then the event is still reported 
as an SAE. If INR is obtained, include values on the SAE for m. INR elevations >1.5 
suggest severe liver injury .   
6.2.9. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as A Es and SA Es
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., EC
Gs, radiological scans, vital signs measurements), 
including those that worsen from baseline, and felt to be clinically  significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs.
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by  the investigator to be more severe than expected for 
the subject’s condition, are notto be reported as AEs or SAEs.
6.2.10. Cardiovascular Events
Investigators will be req uired to fill out event specific data collection tools for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic att ack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularization
This information should be recorded within one week of when the AE/SAE(s) are first 
reported. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
426.2.11. Death Events
In addition, all deaths, whether or not they  are considered SAEs, will re quire a specific 
death data collection tool to be completed.  The death data collection tool includes 
questions regarding cardiovascular (including sudden cardiac death) and 
noncardiovascular death.
This information should be recorded within one week of wh en the death is first reported.
6.2.12. Pregnancy
Any pregnancy  that occurs during study participation must be reported using a clinical 
trial pregnancy  form.  To ensure subject safet y, each pregnancy  must be reported to GSK 
within 2 weeks of learning of its occur rence.  The pregnancy  must be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy complications and elective terminations for medical reasons must be reported 
as an AE or SAE.
  Spontaneous abortions must be reported as an SAE.
Any SAE occurring in association with a pregnancy , brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatment ,must be promptl y reported to GSK.
6.2.13. Time Period and Frequency  of Detecting AEs and SA Es
The investigator or site staff is responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
AEs will be collected from the start of study  treatment and until the follow up contact.  
SAEs will be collected over the same time period as stated above for AEs. However, any  
SAEs assessed as related to study  participation (e.g., study  treatment , protocol -mandated 
procedures, invasive tests, or change in existing therapy ) or related to a GSK concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact. All SAEs will be reported to GSK within 24 
hours, as indicated in Sec tion 6.2.14. 
6.2.14. Prompt Reporting of Serious A dverse Events and Other Events 
to GSK
SAEs, pregnancies, and liver function abnormalities meeting pre -defined criteria will be 
reported promptl yby the investigator to GSK as described in the following table once the 
investigator determines that the event meets the protocol definition for that event. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
43Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool
“CV events” 
and/or “death” 
data collection 
tool(s) if 
applicable24 hours Updated “SAE” 
data collection tool
“CV events” and/or 
“death” data 
collection tool(s) if 
applicable
Pregnancy 2 weeks “Pregnancy 
Notificat ion Form”2 weeks “Pregnancy Follow -
up Form”
Non-serious adverse 
events related to 
study treatment5 calendar 
days“Adverse 
Reaction ”data 
collection tool2 weeks Updated “Adverse 
Reaction ”data 
collection tool
Liver chemistry abnormalities for Phase I t o IV:
ALT3xULN and
Bilirubin 2xULN 
(>35% direct) (or 
ALT3xULN and
INR>1.5, if INR 
measured)124 hours2 “SAE” data 
collection tool.  
“Liver Event CRF” 
and “Liver 
Imaging” and/or 
“Liver Biopsy” 
CRFs, if 
applicable324 hours Updated “SAE” 
data collection 
tool/“Liver Event” 
Documents3
Remaining liver chemistry abnormalities Phase III to IV:
ALT8xULN; 
ALT3xULN with 
hepatitis or rash or 
3xULN and <5xULN 
that persists 4 weeks24 hours2 “Liver Event” 
Documents 
(defined above)324 hours Updated “Liver 
Event” Documents3
ALT5xULN plus 
bilirubin <2xULN24 hours2 “Liver Event” 
Documents 
(defined above) 
do not need 
completing unless 
elevations persist 
for 2 weeks or 
subject cannot be 
monitored weekly 
for 2 weeks324 hours Updated “Liver 
Event” Documents, 
if app licable3
ALT5xULN and 
bilirubin <2xULN that 
persists 2 weeks24 hours2 “Liver Event” 
Documents 
(defined above)324 hours Updated “Liver 
Event” Documents3 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
44ALT3xULN and <5x 
ULN and bilirubin 
<2xULN24 hours2 “Liver Event” 
Documents 
(defined above) 
do not need 
completing unless 
elevations persist 
for 4 weeks or 
subject cannot be 
monitored weekly 
for 4 weeks324 hours Updated “Liver 
Event” Documents, 
if applicable3
1. INR measurement is not required; if measured, the threshold value stated will not apply to patients receiving 
anticoagulants.
2. GSK must be contacted at onset of liver chemistry elevations to discuss subject safety
3. Liver Event Documents (i.e., “Liver Event CRF” and “Liver Imaging CRF” and/or “Liver Biopsy CRF”, as 
applicable) should be completed as soon as possible.
The method of detecting, recording, evaluating and follow- up of AEs and SAEs plus 
procedures for completing and transmitting SA E reports to GSK are provided in the 
SPM. Procedures for post -study  AEs/SAEs are provided in the SPM.
6.2.14.1. Regu latory  reporting requirements for SA Es
Prompt notification of SAEs by  the investigator to GSK is essential so that legal 
obligations and ethical responsibilities towards the safet y of subjects are met.
GSK has a legal responsibility  to notify  both the loca l regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical inves tigation.  GSK will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit
y, Institutional Review B oard (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK policy  and are forwarded 
to investigators as nec essary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
6.2.15. Spirometry Testing
Lung function will be measured b y spirometry at Visits 1, 2, 4, 6, 8, 10, 12, and 14, or at 
Early Withdrawal using site available spirometry  equipment that meets or exceeds the 
minimum performance recommendations of the ATS/ ERS [ Miller , 2005].  For Visits 2 
onward, FEV 1 will be measured prior to administration of morning stud y medication.
For each observation, at least 3 valid (with no more than 8) efforts will be obtained using 
ATS /ERS guidelines.  The largest FEV 1and FVC from the 3 acceptable efforts should be  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
45recorded, even if they  do not come from the same effort. Acceptable spirometry  efforts 
should have a satisfactory  start of test and end of test (i.e. a plateau in the volume -time 
curve) and be free from artifacts due to cough, early  termination, poor effort, obstructed 
mouthpiece, equipment malfunction, or other reasons [ Miller , 2005]. The subject’s 
position during spirometry  measurements (sitting or standing) should rema in constant for 
the duration of the stud y.
A post -albuterol (salbutamol) FEV 1/FVC ratio of < 0.70 and predicted normal value of 
50% ≤ FEV 1 ≤ 70% is required at Screening Visit 1.  
All predicted values will be taken from Hankinson [ Hankinson, 1999].
The investigator will retain a printed cop y of the spirometry data in the subject’s source 
documents.
6.2.15.1. Reversi bility  Testing
At Visit 1, reversibility  to albuterol (salbutamol) will be assessed. To determine 
reversibility , the subject will self -administer 4 puffs (360mcg) of albuterol (salbutamol) 
without the use of a spacer or holding chamber. Triplicate spirom etry efforts will be 
performed immediately  pre-albuterol (salbutamol) and within 30 minutes post -albuterol 
(salbutamol). The highest FEV 1from three valid forced expiratory  curves will be used to 
determine reversibility .
Reversibility  is defined as an inc rease in FEV 1of ≥12% and ≥200mL  following 
administration of albuterol (salbutamol) .  Non- reversible is defined as a post -albuterol 
(salbutamol) increase in FEV 1of <200mL or a ≥200mL  increase that is <12% from pre -
albuterol (salbutamol) FEV 1.
6.2.16. Laboratory  Assessments
Routine, non-fasting clinical laboratory (hematology  and biochemistry ), will be 
performed in all subjects at the S creening Visit 1.  
For women of childbearing potential, a serum pregnancy  test will be included in the 
laboratory  panel collected at Visit 1 if applicable.  
At the discretion of the investigator, additional samples may
 be taken for safet y reasons.  
If the subject has an abnormal laboratory  finding for any  anal yte from the Screening Visit 
laboratory  panel, which in the opinion of the Investigator does not preclude the subject 
from participating in the study , but for which the Investigator feels warrants 
treatment/correction with a non- excluded medication(s) (e.g., calcium supplement for 
hypocalcemia), a blood sample for repeat anal ysis of the anal yte(s) should be collected 
pre-dose at Visit 2 (Randomization)
All protocol required laboratory  assessments, as defined in Appendix 1 must be 
performed b y the central laboratory . Laboratory  assessments must be conducted i n 
accordance with the Central Laboratory  Manual and Protocol Time and Events Schedule.
Laboratory  requisition forms must be completed and samples must be clearly  labelled  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
46with the subject number, protocol number, site/center number, and visit date. Detai ls for 
the preparation and shipment of samples will be provided by the central laboratory .
Reference ranges for all safet y parameters will be provided to the site by the central 
laboratory .
6.2.17. Orophary ngeal Examination
Orophary ngeal examinations for clinica l evidence of infection (i.e., Candida albicans) 
will be performed at each study  visit as shown in the Time and Events Table. If there is 
evidence of infection, a culture swab may  be taken and appropriate therapy  should be 
instituted at the discretion of the Investigator. Subjects with culture-positive infection 
may continue in the study  on appropriate anti -infective treatment at the discretion of the 
Investigator. The results of these assessments, and any  relative pharmacotherapy , will be 
recorded in the subject’s clinic notes and in the eCRF. After randomization, all culture 
positive results must be reported as adverse events.
6.2.18. Diary  Card -Medical Problems/Medications Taken
Subjects will be instructed to record an y medical problems they may have experience d 
and an y medications used to treat those medical problems in their diaries from Screening 
(Visit 1) through the Follow -up Phone Contact.  
Subjects will be instructed on how to complete the diary and will be asked to return 
completed diaries at each clini c visit.  The study  coordinator must review the diary  at 
each clinic visit and will inquire about the diary  data during the Follow- up Phone Contact 
as well.  If the subject does not mention an event which is recorded on the diary , he/she 
should be questioned for further information in order to determine if there was the 
occurrence of an AE.  Any  confirmed AE and/or concurrent medication will be entered 
into the eCRF.
6.2.19. 12
-lead ECG A ssessment
A single 12 -lead ECG and rhy thm strip will be recorded prior to spirometry at the 
Screening Visit 1.
All ECG measurements will be performed with the subject resting in a supine position for 
approximately  5 minutes before each reading, which should be carried out after 
measurement of vital signs and before spirometry .
The i nvestigator, a designated sub -investigator, or other appropriatel y trained site 
personnel, will be responsible for performing the 12- lead ECG recording on each stud y 
visit, if applicable.  The investigator must provide his/her dated signature on the origin al 
paper tracing, attesting to the authenticity  of the ECG machine interpretation.
6.2.20. Smoking Cessation Counselling
During the Screening Visit 1
, 6, 10, and 14or EW visit (if necessary ),subjects will be 
given smoking cessation counselling, which includes ad vice regarding the following: 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
47the health effects that smoking may  cause.
the health benefits that may  result if they  stop smoking.
if they  do not feel capable of discontinuing smoking that their primary  care phy sician 
may be able to discuss anti -smoking st rategies with them. 
that they  may  discontinue smoking at any  time during the study  and will not have to 
be withdrawn from the study  if they  do so.  
6.3. Pharmacogenetic Research
Information regarding pharmacogenetic research is included in Appendix 2.  The 
IEC/IRB and, where required, the applicable regulatory  agency  must approve the PGx 
assessments before these can be conducted at the site.  The approval(s) must be in writing 
and will clearl y specify  approval of the PGx assessments.  I n some cases, approval of the 
PGx assessments can occur after approval is obtained for the rest of the study .  If so, then 
the written approval will clearl y indicate approval of the PGx assessments is being 
deferred and the study , except for PGx assessments, can be initiated.  When PGx 
assessments will not be approved, then the approval for the rest of the study  will clearl y 
indicate this and therefore, PGx assessments will not be conducted.
7. DATA MAN
AGEMENT
For this study  subject data will be entered into GSK defined eCRFs, transmitted 
electronically  to GSK and combined with data (e.g. laboratory  data, diary  data) provided 
from other sources in a validated data s ystem.
Management of clinical data will be performed in accordance with applicable GSK 
standards and data cleaning procedures to ensure the integrity  of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using MedDRA and an internal validated medication dictionary , 
GSKDrug.  An appropriate medical dictionary  that covers all approved drugs in the 
region will be referenced. eCRFs (including queries and audit trails) will be retained b y 
GSK, and copies will be sent to the investigator to maintain as the investigator copy. In 
all cases, subject initials will not be collected or transmitted to GSK according to GSK 
policy .
8. DATA ANALYSIS AND ST ATISTICAL CONSIDERA TIONS
8.1. Hypotheses
The null hy pothesis for the primary  measure is that the change in BMD assessed at the 
total hip is worse fo r the FF/VI combination product arm compared with the VI arm . The 
alternative h ypothesis that the change in BMD assessed at the total hip is not worse for 
the FF/VI arm compared with the VI arm .
This is also the null and alternative h ypothesis f or the seco ndary  measure of BMD 
assessed at the L1-L4 lumbar spine . 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
488.2. Stud y Design Considerations
8.2.1. Sample Size A ssumptions
This study  will evaluate non -inferiority in both males and females separately as key 
secondary  measures.  56 subjects per gender per treatment woul d provide 80% power to 
demonstrate non -inferiority  by comparing the lower boundary  of a two -sided 95% 
confidence interval on the treatment difference to -1%/y ear assuming a true treatment 
difference 
of -0.3%/ year.  In study  SCO40041, approximately  20% of s ubjects did not 
provide post -
baseline data, therefore 70 subjects per gender per treatment will be 
randomized (280 total subjects).  Randomization will be stratified by  gender.
For the primary  evaluation of BMD for the total hip, males and females will be 
combined, and will have >90% power to demonstrate non -inferiority  by comparing the 
lower boundary  of a two -
sided 95% confidence interval on the treatment difference to      
-1%/y ear assuming a true treatment difference of -0.3%/y ear.
8.2.2. Sample Size Sensitivit y
The following table presents the power of the study  under different circumstances in 
terms of the standard deviation and the observed treatment difference in change from 
baseline 
in bone mineral density  for the total hip.
True Treatment Difference betwe en FF/VI and VI
SD -0.2%/yr -0.3%/yr -0.4%/yr
1.3%/yr >99% 99% 96%
1.4%/yr >99% 98% 94%
1.5%/yr >99% 97% 91%
8.2.3. Sample Size Re -estimation
No sample size re -estimation is planned for this study .
8.3. Data Analysis Considerations
8.3.1. Analysis Populations
All Subje cts Enrolled Population: This population will consist of all subjects, for whom a 
record exists on the study  database, including screen failures and an y subject who was 
not screened but signed the informed consent form. This population will be used for 
reporting subject disposition, reasons for withdrawal prior to randomisation, and 
inclusion, exclusion and randomisation criteria deviations and SAEs for non -randomised 
subjects.
(Modified) Intent -to-Treat (ITT) Population: This population will consist of all subjects 
who are randomised and receive at least one dose of study  drug. The ITT Population will 
be the primary  population for all anal yses of safety  and efficacy  measures. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
498.3.2. Analysis Data Sets
The bone mineral density data will comprise the primary  data se t of interest.  Details of 
derived data in anal ysis datasets to be created will be provided in the Reporting and 
Analy sis Plan (RAP).
8.3.3. Treatment Comparisons
8.3.3.1. Primary  Comparisons of Interest
BMD measured for the total hip will be summarized by  visit and as ch ange from baseline 
at each visit for raw values, percent changes from baseline, t -scores, and z -scores.  The 
percent change from baseline in BMD for the total hip will be the primary  endpoint, and 
analyzed using a repeated measures model with terms for tre atment, time, time by 
treatment, baseline BMD , baseline BM I and gender .  Contrasts will be formed using the 
time by  treatment variable to provide 95% confidence intervals for the treatment 
difference with the unit of percent change per year.  The 95% confi dence interval will be 
compared to 
a lower bound of -1%/year in order to assess clinical non-inferiority .  Any 
additional covariates for the model, along with other details, including model inclusion 
and exclusion criteria for those covariates, will be det ermined a priori in a detailed 
Reporting and Anal ysis Plan (RAP) that will be completed prior to unblinding of the 
study .
The percent change from baseline in BMD at the L1-
L4 region of the spine will also by  
summarized and analyzed in the same manner as th e BMD data for the total hip .
8.3.4. Interim A nalysis
No interim anal ysis is planned for this study .
8.3.5. Key Elements of A nalysis Plan
8.3.5.1. Efficacy  Analyses
No efficacy  anal yses areplanned for this study
8.3.5.2. Safety  Analyses
8.3.5.2.1. Extent of Exposure
The extent of exposure to study drug will be summarized by  treatment group.
8.3.5.2.2. Adverse Events (A Es)
AEs will be coded using the standard GSK dictionary , Medical Dictionary  for Regulatory  
Activities (MedDRA), and grouped b y bod y system. AEs occurring pre -treatment, during 
active treatment a nd post -treatment will be summarized separatel y. The number and 
percentage of subjects experiencing at least one AE of an y type, AEs within each bod y 
system and AEs within each preferred term will be presented for each treatment group.  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
50Separate summaries w ill be provided for all AEs, drug related AEs, SAEs, and for AEs 
leading to withdrawal.
8.3.5.2.3. Deaths and SA Es
All SAEs will be listed by treatment group. Deaths and SAEs will be documented in case 
narrative format.
8.3.5.2.4. Fractures
The number and percent of patients experiencing a bone fracture during the study  will be 
summarized.
8.3.5.2.5. COPD Exacerbations and Pneumonias
The number of moderate or severe COPD exacerbati ons and the percent of patients 
experiencing moderate or severe COPD exacerbations will be summarized.
8.3.5.3. Pharmac
ogenetic A nalyses
See Appendix 2: Pharmacogenetic Research for details about the Pharmacogenetics 
Analy sis Plan.
9. STUDY CONDUCT CONSID ERA TIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers 
before enrolment of subjects begins.
9.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a study site, GSK will obtain favourable opinion/ approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with ICH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the D eclaration of Helsinki
2008, including, but not limited to:
Institutional Review Boar d (IRB)/Independent Ethics Committee (I EC) review and 
favourable opinion/approval of study  protocol and any  subsequent amendments.
Subject informed consent.
Investigator reporting requirements. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
51GSK will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
No study related procedures may be performed until the informed consent form 
document has been signed by the subject .  A pre -screening visit may  be required in 
order to administer the informed consent before any changes are made to the subject’s 
current medication regimen . The informed consent may  be given at Screening (Visit 1) if 
the subject does not take or has not taken an y pro tocol excluded medications.
In approving the clinical protocol the IEC/I RB and, where required, the applicable 
regulatory  agency  are also approving the optional assessments e.g., PGx assessments 
described in Appendix 2, unless otherwi se indicated.  Where permitted by  regulatory  
authorities, approval of the optional assessments can occur after approval is obtained for 
the rest of the stud y.  If so, then the written approval will clearl y indicate approval of the 
optional assessments is being deferred and the study , except for the optional assessments, 
can be initiated.  When the optional assessments are not approved, then the approval for 
the rest of the stud y will clearl y indicate this and therefore, the optional assessments will
not be conducted.
9.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study  to review with the site staff the protocol, 
study  requirements, and their r esponsibilities to satisfy  regulatory , ethical, and GSK 
requirements.  When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the CRF will serve 
as the source document.
GSK will monitor the study  to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all ap plicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents .
9.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory requirements, GSK may  
conduct a qualit y assurance assessment and/or audit of the site records, and the regulatory  
agencies may  conduct a regulatory  inspection at any  time during or after completion of 
the study . In the event of an assessment, audit or inspection, the investigator (and 
institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to 
all relevant documents and to allocate their time and the time of their staff to discuss the  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
52conduct of the stud y, an y findings/rel evant issues and to implement any  corrective and/or 
preventative actions to address an y findings/issues identified .
9.5. Stud y and Site Closure
Upon completion or termination of the study , the GSK monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, GCP, and GSK Standard Operating Procedures.
GSK reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safety  issues, ethical issues, or severe non-
compliance.  If GSK determines that such action is required, GSK will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
(where applicable).  When feasible, GSK will provid e advance notice to the investigator 
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons, GSK will promptly inform all 
investigators, heads of the medical institutions (where applicable),and/ or institutions 
conducting the study .  GSK will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applicable regulations, the investigator or head of the medica l institution must inform the 
IRB/IEC promptly  and provide the reason(s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the investigator or head of the medical institution (where 
applicable) must maintain all site study  records (except for those required by  local 
regulations to be maintained elsewhere) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a GSK audit or regulatory inspection) and 
must be available for review in conjun ction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard copy  (e.g., microfiche, scanned,
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In addition, they  must meet accessibility  and retrieval standa rds, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control procedure in place for creating the reproductions.
GSK will i nform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y local 
laws/regulations, GSK standard operating procedures, and/or institutional requirements.
The investigator must notify  GSK of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off- site facility  or transfer of owner ship of the 
records in the event that the investigator is no longer associated with the site. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
539.7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable r egulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study results at a GSK site or other mutually -
agreeable location.
GSK will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as
appropriate.
GSK will provide the investigator with the randomization codes for their site only after 
completion of the full statistical analy sis
.
GSK aims to post a results summary  to the GSK Clinical Study  Register and other 
publicly  available registers no later than 8 months after the last subject’s last visit (L SLV) 
[this applies to each data anal ysis phase for studies with multiple phases, e.g., primary  
analysis, follow up anal ysis etc]. I n addition, the aim is to submit a manuscript to a peer-
reviewe d journal for publication within 18 months of L SLV. GSK also aims to publish 
the full study  protocol on the GSK Clinical Study  Register at the time the results of the 
study  are published as a manuscript in the scientific literature. 
When manuscript public ation in a peer -reviewed journal is not feasible, further study  
information will be posted to the GSK Clinical Study  Register to supplement the results 
summary .
9.8. Independent Data Monitoring Committee (IDMC)
There is no IDMC in this study . 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
5410. REFERENCES
Calver ley PM, Anderson JA, Celli B. Salmeterol and fluticasone propionate and survival 
in chronic obstructive pulmonary  disease. NEJM. 2007;356:775 -89.
Celli BR, MacNee W. Standards of the diagnosis and treatment of patients with COPD: a 
summary  of the ATS/ERS position paper. Eur Respir J. 2004;23:932 -46.
Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C. 
Epidemiology  and costs of chronic obstructive pulmonary  disease. Eur Respir J. 
2006;27:188 -207.
Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.  Effect of fluticasone 
propionate/salmeterol ( 50/250 g) or salmeterol (50 g) on COPD exacerbations. Resp 
Med. 2008;102:1099-1108.
GOLD. Global Initiative for Chronic Obstructive Lung Disease. Executive Summary : 
Global strategy  for the diagnosis, management, and prevention of chronic obstructive 
pulmonary  disease (Updated 2010).  http://www.gold.copd.org
Hankinson JL , Odencrantz JR, Fedan KB. Spirometric reference values from a sample of 
the general US population.  Am J Resp Crit C are Med. 1999;159:179 -187.
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37: 1779 -1784. 
Kardos P, Wencker M, Glaab T. Impact of Fluticasone Propionate/Salmeterol versus 
salmeterol on exacerbations in severe chronic obstructive pulmonary  disease. Am J Resp 
Crit Care Med. 2007;175:144 -
149.
Lopez AD, Shibu ya K, Rao C, Mathers CD, Hansell AL ,Held L S, Schmid V, Buist S. 
Chronic obstructive pulmonary  disease: current burden and future projections. Eur Respir 
J. 2006;27:397-412.
Miller MR, Hankinson J, Brusasco Vet al. Standardisati on of spirometry . Eur Respir J. 
2005;26:319 -338.
WHO. Chronic Ob structive Pulmonary  Disease ( COPD). Burden of COPD. WHO. 2010 . 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
5511. APPENDICES
11.1. Appendix 1: Laboratory  Assessments
Refer to the Time and Events Table 3 for information regarding the timing of laboratory  
tests.
CHEMISTRY HEMATOLOGY OTHER
Albumin Hemoglobin Hepatitis B surface antigen1
Alkaline phosphatase Hematocrit Hepatitis C virus antibody1
Alanine amino -transferase (ALAT or SGPT) Platelet count Urine pregnancy test (in 
clinic/home test)2
Aspartate amino -transferase (ASAT or 
SGOT)WBC count Fungal culture of oral mucosa (if 
visual evidence of candidiasis )
Bilirubin, direct Neutrophils, absolute hCG qualitative (serum 
pregnancy)2 
Bilirubin, indirect Neutrophils, segs (%)
Bilirubin, total Neutrophils, bands 
(%)
Calcium Basophils (%)
Chloride Eosinophils (%)
CO 2content/Bicarbonate Eosinophils , absolute
Creatinine Lymphocytes (%)
Creatine phosphokinase (CPK), total Monocytes (%)
Gamma glutamyl transferase (GGT)
Glucose
Phosphorus 
Potassium
Protein, t otal serum
Sodium
Urea nitrogen (BUN)
Uric Acid 
1. Assessed at Visit 1 (Screening) only, result is not exclusionary
2. Only females of child -bearing potential; refer to Time and Events Table for specific visit information
11.2. Appendix 2: Pharmacogenetic Research
Pharmacogenetics –Background
Pharmacogenetics (PGx) is the study  of variability in drug response due to hereditary  
factors in populations.  There is increasing evidence that an individual's genetic 
background (i.e., genot ype) may  impact the ph armacokinetics (absorption, distribution, 
metabolism, elimination), pharmacod ynamics (relationship between concentrations and 
pharmacologic effects or the time course of pharmacologic effects) and/or clinical 
outcome (in terms of efficacy  and/or safety  and tolerability ).  Some reported examples of 
PGx associations with safety /adverse events include: 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
56Drug Disease Gene Variant Outcome
Abacavir HIV 
[Hetherington ,2002; 
Mallal ,2002; 
Mallal ,2008]HLA-B* 5701 Carriage of the HLA -B*5701 variant has been shown to 
increase a patient's risk for experiencing 
hypersensitivity to abacavir.  Prospective HLA -B*5701 
screening and exclusion of HLA -B*5701 positive 
patients from abacavir treatment significantly decreased 
the incidence of abacavir hypersensitivity.  Treatment 
guidelines and abacavir product labeling in the United 
States and Europe now recommend (US) or require 
(EU) prospective HLA -B*5701 screening prior to 
initiation of abacavir to reduce the incidence of abacavir 
hypersensitivity.  HLA -B*5701 screening should 
supplement but must never replace clinical risk 
management strategies for abacavir hypersensitivity.
Carbamazepin
eSeizure, Bipola r 
disorders & 
Analgesia Chung , 
2010; Ferrell , 2008HLA-B*1502 Independent studies indicated that patients carrying 
HLA-B*1502 are at higher risk of Stevens -Johnson 
Syndrome and t oxic epidermal necrolysis and that this 
marker is prevalent in some populations, particularly 
with Asian ancestry.  Regulators, including the US FDA 
and the Taiwanese TFDA, have updated the 
carbamazepine drug label to indicate that patients with 
ancestry i n genetically at risk populations should be 
screened for the presence of HLA -B*1502 prior to 
initiating treatment with carbamazepine.
Irinotecan Cancer [ Innocenti , 
2004; Liu , 2008; 
Schulz, 2009]UGT1A1*28 Variations in the UGT1A1 gene can influence a 
patient’s ability to break down irinotecan, which can 
lead to increased blood levels of the drug and a higher 
risk of side effects. A dose of i rinotecan that is safe for 
one patient with a particular UGT1A1 gene variation 
might be too high for another patient without this 
variation, raising the risk of certain side -effects, that 
include neutropenia following initiation of Irinotecan 
treatment.  T he irinotecan drug label indicates that 
individuals who have two copies of the UGT1A1*28 
variant are at increased risk of neutropenia.  A genetic 
blood test is available that can detect variations in the 
gene.    
A key component to successful PGx resear ch is the collection of samples during the 
conduct of clinical studies.
Collection of whole blood samples, even when no a priori hypothesis has been identified, 
may enable PGx anal ysis to be conducted if at any time it appears that there is a potential 
unexpected or unexplained variation in response toFF/V I Inhalation Powder . 
Pharmacogenetic Research Objectives
The objective of the PGx research (if there is a potential unexpected or unexplained 
variation) is to investigate a relationship between genetic f actors and response to FF/V I 
Inhalation Powder.   If at any  time it appears there is potential variability  in response in 
this clinical study  or in a series of clinical studies with FF/VI Inhalation Powder , the 
following objectives may be investigated – therelationship between genetic variants and 
study  treatment with respect to: 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
57Relationship between genetic variants and the pharmacokinetics and/or 
pharmacod ynamics of investigational product
Relationship between genetic variants and safet y and/or tolerabili ty of investigational 
product
Relationship between genetic variants and efficacy of investigational product
Study Population
Any subject who is enrolled in the clinical study , can participate in PGx research.  Any  
subject who has received an allogeneic bon e marrow transplant must be excluded from 
the PGx research.
Subject participation in the PGx research is voluntary  and refusal to participate will not 
indicate withdrawal from the clinical study  or result in any  penalty  or loss of benefits to 
which the sub ject would otherwise be entitled.
Study Assessments and Procedures
Saliva samples can be taken for Deoxy ribonucleic acid (DNA) extraction and used in 
PGx assessments.
No additional whole blood samples will be necessary  for the PGx anal ysis. Saliva (2mL ) 
iscollected into the DNA self -collection kit. A single sample will be taken but can be 
duplicated if the first sample is unusable. I t is recommended that the saliva sample be 
collected at Visit 2.  
The PGx sample is labelled (or “coded”) with a study  speci fic number that can be 
traced or linked back to the subject b y the investigator or site staff.  Coded samples 
do not carry  personal identifiers (such as name or social securit y number).  The 
saliva sample is taken on a single occasion unless a duplicate sa mple is required due 
to inability  to utilize the original sample.  
The DNA extracted from the saliva sample may  be subjected to sample quality  control 
analysis.  This anal ysis will involve the genot yping of several genetic markers to confirm 
the integrit yof individual samples.  If inconsistencies are noted in the analy sis, then those 
samples may  be destroy ed.
The need to conduct PGx anal ysis may  be identified after a study  (or a set of studies) of 
FF/V I Inhalation Powder has been completed and the clinica l study  data reviewed.  In 
some cases, the samples may  not be studied. e.g., no questions are raised about how 
people respond to FF/V I Inhalation Powder .
Samples will be stored securel y and may be kept for up to 15 years after the last subject 
completes th e study  or GSK may  destro y the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will use samples collected from the study  for 
the purpose stated in this protocol and in the informed consent form.  
Subjects can request their sample to be destro yed at any  time. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
58Subject Withdrawal from Study
If a subject who has consented to participate in PGx research and has had a sample taken 
for PGx research withdraws from the clinical study  for any  reason other than lost to 
follow -up, the subject will be given the following options:
Retain the sample for PGx research 
Destro y the PGx sample 
If a subject withdraws consent for PGx research or requests sample destruction for any  
reason, the investigator must complete the appropriate documentat ion to request sample 
destruction within the timeframe specified b y GSK and maintain the documentation in 
the site study  records . 
Screen and Baseline Failures
If a blood sample for PGx research has been collected and it is determined that the 
subject does not meet the entry  criteria for participation in the clinical study, then the 
investigator should instruct the participant that their PGx sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the conse nt
and sample reconciliation process.  In this instance a sample destruction form will not be 
available to include in the site files.
Pharmacogenetics A nalyses
Pharmacogenetics Anal yses
1.Specific genes may  be studied that encode the drug targets, or drug me chanism of 
action pathway s, drug metabolizing enzymes, drug transporters or which may
underpin adverse events, disease risk or drug response . These candidate genes may  
include a common set of ADME (Absorption, Distribution, Metabolism and 
Excretion) genes that are studied to determine the relationship between gene variants 
or treatment response and/or tolerance. 
In addition, continuing research may  identify  other enzy mes, transporters, proteins or 
receptors that may  be involved in response to FF/VI Inhalat ion Powder .  The genes that 
may code for these proteins may  also be studied.
2.Genome -wide scans involving a large number of poly morphic markers (e.g., single 
nucleotide poly morphisms) at defined locations in the genome, often correlated with 
a candidate gen e, may  be studied to determine the relationship between genetic 
variants and treatment response or tolerance. This approach is often employ ed when 
a definitive candidate gene(s) does not exist and/or the potential genetic effects are 
not well understood. 
If applicable and PGx research is conducted, appropriate statistical anal ysis methods will 
be used to evaluate pharmacogenetic data in the context of the other clinical data. Results 
of PGx investigations will be reported either as part of the main clinica l study  report or as 
a separate report. Endpoints of interest from all comparisons will be descriptively  and/or 
graphicall y summarized as appropriate to the data.  A detailed description of the anal ysis  2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
59to be performed will be documented in the study  repor ting and anal ysis plan (RAP) or in 
a separate pharmacogenetics RAP, as appropriate.   
Informed Consent
Subjects who do not wish to participate in the PGx research may  still participate in the 
clinical study .  PGx informed consent must be obtained prior to an ysaliva being taken for 
PGx research.
Provision of Study Results and Confidentiality  of Subject’s PG x Data
GSK may  summarize the PGx research results in the clinical study  report, or separatel y, 
or may  publish the results in scientific journals. 
GSK does not inform the investigator, subject, or any one else (e.g., family  members, 
study  investigators, pri mary  care ph ysicians, insurers, or emplo yers) of individual 
genot yping results that are not known to be relevant to the subject’s medical care at the 
time of the study , unless required b y law. This is due to the fact that the information 
generated from PGx studies is generall
y preliminary in nature, and therefore the 
significance and scientific validity  of the results are undetermined. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
60References
Chung WH, Hung SL , Chen YT. Genetic predisposition of life -threatening antiepileptic -
induced skin reactions.  Ex pert Opin. Drug Saf. 2010; 9: 15 -21.
Ferrell PB, McLeod HL.  Carbamazepine, HLA -B*1502 and risk of Stevens -Johnson 
syndrome and toxic epidermal necrol ysis: US FDA recommendations.  
Pharmacogenomics. 2008; 9: 1543 -46.
Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, 
Davies K, Handley  A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond L M, Roses 
AD. Genetic variations in HLA- B region and h ypersensitivity  reactions to abacavir. 
Lancet . 2002; 359:1121-2.
Innocenti F, Undevia SD, Iy erL, Chen PX, Das S, Kocherginsk y M, Karrison T, Janisch 
L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ.  Genetic variants in the UDP -
glucuronosy ltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J 
Clin Oncol 2004; 22: 1382 -1388.
Liu C Y, Chen PM, Chiou TJ, L iu JH, Lin JK, L in TC, Chen WS, Jiang JK, Wang HS, 
Wang WS.  UGT1A1*28 poly morphism predicts irinotecan- induced severe toxicities 
without affecting treatment outcome and survival in patients with metastatic colorectal 
carcinoma.  Can cer. 2008; 112: 1932-40.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Say er D, Castley  A, Mamotte 
C, Maxwell D, James I .  Association between presence of HLA- B*5701, HLA -DR7, and 
HLA -DQ3 and hy
persensitivity  to HIV -1 reverse -transcriptase inhibitor abacavir.  
Lancet . 2002; 359:727-32.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel -Guedes E, 
Rugina S, Kozy rev O, Cid JF, Hay  P, Nolan D, Hughes S, Hughes A, Ry an S, Fitch N, 
Thorborn D, Benbow A; PREDI CT-1 Study  Team.  HLA -B*5701 screening for 
hypersensitivity  to abacavir. N Engl J Med. 2008; 358; 568 -78
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, 
Stemmler HJ. UGT1A1 gene pol ymorphism: I mpact on toxicity  and efficacy  of 
irinotecan -based regim ens in metastatic colorectal cancer.  World J. Gastroenterol. 2009; 
15: 5058-66. 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
6111.3. Appendix 3: Country  Specific Requirements 2018N368712_00
2012N150072_00 CONFIDENTIA L
HZC102972
6211.4. Appendix 4: Liver Chemistry  Stopping and Followup Criteria
Phase III -IV Liver Safety Algorithms
ALT>3xULN
plus 
bilirubin >2x 
ULN (>35%
direct) (or plus
INR >1.5, if   
measured)*NoYes
Yes•Instruct subject to stop investigational product (IP)
•Notify GSK within 24h and arrange clinical followup 
within 24-72h
•Perform liver chemistries and liver event follow up 
assessments (serology , PK sample etc as in protocol) 
•Complete liver event CRF , SAE data collection tool if 
appropriate, and liver imaging and/or biopsy  CRFs if  
tests performed.
•Obtain weekly liver chemistries [**as far as possible in 
these subjects] until resolved, stabilised or returned to 
baseline 
•Withdraw subject from study  after monitoring 
complete unless protocol has option to restart drug•Instruct subject to stop investigational product (IP)
•Notify GSK and arrange clinical followup within 24h
•Perform liver chemistries and liver event follow up 
assessments (serology , PK sample etc as in protocol) 
•Report as SAE (excl. hepatic impairment or cirrhosis 
studies) and complete liver event CRF , SAE data 
collection tool, and liver imaging and/or biopsy  CRFs if 
tests performed.
•Obtain twice weekly liver chemistries until resolved, 
stabilised or returned to baseline values
•Consultation with hepatologist/specialist recommended
•Withdraw subject from study  after monitoring 
complete unless protocol has option to restart drugHepatitis 
symptoms
or rash?NoAble to 
monitor 
weekly for 
4 weeks?Yes
No**
YesContinue IP
Obtain twice 
monthly liver 
chemistries until 
normalised or 
back to baseline 
values
YesYesALT<3xULN 
+ bilirubin 
<2xULN 
after ≤ 4 
wks?
Yes
ALT 
>5xULN 
but 
<8xULNNo ALT  
>8xULNYesALT >5 
and 
<8xULN 
for >2 
wks
Yes NoALT>3xULN 
but <5xULN + 
bilirubin 
<2xULN+no 
symptomsNoAble to 
monitor 
weekly for 
>2 wks?No
NoNotify GSK within 24h 
to discuss subject 
safety; continue IP;
check liver chemistry 
weekly for 4 weeksYesNo
*INR value not applicable to subjects on anticoagulants 2018N368712_00